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ABSTRACT 
The Role of Diet, Erythrocyte Fatty Acid Concentration, and Alzheimer’s-Related 
Genes in Systemic Inflammation 
in the Cache County Memory Study 
by 
Rola A. Jalloun, Doctor of Philosophy 
Utah State University, 2015 
Major Professor: Dr. Ronald Munger  
Department: Nutrition, Dietetics, and Food Sciences 
This project examined the association between dietary patterns, erythrocyte 
membrane fatty acids concentration, and Alzheimer’s-related genes in systemic 
inflammation, as indicated by C-reactive protein (CRP) levels, in order to achieve 
more comprehensive knowledge of how nutrition and genetics influence systemic 
inflammation among the elderly residents of Cache County, Utah. 
First, the associations between dietary patterns defined by Dietary Approaches 
to Stop Hypertension (DASH) and Mediterranean dietary patterns (MED) and the risk 
of having a high level of CRP were examined. This study showed that a healthy 
dietary pattern score was associated with CRP levels; a higher score reflecting the 
ideal DASH diet and MED diet was associated with a 26% and 27% reduction in the 
risk of having high CRP levels respectively. This association appeared stronger 
among overweight and obese individuals. 
Second, the association between erythrocyte membrane fatty acids (EMFAs) 
and elevated serum C-reactive protein (CRP) levels was examined. Those that had 
high EMFAs composition of palmitoleic acid and nervonic acids, both 
monounsaturated fatty acids (MUFAs), and dihomo-y-linolenic acid (DGLA), 
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docosapentaenoic acid (DPA-6), docosahexaenoic acid (DHA), all polyunsaturated 
fatty acids (PUFAs), had an increased risk of having CRP elevation. In contrast, risk 
of CRP elevation was reduced in those that have highest levels of saturated fatty acids 
(SFAs) of margaric acid, stearic acid, and arachidic acid.  These associations were 
generally observed to be stronger among women compared to men. 
Lastly, the study examined whether AD-related genes identified in previous 
genome-wide association studies are associated with elevated levels of inflammatory 
CRP. Results revealed a strong association between APOE-epsilon genotypes and 
CRP levels. Results also showed an association between major alleles of APOE 
rs439401, TOMM40 rs157580, and minor alleles MMP8 rs1892886, CR1 rs6656401, 
CR1 rs3818361, and CR1 rs4844609 that were associated with a risk of elevation of 
CRP. These associations were stronger among men compared to women. 
Reduction in the prevalence of AD could have tremendous importance; the 
results of this dissertation may help identify factors important to AD etiology and, in 
turn, provide valuable targets for prevention.                                     




The Role of Diet, Erythrocyte Fatty Acid Concentration, and Alzheimer’s-Related 
Genes in Systemic Inflammation in the Cache County Memory Study 
Rola Jalloun 
 Alzheimer’s disease (AD) is the most common type of dementia in the elderly, 
accounting for 60 to 80% of all dementia cases. It affects 5.2 million Americans and 
44 million worldwide. This project examines the association between dietary patterns, 
erythrocyte membrane fatty acids concentration, and AD-related genes in systemic 
inflammation as indicated by serum C-reactive protein (CRP). All studies performed 
in this project used the data collected in the Cache County Memory Study (CCMS).  
 Higher levels of accordance with the Dietary Approaches to Stop 
Hypertension (DASH) and Mediterranean dietary (MED) patterns were associated 
with consistently lower levels of CRP in elderly men and women. Interestingly, this 
association appeared stronger among overweight and obese participants when 
compared with normal weight participants. These results emphasize that the DASH 
and Mediterranean diets may play an important role in reducing systemic 
inflammation, which may lower AD risk, especially among overweight and obese 
persons.  
A high erythrocyte fatty acid concentration of palmitoleic acid, and nervonic 
acids, both monounsaturated fatty acids (MUFAs), dihomo-y-linolenic acid (DGLA), 
docosapentaenoic acid (DPA-6), docosahexaenoic acid (DHA), all polyunsaturated 
fatty acids (PUFAs), were similarly associated with increased risk of CRP elevation. 
Margaric acid, stearic acid, and arachidic acid, all saturated fatty acids (SFAs), were 
associated with a reduced risk of elevated CRP. These associations was stronger 
among women than men. 
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Several AD-related genes were found to influence risk for having CRP 
elevation. APOE-epsilon alleles were associated with CRP levels among elderly men 
and women. A major alleles of APOE (C/C) rs439401 and TOMM40 (A/A) rs157580, 
and minor alleles of MMP8 (T/T) rs1892886, CR1 (A/A) rs6656401, CR1 (A/A) 
rs3818361, and CR1 (A/A)  rs4844609 lowered the risk of elevated CRP among 
elderly men. These results emphasize the need to consider gene-environment 
interactions when searching for genes influencing AD risk.  
With the increased prevalence of AD and the association of systemic 
inflammation, the results of this dissertation may help identify factors important to 
AD etiology and, in turn, provide valuable targets for preventive intervention to 
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Alzheimer's Disease (AD) is an irreversible, progressive brain disease that 
slowly degrades the memory and thinking skills and ultimately eliminates the 
capability to perform the simplest tasks [1]. AD is the most common form of 
dementia. The Alzheimer’s Association documents that Alzheimer’s disease (AD) in 
the U.S. is the sixth leading cause of death for people who are 65 years or older. In 
2015, 5.3 million Americans of all ages had AD and 44 million worldwide [2].  
Evidence for the role of inflammation in AD still cannot be definitively stated 
whether inflammation is a cause, contributor, or secondary phenomenon in AD [3]. 
Biochemical and neuropathological evidence suggest that astrocytes and microglia are 
the major immune cells in the brain. In AD brain, astrocytes and microglia activate 
and release inflammatory mediators due to the presence of Aβ plaques and 
neurofibrillary tangles [4]. Until now, emerging evidence suggests that inflammation 
in AD is complex, and it involves interaction with multiple factors that challenge the 
researcher to find ways to tune inflammation to delay, prevent, or treat AD.  
Inflammation is the first step of a non-specific immune response that occurs in 
reaction to any bodily injury [5]. Inflammation can be acute or chronic [5]. When it is 
acute immediate and rapid response occurs to the site of tissue injury. Chronic 
inflammation occurs as a result of the progression of the acute inflammation, which 
may last for weeks or months, and in some instances, for years [6].  In the central 
nervous system, inflammatory components are linked to AD neuroinflammation. The 
production of a proinflammatory cytokines such as tumor necrosis factor α (TNF-α) 
plays a role in brain communication [7]. During infection, extensive communication 
between the immune system and the central nervous system, in which neural activity 
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is altered quite extensively during a peripheral infection [8]. Chronic systemic 
inflammation, as indicated by increases in inflammatory biomarkers were linked with 
an increase in cognitive decline in Alzheimer disease patients [7, 9-12].  
C-reactive protein (CRP) is the sensitive marker of acute-phase response to 
most forms of inflammation, infection, and tissue damage. Many cytokine levels 
including interleukin-1β (IL-1β), interluken-6 (IL-6), and tumor necrosis α (TNF-α) 
enhances CRP expression in humans [13]. It has been proposed that CRP predicts the 
incidence of many diseases including cancer [14], type 2 diabetes [15], coronary 
artery disease, heart attack [16], inflammatory bowel disease [17], arthritis [18], 
pelvic inflammatory disease [19], lupus [18], and AD [20].  
Scientific knowledge is far from complete regarding the relationship between 
peripheral blood inflammatory biomarkers and AD. However, scientific advances 
recently have been noticeably changing the understanding of the role of high levels of 
peripheral blood inflammatory biomarkers in AD patients [21]. Strong evidence 
suggest that CRP levels represented a strong risk predictor of systemic inflammation 
in 60 patients with Late Onset Alzheimer's Disease (LOAD), 35 patients with 
(Vascular Disease) VD, 25 subjects affected by cognitive impairment no-dementia 
(CIND), and 40 cognitively normal controls [22]. O'Bryant et al. observed the same 
when he evaluated CRP levels and compared 192 patients with AD with 174 non-
demented [23].  
Diet may influence the risk of AD and through its effects on systemic 
inflammation [24]. Dietary components are important factors that should be 
considered in inflammatory processes [25]. The Dietary Approaches to Stop 
Hypertension Diet (DASH) and the Mediterranean diet (MED) have been associated 
with protection against cognitive decline [26] and reduced risk for inflammatory 
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biomarkers and AD [27, 28].  In recent years, a rapidly increasing number of studies 
reported that due to the components of both diets components, the DASH and 
Mediterranean diets are considered to be anti-inflammatory [29, 30]. These findings 
support the hypothesis that DASH diet and the Mediterranean diet may be associated 
with inflammatory biomarkers level in several conditions such as myocardial 
infarction [31], diabetes [32], elevated triglycerides, elevated systolic and diastolic 
blood pressure, colorectal cancer, insulin resistance, HDL cholesterol [33, 34], and 
AD [27].  
The metabolic effects of some diets may be attributable to pro-inflammatory 
and anti-inflammatory properties [35] and their dietary constituents including aspects 
of the Western diet such as higher intake of the fats and processed meats [36]. Fatty 
acid is a carboxylic acid with a long aliphatic tail (chain), which is either saturated or 
unsaturated [37]. The two main essential fatty acids are linoleic acid (LA) omega-6 
fatty acid, and α-linolenic acid (ALA) omega-3 fatty acid [38]. Both omega-6 and 
omega-3 polyunsaturated fatty acids (PUFA) play important roles in the regulation of 
inflammation by being precursors of potent lipid mediators [39] and altering gene 
expression [40]. High intake of fatty fish or n-3 PUFA oil fish supplements may 
improve anti-inflammatory profiles by changing the production of lipid mediators and 
regulating immune responses [39]. Consuming refined vegetable oils rich in omega-6 
fatty acids and foods containing a low level of long-chain omega-3 fatty acids has 
been associated with an increase in inflammation levels [41] in some but not all 
studies.  
 Genes associated with AD may influence AD risk via their effects on 
inflammation.  It has been proposed that the overall chances of an individual 
developing AD is strongly influenced by a "susceptibility profile" reflecting the joint 
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effects of inheriting multiple high-risk alleles and environmental factors. In complex 
inflammatory diseases, inflammation gene polymorphisms may alter gene expression 
and function [42]. Gene polymorphisms in both acute and chronic inflammation 
produce different types of inflammatory responses [43]. The risk of AD was 
substantially affected by ten polymorphisms in many inflammatory biomarkers [44, 
45].  
Dissertation Hypotheses and Objectives 
The purpose of this study is to determine the extent to which dietary factors, 
erythrocyte membrane fatty acid, and genes, previously associated with C-reactive 
protein (CRP) markers of systemic inflammation among participants in the Cache 
County Memory Study. The specific objectives and hypotheses of this dissertation 
are: 
 
1. To determine whether healthy dietary patterns, defined by the DASH and 
Mediterranean diets, are associated with a reduced level of systemic 
inflammation as indicated by level of inflammatory CRP in plasma obtained 
from participants in the Cache County Memory Study (CCMS). 
2. To determine whether erythrocyte membrane fatty acids are associated with 
elevated levels of inflammatory CRP in the Cache County Memory Study 
(CCMS). 
3. To determine whether AD-related genes, identified in previous genome-wide 
association studies, are associated with elevated levels of inflammatory CRP 






This dissertation is divided into six chapters. Chapter 1 provides an 
introduction to the research along with outlines covering study objectives and 
hypotheses. Chapter 2 is titled “The role of diet, erythrocyte membrane fatty acid, and 
Alzheimer’s-related genes in systemic inflammation in the Cache County Memory 
Study: A Review.” This chapter provides the literature review of each of these three 
modifiers and evidence that they are related to the risk of systemic inflammation. 
Chapter 3 is titled “The role of dietary approach to stop hypertension and 
Mediterranean-style dietary patterns in systemic inflammation in the Cache County 
Memory Study.” This chapter examines the association between the dietary approach 
to stop hypertension and Mediterranean- style dietary patterns and CRP levels in the 
CCMS. Chapter 4 is titled “Erythrocyte membrane fatty acid concentration and 
systemic inflammation in the Cache County Memory Study.” This chapter examines 
the association between the erythrocyte membrane fatty acid composition and CRP 
levels in the CCMS. Chapter 5 is titled “The role of Alzheimer’s-related genes in 
systemic inflammation in the Cache County Memory Study.” This chapter examines 
the association between Alzheimer’s-related genes and CRP levels in the CCMS. 
Chapter 6 wraps up with a discussion of the findings and provides conclusions and 
recommendation for further research directions and practitioners. The references for 
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THE ROLE OF DIET, ERYTHROCYTE MEMBRANE FATTY ACID 
CONCENTRATION, AND ALZHEIMER’S- RELATED GENES IN SYSTEMIC 
INFLAMMATION IN THE CACHE COUNTY MEMORY STUDY: A REVIEW 
 
ALZHEIMER’S DISEASE (AD) 
Alzheimer's disease (AD) is an irreversible, progressive brain disease that 
slowly degrades memory and thinking skills and ultimately destabilizes the capability 
to perform the simplest tasks [1]. It is the most common type of dementia and 
gradually worsens over time. It accounts for an estimated 60 to 80 percent of all 
dementia cases. It affects memory, thinking, and behavior. Most often, AD is 
diagnosed in people over 65 years of age, but the less-prevalent, early-onset of 
Alzheimer's can occur at a much earlier age. In 2015, Alzheimer’s disease affected 5.3 
million Americans and 44 million people worldwide. Alzheimer's prevalence is 1 in 9 
older Americans. The Alzheimer’s is predicted to affect 1 in 85 people globally by 
2050. It accounts for over 226 billion dollars in annual costs in the U.S. alone and this 
is estimated to rise to 1.1 trillion by 2050 [2]. The National Center for Health 
Statistics 2015 indicates that Alzheimer’s disease is the United States’ sixth-leading 
cause of death for people who are 65 years or older [2].  The Alzheimer’s Association 
reported that between 2000 and 2025, the number of people with AD in Alaska, 
Colorado, Idaho, Nevada, Utah, and Wyoming is expected to double or more. In 
2015, the Utah percentage of AD will increase from 45% to 127% by the year 2025 
[2]. AD patients need help with daily activities such as bathing, dressing, using the 
bathroom, and eating [1, 3]. Patients lose their ability to communicate with others; 
they find it hard to recognize their loved ones, and they spend most of their time in 
bed with constant caregiver supervision. 
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The main features of AD include: memory loss, impaired judgment, 
disorientation, confusion, behavioral changes, and difficulty speaking, swallowing 
and walking [4]. The main early characteristics of Alzheimer's disease are the loss of 
neurons and synapses in the hippocampus. These losses caused significant atrophy in 
some affected areas [5, 6]. In 2009, Clifford and his colleague used magnetic 
resonance imaging (MRI) to study 21 healthy cognitively normal subjects, 32 with 
amnestic mild cognitive impairment, and 8 with Alzheimer's disease. In this study, 
they found that the brain size in AD patients became smaller over the time starting 
from the mild cognitive impairment stage and worsening until it developed into 
Alzheimer’s disease [7]. 
There are two types of AD: early onset and late onset [8]. The symptoms for 
early onset AD appear before age 60. Research has narrowed down the main genetic 
causes for some early onset as mutations in the amyloid precursor protein (APP) gene 
located on chromosome 21 and the presenilin gene (PSEN1& PSEN2) [8]. Having 
any of these mutated early onset AD genes indicates that this person will likely 
develop AD before the age of 60 and in some cases as early as age 30. This type of 
AD is called “familial” Alzheimer’s disease [9]. Early onset people tend to have 
shorter survival and these patients show more extensive functional and structural 
neuroimaging changes than late onset [10, 11]. Late onset Alzheimer’s disease 
(LOAD) is defined by the onset of symptoms after age 65. It has yearly incidence 
rates rising from 1% at 65–70 years to 6–8% at 85 years and older [12]. Genes play an 
important role in increasing AD risk, especially for LOAD [13].  
Even now it’s still hard to identify the main causes of Alzheimer’s disease. 
AD occurs as a result of many diverse risk factors rather than one single factor, and 
because of that, it is considered a multifactorial chronic disease [14]. Recent data 
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reports that genetic factors, physical activity, diet, social isolation, cardiovascular 
disease, and diabetes have been related to AD pathology [15].  For example, a diet 
high in vegetables, fruit, and fiber intake may lower neurodegenerative disorders risk 
by affecting the pathological processes of these diseases [16].   
 
Inflammation 
 The base word for inflammation is the Latin word “inflammare”, which means 
“to ignite or set on fire.” Cornelius Celsus, a Roman encyclopaedist, was the first to 
describe the symptoms of inflammation [17, 18]. Inflammation is a natural step of a 
non-specific immune response that occurs in reaction to any bodily injury. 
Inflammation can be acute or chronic [19]. When it is acute, an immediate and rapid 
response occurs at the site of the injured tissue. The main characteristics of acute 
inflammation are vascular and leukocyte responses, fluid accumulation, and 
inflammatory mediators such as cytokines. Acute inflammation has many 
macroscopic events that lead to rubor (redness), calor (heat), dolor (pain) and tumor 
(swelling) [18, 20]. The transformation from acute to chronic inflammation is still not 
completely understood. Excess proinflammatory mediators are a main characteristic 
of chronic inflammation [21]. Chronic inflammation occurs as a result of 
inflammatory progression in acute inflammation and may last for weeks or months, 
and in some instances for years [22]. Chronic inflammation is mainly characterized by 
tissue destruction and fibrosis combination due to the prolonged and repeated 
inflammation. Chronic inflammation involves complex interactions between several 
cell populations and their secreted mediators causing leukocyte activation and 
excessive infiltration that leads to resultant tissue damage and loss of function [20]. 
Chronic low-level inflammation is considered to be below the threshold of pain and in 
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some cases it is called “silent inflammation” [23]. 
  Both acute and chronic systemic inflammations are characterized by increases in 
inflammatory biomarker levels in blood such as C-reactive protein (CRP), cytokines, 
and chemokines [24]. In the central nervous system, acute and chronic systemic 
inflammatory responses may begin with the detection of either bacterial or viral 
invasions. When the immune response detects bacteria, products are produced that 
activate diverse innate immune responses such as nucleotide-binding oligomerization-
domain protein-like receptors (NLRs) and Toll-like receptors (TLRs) [25-27]. TLRs 
are a set of single membrane-spanning noncatalytic receptors that recognize 
structurally conserved molecules derived from microbes. Identification of bacterial 
products by TLRs and NLRs cause direct cell activation leading to the expression of 
many immune factors such as proinflammatory CRP, cytokines, and chemokines [28]. 
Mechanistic studies suggest that viral inflammation has many effects such as 
damaging the infected cells [29], destroying the body's immune system, altering the 
genetic material (DNA) of infected cells [30], or causing inflammation that can 
damage an organ [31]. 
 A large body of epidemiological evidence supports the hypothesis that 
peripheral inflammatory markers predict disease progression and determine whether 
therapies targeting these markers alter prognosis in patients with these diseases [32, 
33]. Many animal and human studies provide conflicting evidence about whether 
inflammatory markers are the direct causes of adverse events or if they simply are the 
result of illness in older adults [34]. When peripheral inflammatory markers were 
evaluated in elderly patients with Mild cognitive impairment (MCI), AD, and normal 
elderly, it was found that this method helped to detect early progression of both MCI 
and AD [35]. Another study concluded the same result when they measured tumor 
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necrosis factor α (TNF-α) in AD patients [33].  
 For a long time, the evidence of inflammatory processes in the pathogenesis of 
AD involvement has been acknowledged, however, the inflammation theory in AD 
pathology has recently surged to the surface [36]. The fact that diseases with a chronic 
systemic inflammatory component are risk factors for Alzheimer’s disease implies 
that crosstalk occurs between systemic inflammation and microglia in the Central 
nervous system (CNS) [37]. Microglial cells are considered the first line of defense in 
the CNS. In a healthy brain, microglia is relatively inactive, but in AD patients 
microglia are always switched on [38]. Neuroinflammation is recognized as a 
downstream consequence of amyloid theories causing activation of microglia and 
starting a pro-inflammatory cascade. These changes cause neurotoxic substances to 
release cytokines, chemokines, reactive oxygen and nitrogen species, and various 
proteolytic enzymes, inducing deteriorating changes in neurons [39]. It has also been 
proposed that microglia activation may cause phosphorylation of tau and the 
formation of neurofibrillary tangles (NFTs) [40, 41].  
 
C-reactive protein (CRP) 
C-reactive protein (CRP) is a nonspecific marker of an acute-phase response 
to most forms of inflammation, infection, and tissue damages [42]. Interleukin-1β (IL-
1β), interluken-6 (IL-6), and TNF-α are strongly induced by the expression of CRP in 
human [43] hepatocytes and hepatoma. Human atherosclerotic studies showed that 
indirect deposit of CRP from circulating cells or direct production of CRP by cells in 
the arterial wall [44, 45]. Additionally, human neuronal cells were found to produce 
CRP in Alzheimer’s disease patients [46]. CRP has also been found in renal cortical 
tubular epithelial cells, which can be a result of inflammatory stimuli [47].  
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CRP has several immune-related functions including: detecting the invading 
particle to the phagocyte, activation of classical complement binding, modulation of 
polymorphonuclear function [48], inhibition of growth and/or metastases of tumor 
cells and a few additional diverse activities [49]. Casas and his colleague reported that 
the normal function of CRP continues [50]. However, many extensive research 
projects reported that CRP has a beneficial role in both innate immunities against 
infection, appropriate, safe handling, and disposal of damaged autologous cells and 
lipids [50].   
Although, in normal healthy subjects CRP is at trace levels in plasma, high 
levels of CRP indicates that there is inflammation somewhere in the body [51]. The 
plasma half-life of CRP in humans is about 19 hours which is the same in all 
individuals regardless of circulating concentrations of CRP [50]. Despite many claims 
and assertions in the literature, genetic factors may affect the variation in the levels of 
CRP [52]. Factors including diet and smoking cessation remain critical tools for CRP 
reduction, and body mass index (BMI) has been associated with inflammatory 
mediators including CRP [53, 54].  
Indeed, CRP is the most extensively studied systemic marker of inflammation 
[55]. CRP levels have been used to predict the incidence of many diseases including 
cancer [56], type 2 diabetes [57], coronary artery disease risk, damage from a heart 
attack [58], inflammatory bowel disease [59], some forms of arthritis [60], pelvic 
inflammatory disease [61], lupus [60], and AD [62].  
Scientific advances have been noticeably changing over the last decades 
regarding our understanding of the role of high levels of CRP in AD patients. Cross-
sectional studies of AD patients and controls found that there were small differences 
in IL-6, but mean levels of CRP were significantly different between AD cases and 
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controls [63, 64]. Among 99 cases and 99 controls in a cross-sectional study, the 
results found high serum CRP levels among demented participants when they were 
compared with the controls. The same study also compared 34 AD patients with 64 
vascular dementia (VaD) patients by checking the CRP levels in both groups. The 
results indicated that AD patients had higher CRP levels than VaD [65]. An Italian 
population-based elderly cohort (n = 804, 53.2% women, mean age 74 years old), 
examined the relationships of baseline plasma CRP, serum IL6, plasma alpha-1-
antichymotrypsin, and hyperhomocysteinemia with the risk of incident Alzheimer’s 
disease (AD) and vascular dementia (VaD). The study found that CRP and IL-6 were 
the only inflammatory biomarkers related to the risk of VaD, but not with the 
prediction of AD risk [66]. O’Bryant et al., found the same result when they 192 
patients with AD and 174 non-demented controls and their CRP levels were evaluated 
[67]. 
 
Diet and Inflammation 
 
Numerous research studies indicate that dietary patterns have been used over 
the last few decades to analyze human health [68]. While many dietary patterns have 
been used in human health studies, much evidence shows that Mediterranean Diet [69, 
70] and Dietary Approaches to Stop Hypertension (DASH) are effective for a short 
and long term. Both diets are helpful in fighting or preventing metabolic diseases and 
are anti-inflammatory [71, 72]. 
Mediterranean Diet (MED) 
The Mediterranean Diet (MED) is a traditional dietary pattern from different 
countries bordering the Mediterranean Sea. MED is a boasting a modern nutritional 
recommendation inspired by the time tested way of eating traditional foods and drinks 
from these countries [73]. The Mediterranean Diet is rich in fruits, vegetables, 
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legumes, and complex carbohydrates, with a moderate consumption of fish, while the 
consumption of olive oil is the main source of fat, and with a low-to-moderate amount 
of red wine during meals [74]. This diet was noted by American scientist Ancel Keys 
stationed in Pioppi, Italy in 1945, but it didn’t gain national attention until the Seven 
Countries Study reported in 1960 that a Mediterranean Diet is a healthy diet [75].    
Many large epidemiologic studies in different cohorts showed that there is a 
positive association between Mediterranean Diet adherence and a reduction in the risk 
of mortality and the incidence of major chronic diseases [76, 77]. A systematic review 
of 12 studies with a grand total of 1,574,299 subjects reported that a high adherence to 
the Mediterranean Diet in southern Europe is associated with a 6% reduction in 
cancer, a 9% reduction in total cardiovascular mortality, and a 13% reduction in 
Parkinson’s and Alzheimer’s disease incidence [78]. Meta-analysis of a larger number 
of subjects and studies confirmed that Mediterranean Diet adherence was associated 
with a lower risk of major chronic degenerative occurrences [79]. Subsequently, these 
findings were confirmed by Francesco and colleagues, who reported a significant 
inverse relationship between higher adherences to Mediterranean Diet and a reduced 
risk of AD [80-82].  
 
Mediterranean diet (MED) and Inflammation 
Human observational studies:  
Strong evidence suggests that the Mediterranean Diet could serve as an anti-
inflammatory diet by reducing CRP concentrations in plasma that have a protective 
effect against several diseases [83, 84]. Two longitudinal studies reported that a 
significantly higher adherence to MED reduced CRP levels when a diet score was 
used to assess MED adherence. The Attica epidemiologic study in Greece examined 
the high adherence of MED in randomly enrolled 3,042 participants (1,514 men and 
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1,528 women). They found a higher adherence to MED had on average, 20% lower 
CRP levels when compared with lower adherence to MED [85]. Later, Panagiotakos 
et al. found that high adherence to MED had a protective effect that reduces CRP 
levels by 3.1% after controlling for age, gender, body mass index, physical activity, 
smoking status, diabetes and medication intake in myocardial infarction (MI) 
survivors. The study was performed in six European countries: Greece, Germany, 
Spain, Finland, Italy, and Sweden, which included 200 post-MI survivors [86]. Only 
one cohort study assessed the association between MED adherence, inflammatory and 
metabolic biomarkers, and risk of Alzheimer’s disease. This intervention diet had 
significantly reduced serum concentrations of hs-CRP, and 118 incident AD cases 
were identified among the 1,219 non-demented elderly (age ≥ 65) after four-year 
follow up [87]. The Nurses' Health Study conducted a study of 690 nurses and 
concluded that participants who were in the highest quintile of the diet score had on 
average 24% lower CRP levels as compared with those in the lowest quintiles [88]. 
Human experimental feeding studies:  
 Results from clinical trial studies have given contradicting findings. Six 
studies assessed whether there were significant associations between the 
Mediterranean Diet and sensitive markers of systemic inflammation for CRP. 
Esposito et al. wanted to determine the effect of MED on endothelial function and 
vascular inflammatory markers in 180 metabolic syndrome patients (99 men and 81 
women). When comparing patients who consumed the intervention diet (cases) with 
the control diet (control), better adherence to MED was associated with lower levels 
of hs-CRP [89]. The PREDIMED (Prevención con Dieta Mediterránea) study 
compared three dietary interventions: MED with supplemental virgin olive oil (VOO), 
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MED with supplemental nuts, and a low-fat diet. Among 112 participants, the study 
found that CRP levels decreased only in the MED group given virgin olive oil [90].  
Other studies confirmed the association between CRP levels and adherence to 
MED in individuals with metabolic syndrome. Estruch et al. demonstrated that the 
Mediterranean Diet plays an important role in decreasing inflammation by reducing 
lipid accumulation in atherosclerosis and diabetes patients. In the study, a low-fat diet 
(n = 257) compared with a Mediterranean Diet with those that consumed either free 
virgin olive oil, 1 liter per week (n = 257), or free nuts, 30 g/d (n = 258). The data 
showed that participants who were allocated to the Mediterranean Diet plus olive oil 
group were associated with a lower CRP concentration when compared with 
participants with a low fat diet and the Mediterranean Diet with olive oil groups [91]. 
Consistently, Viscogliosi et al. examined the associations between adherence to MED 
and the prevalence of metabolic syndrome. They found the MED score to be inversely 
associated with hs-CRP among 120 subjects [92].  
Studies reported no association between MED and inflammatory biomarkers:  
 Five studies found no association with high adherence to MED and lowered 
risk of developing systemic inflammation by reducing CRP levels. The studies by 
Michalsen [93] et al, Ambring et al [94], Dai et al [95], Salvadó [96], and Rallidis et 
al [97] showed no strong or consistent association between the MED and 
inflammatory markers. Two hospitals recruited 101 patients with established coronary 
artery disease (CAD) as verified by coronary angiography after undergoing diagnostic 
coronary angiography to consume the MED diet for 12 months. CRP, fibrinogen, 
fasting insulin, homocysteine, serum lipids and plasma fatty acids were measured 
before and after the intervention. The study found that following the MED diet had no 
effect on inflammation and metabolic risk factors in CAD patients [93]. Healthy 
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individuals consumed either the MED diet or an ordinary Swedish diet for four weeks. 
While MED lowered the number of platelet and leukocytes and vascular endothelial 
growth factor, it did not change CRP levels between the two diets [94]. Moreover, an 
investigation of psychological, behavioral, and biological risk factors for subclinical 
cardiovascular disease using twins in The Twins Heart Study (THS) found that a high 
adherence to MED did not help reduce CRP after adjustment for total energy intake 
and other nutritional factors. These results suggest that the association between MED 
adherence and systemic inflammation is unlikely to be affected by shared genetic and 
environmental factors [95]. A study of Spanish men and women with a high risk of 
cardiovascular disease by Salvadó did not find any association between adherence to a 
Spanish Mediterranean diet and reduced inflammatory markers. Concomitantly, they 
did find an inverse association between the high Spanish MED and hs-CRP levels. 
Also, hs-CRP ranked the lowest in those categories with the highest consumption of 
olive oil and nuts and IL-6 with the consumption of fruits and cereals [96]. A Greek 
study by Rallidis did not show any effect of MED on hs-CRP, but they found that 
endothelial function such as flow-mediated vasodilatation and diastolic blood pressure 
improved after consuming a Mediterranean Diet for two months [97].  
 
Dietary Approaches to Stop Hypertension (DASH) 
The Dietary Approaches to Stop Hypertension (DASH) diet is a dietary 
pattern developed by the U.S.-based National Heart, Lung, and Blood Institute to 
prevent and control hypertension [98]. DASH diet is characterized by a high 
consumption of fruits, vegetables, whole grains, and low-fat dairy foods, meat, fish, 
poultry, nuts and beans, and is limited in sugar-sweetened foods and beverages, red 
meat, and added fats [99].  
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Evidence gathered from studies conducted approximately a decade ago 
indicated that the DASH diet helps lower the risk of several diseases [100]. In 1999, a 
study of 459 adults found that a DASH diet may be an effective alternative to drug 
therapy in hypertension. It may also prevent hypertension in African-Americans when 
compared to Caucasians [101]. Obarzanek et al. demonstrated that the DASH diet 
may help reduce coronary heart disease in 436 randomized controlled outpatients 
[102]. Two case-control studies found significant associations between adherence to a 
DASH diet and blood pressure levels among patients with and without hypertension 
issues when comparing DASH with two other dietary patterns [103, 104]. A 
randomized crossover study of 12 obese patients with high-normal to stage 1 
hypertension and 12 lean normotensive volunteers found that following a DASH diet 
for four weeks raised antioxidant capacity, lowered blood pressure, and reduced 
oxidative stress [99].  Many studies have reported that a DASH diet may reduce the 
risk of contracting some cancers such as postmenopausal breast cancer [105] and 
colorectal cancer [71]; while the calcium in dairy products would help lower the risk 
of osteoporosis [105]. Wengreen et al. conducted a study to determine the associations 
between DASH and Mediterranean-style dietary patterns and age-related cognitive 
change in a prospective, population-based study. The study found that a higher 
adherence to DASH and MED was associated with higher levels of cognitive function 
in elderly men and women over an 11-year follow-up period [82].  
 
Dietary Approaches to Stop Hypertension and Inflammation 
In recent years, a rapidly increasing number of studies reported that the DASH 
diet contributes to a decrease of several risk factors such as triglycerides, systolic 
blood pressure, diastolic blood pressure, colorectal cancer, reduced insulin resistance, 
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and increase HDL cholesterol. All of these factors would support the role of the 
DASH diet in decreasing inflammation [71, 72]. A DASH diet improved 
neurocognitive function among 124 participants [106]. The DASH diet is considered 
an anti-inflammatory diet for diabetes patients because it helps to reduce liver 
aminotransferases and fibrinogen levels [107]. 
Human experimental feeding studies:  
A randomized crossover intervention trial was done of two diets, a high-fiber 
(30-g/d) DASH diet or fiber-supplemented diet (30 g/d) for three weeks. Among 35 
participants (18 lean normotensive and 17 obese hypertensive individuals), adherence 
to the DASH diet, including high fiber intake levels, helps to reduce CRP levels 
[108]. Similar results reported by Saneei et al. investigated the effects of the DASH 
diet on systemic inflammation markers in adolescents with metabolic syndrome. After 
six weeks of follow up among 60 post pubescent girls, CRP levels were reduced by 
the DASH diet among participants, but it had no effect on other inflammatory markers 
[109].  
Two crossover clinical trials by Azadbakht et al. provide evidence of the effect 
of DASH on CRP levels. The first study was of 42 postmenopausal women with 
metabolic syndrome. These women consumed either a DASH diet, soy nut diet, or soy 
protein diet for 8 weeks. Red meat in the DASH diet (one serving/day) was replaced 
by soy protein in the soy protein diet and by soy nut in the soy nut diet. The study 
found that replacing red meat with soy protein and soy nut lowered CRP levels more 
than consuming a regular DASH diet [110]. The second study was of 60 patients 
diagnosed with type 2 diabetes at the Shaheed Motahari Hospital of Fooladshahr in 
Isfahan, Iran. The participants received either a control diet that included a 
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macronutrient composition of 50–60% carbohydrates, 15–20% protein, 30% total fat, 
and a 5% energy intake from simple sugars and DASH which included fruits, 
vegetables, whole grains, and low fat dairy products, or a diet low in saturated fat, 
total fat, cholesterol, refined grains, and sweets. The data suggests a beneficial effect 
of DASH adherence in these participants because the decrease in CRP plasma and 
other inflammatory markers during the DASH diet period was greater than that of the 
control diet [111].  
Other observational studies have provided equally confusing results, with 
some findings suggestive, while others had statistically insignificant effects for DASH 
on CRP levels and others found no effects. A case-control study evaluated the 
association between inflammation levels and a low-fat/reduced-cholesterol diet versus 
the DASH diet. In this randomized study, 100 participants were assigned to receive 
either the DASH diet or the control diet for two weeks. The study found that the 
consumption of the DASH diet had no effect on CRP levels [112]. Similarly, Asemi et 
al. reported that the consumption of the DASH diet for four weeks in randomized 
controlled clinical trials of 32 pregnant women had no effect on CRP levels [113]. 
Another observational study by Shenoy et al. found no preventive effects from DASH 
on CRP in 81 (22 men and 59 women) participants with metabolic syndrome after 
consuming the DASH diet [114].  
Fatty Acids 
Fatty acids are carboxylic acids with short, medium, and long chains, which 
are either saturated or unsaturated. Most naturally occurring fatty acids have an even 
number of carbon atoms, from 4 to 28 [115]. The structured name for a fatty acid is 
based on the number of double bonds and the number of carbons in the acyl chain 
[116]. Saturated fats (SFA) have no double bonds in the fatty acid chain. In contrast, 
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unsaturated fatty acids contain either one double-bound monounsaturated fat (MUFA) 
or more than one in polyunsaturated fat (PUFA) [117, 118]. Essential fatty acids 
foods are the main source [119] including for linoleic acid (LA) omega-6 (n-6) fatty 
acid, and α-linolenic acid (ALA) omega-3 fatty acid (n-3) [120].  
Docosahexaenoic acid (DHA) is one of the major fatty acids in the brain. It 
plays an important role in the development of the human central nervous system 
[121]. There is a strong relation between a higher consumption of essential PUFAs 
and improved cognitive function [122]. Human studies found the high consumption of 
DHA increased IL-6 and IL-1 receptor antagonists which decreased levels of pro-
inflammatory markers [123, 124]. In 2009, The Academy of Nutrition and Dietetics 
reported that adequate DHA/EPA fatty acids may delay the onset of Alzheimer’s 
disease [125].  
 
Fatty acids and Inflammation 
Recent works highlight the importance of fatty acid consumption and 
inflammation levels. A growing body of literature shows strong correlations between 
SFA consumption and the inflammatory state of white adipose tissue [126]. It has 
been reported that a low consumption of SFA reduces the risk of CHD [127], liver 
disease [128], many metabolic disorders [129], all causes of death [130]. In 1965, 
Keys and his colleagues reported that a high intake of SFA and a low intake of PUFA 
increase deaths from coronary heart disease, cancer, and stroke. These findings lead to 
recommending higher PUFA consumption to replace SFA. In 2009, the American 
Heart Association (AHA) reported that a high intake of n-6 is safe and may be 
beneficial when it replaces with SFA [131, 132].  
Omega-3 FAs make up a family of PUFAs. Omega-3 metabolism starts with 
α-alpha linolenic acid (ALA). ALA is the simplest member of this omega-3 and it 
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converts to Eicosapentaenoic acid (EPA) which forms prostaglandin (PGE3) and 
docosahexaenoic acid (DHA). Both PGE3 and DHA have anti-inflammatory effects. 
Biochemical studies have suggested that AA competes with EPA for the same set of 
enzymes to form the long chain of PUFA derivatives [123, 124]. Strong evidence 
suggests that high intake of omega-3 fatty acids increases fatty acid levels in human 
immune cells, which leads to an improved anti-inflammatory profile by changing 
mediator production and regulating immune response [121]. Animal experiments and 
clinical intervention studies show that EPA and DHA have varied anti-inflammatory 
effects by managing inflammation and autoimmune disease [133], modulating the 
types and the amount of eicosanoids and cytokines, as well as altering gene 
expression [134]. These effects are based on dosage, time, and baseline characteristics 
of the subjects. Also, epidemiological observations from case-control studies found 
that fish oils help to reduce the activity of chronic inflammatory diseases and it 
naturally mimics anti-inflammatory drugs [135-137]. 
Until now, we are still unsure if n-6 fatty acids are harmful, harmless, or 
helpful. Omega-6 fatty acids is another family of PUFAs. In 1985, the National 
Academy of Sciences, the National Academy of Engineering, and the Institute of 
Medicine reported that fish consumption had dropped and vegetable oil consumption 
increased considerably [138]. Even then, scientists continued to debate over whether 
Americans and others on a typical Western diet are eating too much of n-6. Many 
epidemiological studies reported the negative effect of n-6 consumption on health, 
which causes increased risks of contracting several diseases [139-141]. Andoh 
reported that a higher consumption of a diet rich in omega-6 promotes immune 
responses by increasing the cytokine IL-6 level and limited mucosal damage [142]. 
Chapkin and his colleague used interleukin 10 (IL-10) knock-out mice to investigate 
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the association between n-6 and inflammation. The study concluded that chronic 
inflammation level was high in the group who consumed corn oil (n-6) than the other 
group who consumed fish oil (n-3) [143]. In Japan, a case control study of 111 
patients reported that high intakes of n-6 was associated with coronary heart disease 
(CHD) incidence [144] because n-6 increases the production of ROS from 
inflammatory cells [145]. Two cross sectional studies provide evidence of higher 
consumption of n-6 that has pro-inflammatory effects among Nonalcoholic fatty liver 
disease (NAFLD) patients. The first study was in 45 NAFLD patients (cases) 
compared with a sample of 856 (controls), matched for sex and age. The results of 
that study suggest that increased n-6 intake may contribute to neuroinflammation 
[146]. The second study was in 349 volunteers from the Israeli National Health and 
Nutrition Survey. Diet history assessed by food frequency questionnaires (FFQ) 
demonstrated higher meat intake and a tendency of having a lower intake of fish rich 
in omega-3 in NAFLD patients [147].  
Recently, researchers challenged the dogma of omega-6 as pro-inflammatory, 
because they report that omega-6 fatty acids have both anti-inflammatory properties 
and pro-inflammatory properties [131, 148, 149].  Relevant cell culture studies 
reported that omega-6 fatty acids have anti-inflammatory properties by inhibiting the 
production of interleukins, chemokines which reduces atherosclerosis progression 
[150]. Omega-6 has an anti-inflammatory effect on regulating PGE2 production from 
macrophages, which inhibits TNF-α synthesis [7] and lipoxins formation [9]. 
Likewise, two studies found that PPAR-alpha (PPARα) expression in pretreated 
cultured human endothelial cells and human aortic smooth-muscle cells were 
significantly expressing the anti-inflammatory effects of both n-6 (AA) and n-3 by 
suppressing nuclear factor-kB (NF-kB) signaling [151, 152]. PUFAs, both n-6 (AA) 
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and n-3, have anti-inflammatory properties due to the unsaturated double bond that 
inactivates reactive oxidative species (ROS) and inhibits the interaction with NF-kB 
[153, 154]. Concomitantly, human observational studies suggested that high plasma 
levels of omega-6 maintained a positive correlation to IL-10, which is the anti-
inflammatory cytokine [155]. Meanwhile, human experimental studies reported that 
feeding healthy volunteers 7 times (15g/d) the usual intake of AA for 7 weeks had no 
effect on platelet aggregation, bleeding times, the balance of vasoactive metabolites, 
serum lipid levels, or immune responses [156, 157]. Likewise, when habitual dietary 
intake was investigated among healthy men and women, the combination of total n-6 
and n-3 contributed to lowering the inflammatory biomarkers including TNF. 
Moreover, when participants consumed a high level of EPA, DHA, LA, and n-6 fatty 
acids did not suppress the effects of n-3 anti-inflammatory properties [158]. In Japan, 
two studies confirm that a high intake AA supplement had no effect on platelet 
function or any metabolic parameter [159] although it may have the ability to prevent 
CVD [160]. GLA is one type of omega-6 that has been studied for a while to explain 
the anti-inflammatory effects of omega-6 [161]. Moreover, some prospective cohort 
studies have not found significant associations between n-6 intake and hemorrhagic 
[162, 163], stroke or stroke mortality [164], and ischemic [162, 163, 165]. 
  Fatty acid composition of the modern Western diet has changed. Typically the 
ratio of n-6: n-3 in the Western diet has been estimated to be 15:1 to 16.7:1 [166, 
167]. High levels of n-6 intake could escalate in vivo susceptibility to low-density 
lipoprotein (LDL) oxidation that can promote vascular inflammation [168, 169]. Even 
though omega 3 has anti-inflammatory effects in humans, a high ratio of n-6: n-3 may 
increase pro-inflammatory cytokine production [170]. These changes might be a 
cause of the increase in inflammatory diseases [171, 172].  
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Until now, it’s still hard to be sure that diet may reduce IBD cases, it has been 
proposed that a high incidence of IBD is related to a high ratio of n-6:n-3 [173]. 
Animal studies are used trinitrobenzene sulfonic acid (TNBS) rat models to 
investigate the effect of n-6:n-3 with colitis [139]. Using TNBS model studies 
demonstrated that a diet rich in safflower oil (n-6) rather than omega-3 rich foods 
including cod liver oil and perilla oil increases colonic ulceration damage and 
inflammation levels including Leukotriene B4 (LTB4)
1
 levels [174-176]. Moreover, it 
has been proposed that consuming a diet with a high ratio of n-6:n-3 is related to the 
severity and the thickness of the inflammatory infiltrate [177] and it increases 
intestinal damage and inflammation during infection-induced colitis [173]. Fat-1 
transgenic mice revealed that low ratio of n-6:n-3 reduces pro-inflammatory 
cytokines, IL-6, and IFNγ and decreases the incidence of colitis [178]. Moreover, a 
recent prospective cohort study in Denmark examined the high levels of n-6:n-3 ratio 
in adipose tissue in ulcerative colitis (UC) patients (57,053 men and women). They 
found that inflammation was the interacting factor between diet and disease 
progressions by increasing inflammatory responses [179]. In colonic biopsies, high 
levels of n-6:n-3 ratio regulate LTB4 that are pro-inflammatory lipid mediators that 
have been correlated with IBD [180, 181].  
In Japan, a case control study of 111 patients reported that high intakes of n-6 
was associated with CD incidence [144] because n-6 increases the production of ROS 
from inflammatory cells [145]. In 2003, a double-blind, randomized controlled trial 
enrolled patients to assess the effect of a low ratio of n-6:n-3 and atherosclerotic 
plaques progression. Fewer plaques and thin fibrous caps and signs of inflammation 
were found in patients who consumed high n-3 fatty acids. However, the high n-6 
                                                             
1 Leukotriene B4 (LTB4) is a leukotriene involved in inflammation. 
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group had more plaques and thick fibrous caps with no signs of inflammation [182]. 
Table 2.1 illustrates the studies that have investigated the relationships between fatty 
acids and inflammatory biomarkers.   
To sum up, aggregate data from animal experiments, in vitro studies, and 
human observational and experimental feeding studies indicate that high n-6:n-3 
ratios may lead to increased risk of contracting many diseases 
Alzheimer’s-Related Genes and Its Associations with Systemic Inflammation 
Recent large genome-wide association studies (GWAS) have identified many 
genes/loci (CR1, BIN1, CLU, PICALM, MS4A4/MS4A6E, CD2AP, CD33, EPHA1, 
and ABCA7) that are associated with late-onset Alzheimer's disease (LOAD) [183]. 
Recent genetic data reveal that some risks of disease initiation, progression, and 
severity are linked to different gene alleles by affecting inflammation pathways. Gene 
diversity plays an important role in immunity, inflammation, and inflammatory 
disease [184]. For instance, Familial Cold Autoinflammatory Disease occurs as a 
result of single missense heritable mutation [185,186, 187].  
 
Alzheimer’s-Related Genes 
Apolipoprotein E (APOE) 
Apolipoprotein E (APOE) is a lipoprotein class that is found in chylomicron 
and intermediate-density lipoproteins (IDLs). APOE is essential to regulate 
triglyceride levels and metabolism and transport of cholesterol by binding to a 
specific receptor on the liver and peripheral cells and by the catabolism of 
triglyceride-rich lipoprotein constituents [188, 189]. Functionally, it contributes to 




Even though APOE is considered the strongest genetic risk factor for AD, it 
still accounts for only 10–20% of LOAD susceptibility when combined with 
environmental factors [192]. The results of meta-analysis have firmly established that 
apolipoprotein E epsilon polymorphism leads to the generation of APOE 2, APOE 3, 
and APOE 4, which are coded by three alleles ε2, ε3, and ε4 [193]. Later, 
rs439401was found to be another type of APOE polymorphism that displays an 
association with AD [194]. Very few studies have investigated putative associations 
between APOE rs439401 and triglyceride traits [194-196].  
Numerous data suggest that APOE has pro-inflammatory roles in the CNS 
[197, 198]. Brain biology and neurodegeneration studies suggest that APOE genotype 
ε4 has a role as an immunomodulatory agent and it has an effect on inflammatory 
mediators [199-201]. Other studies have focused on understanding the role of APOE 
in regulating acute inflammation [202] by increasing monocyte production of IL8 and 
TNF-α in human cells [203]. APOE and amyloid plaque association have been 
hypothesized to increase inflammation levels in the CNS by modifying beta-amyloid 
(Abeta)-induced glial activation [197]. Animal studies found that the APOE ε4 
genotype is associated with cytokines by increasing pro-inflammatory cytokines IL-6 
and TNF-α in mice that express human APOE [200, 204]. It has also been 
demonstrated that APOE deficiency in mice diminishes immune response, increases 
macrophage levels, and causes inflammation [205, 206].  
Furthermore, other features work the implication of the anti-inflammatory role 
for APOE. APOE genotypes ε2/ ε2 are thought to reduce inflammation levels when 
researchers mixed neuronal-glial cultures from APOE deficient mouse pups and 
measured the secretion of TNFα after stimulation with lipopolysaccharide (LPS), and 
when they compared the inflammatory responses of targeted-replacement mice 
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expressing the human gene after intravenous administration of lipopolysaccharide 
[207] [200]. Negative effects on the inflammatory responses occurred as a result of 
isolating APOE ε4 from peripheral blood mononuclear cells [208].  
BIN1 
Bridging integrator 1 (BIN1) is located on chromosome 2q14.3. BIN1 encodes 
many isoforms of nucleocytoplasmic adaptor proteins. BIN1 has many roles in the 
human body such as tumor suppression, transcriptional regulation, DNA repair, and 
cytoskeletal organization [209]. BIN1 isoforms have many biological functions in the 
central nervous system. BIN1 may be involved in synaptic vesicle endocytosis and 
may interact with endophilin, dynamin, clathrin, and synaptojanin [210]. Many mouse 
genetic studies reported that BIN1 is associated with a decreased risk of chronic 
inflammation in the liver, pancreas, heart, prostate [211], inflammatory bowel disease 
[212] cancer [213] and AD [214]. There are several isoforms of BIN1 that are 
expressed in the brain. Knockout mosaic mice show that BIN1 reduced inflammation 
levels when they are aging [215]. Another study of aged mice reported the benefits 
effects of having BIN1 by reducing inflammation and cancer susceptibility [216].  
Moreover, it has been found that BIN1 plays a role in cancer patients by suppressing 
the production of interferon-y (IFN-y), which is one kind of proinflammatory 
biomarker [217].  
CLU  
Clusterin (CLU) is a protein that can be found in the cytosol and is secreted 
under stress conditions, also known as apolipoprotein J [218]. A CLU gene may play 
a role in initiating the immune system because it is one of the phospholipid transfer 
proteins (PLTP), which links with apolipoprotein A-I – the major HDL protein [219]. 
It has several functions in neurodegenerative disorders, cell death, and tumor 
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progression [220]. CLU has a dual effect on inflammation. When CLU works as an 
anti-inflammatory, it enhances anti-apoptotic properties [221]. When CLU works as 
pro-inflammatory, it regulates a wide variety of stimuli that may increase the 
production of protein such as growth factors and cytokines  [222, 223]. CLU has been 
linked to several diseases such as diabetes, aging, degenerative diseases [222], 
atherosclerosis [222, 224], and increased the risk of AD 8.2% [223]. It has been 
hypothesized that CLU might have a protective role in neuroinflammation and AD 
[224, 225].  
CD2AP 
CD2AP is an 80-kDa CD2 protein, which was initially replicated from a 
protein that works together with the CD2’s cytoplasmic domain [226]. Extensive 
studies about human podocytes reported that low expression of CD2AP is associated 
with increased inflammatory biomarkers [227-230]. CD2AP plays an important role 
in the transportation of proteins and lipids within cells, and inflammation, and these 
are potential pathways for the development of Alzheimer’s disease. Other studies 
suggest that this association might happen as a result of gene variants that contribute 
to late onset AD [226].  The gene CD2AP plays an important role as a cerebral 
inflammation regulator, a process that is associated with the brain being inhabited by 
viruses, in a dormant state. Scientists have found that there is a high presence of 
inflammatory-related genes in the brains of people suffering from Alzheimer disease. 
Essentially, the genes that are associated with the risk of Alzheimer’s include CD2AP, 
which is also an inflammatory gene [231]. 
AGTR1 
Angiotensin II receptor, type 1 (AGTR1) is the main product of aldosterone 
secretion [232]. It helps control blood pressure and the cardiovascular system 
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capacity. AGTR1 is responsible for mediating the cardiovascular system by affecting 
angiotensin II [233]. An experimental study revealed the proinflammatory effects of 
AGTR1 in the lungs of chronic antigen exposure to rats [230]. There was a significant 
relationship between CRP levels and AGTR1 polymorphisms that led to increased 
inflammation levels in 42-year-old women recruited from a population registry [232],  
a case-control community-who acquired pneumonia [258], a case-control community-
who acquired pneumonia [234], and in a twin hypertension cohort [235].   
MPP7 
Membrane protein palmitoylated 7 (MAGUK p55 subfamily member 7) 
(MPP7) can be found in synapse adherence junctions [236]. MPP7 has been linked to 
increased inflammatory bowel disease, which may lead to malignant transformation 
of normal tissue [237]. A recent study found that MMP7 polymorphism probably 
helps manifestations within aspects of immune/inflammatory activity that are 
macrophage/monocyte-mediated [238] in ulcerative colitis [239]. The same result was 
observed in human [240] and mice epithelial cells [241]. 
MMP8 
Matrix metallopeptidase 8 (neutrophil collagenase) (MMP8) is a part of the 
MPP7 family. MMP8 helps break down the extracellular matrix in normal 
physiological processes such as tissue remodeling in embryonic development and 
disease processes [242]. The main function for MPP8 is to degrade type I, II and III 
collagens [243]. It has been proposed that the absence of MMP8 in mice has been 
linked to increased lung inflammatory responses by modulating two major products 
S100A8 and S100A9, which activate macrophages regulating cell damage [244]. 
Strong evidence suggests that having MMP8 enhances inflammatory biomarkers 
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including TNF-α and IL-1β in metabolic syndrome [245], ischemic stroke [246], and 
cancer [242, 247].   
TOMM40 
Translocase of outer mitochondrial membrane 40 homolog (yeast) (TOMM40) 
is an essential protein importer in mitochondria. It forms channels to translocase the 
mitochondrial outer membrane (TOM) complex [248]. TOMM40 locus is located 
close in linkage disequilibrium with APOE on 19q13.2. This gene encodes an outer 
mitochondrial membrane translocase involved in the transport of amyloid-β and other 
proteins into mitochondria that have been involved in AD progression [249, 250]. 
Concomitantly, APOE-TOMM40 genotypes have been revealed to modify disease 
risk and age at onset of symptoms. TOMM40 has been linked to CRP and triglyceride 
levels in Australian families [251]. TOMM40 was found to have a pro-inflammatory 
effect in metabolic syndrome of 85,500 participants from 14 large epidemiological 
studies within the Cross Consortia Pleiotropy Group [252], and in the Candidate gene 
Association Resource (CARe) study and race-combined meta-analyses that included 
29,939 additional individuals of European descent from CARe, and the Women's 
Health Initiative (WHI) [253].  
CR1 
Complement receptor 1 (CR1) can be found on leukocytes, glomerular 
podocytes, splenic follicular dendritic cells, and erythrocytes [254]. It encodes a 
monomeric single-pass type I membrane glycoprotein. CR1 helps to mediate and 
activate cellular binding to immune complexes and particles by activating T-cells 
[255]. CR1 has been associated with autoimmune and inflammatory disorders in the 





CD33 or Siglec-3 is a trans-membrane receptor expressed on cells of myeloid 
lineage and sometimes can be found on lymphoid cells [262, 263]. CD33 inhibits 
cellular activity because it contains immunoreceptor tyrosine-based inhibitory motifs 
that activate the intracellular portion. CD33 is considered as an immunoglobulin 
superfamily because it has immunoglobulin domains (one IgV and one IgC2 domain) 
that affect the extracellular portion in cells [264]. Many studies have shown that 
CD33 is associated with an increased risk of AD in a Caucasian population. A new 
study among the Chinese Han population revealed that a higher AD risk is associated 
with allele T in MS4A6A and allele C in CD33 [192, 265]. Later, inflammation was 
proposed as one way that CD33 affects AD [266].     
PICALM 
Phosphatidylinositol Binding Clathrin Assembly Protein (PICALM) is a 
clathrin assembly protein that recruits adaptor protein complex 2 (AP2) and clathrin 
[267]. Even though PICALM polymorphisms are associated with the risk of 
Alzheimer’s disease [268], this association is still far weaker than APP, PSEN1, 
PSEN2, and APOE [267].  
MS4A6A  
Membrane-spanning 4-domains, subfamily A, member 6A (MS4A6A) is a 
gene that encodes a member of the membrane-spanning 4A gene family [265]. 
Hematopoietic cells and nonlymphoid tissues are the unique expressions for MS4A6A 
in human. MS4A6A has different protein isoforms due to unusual splicing [269]. 
Membrane-spanning 4-domains, subfamily A, member 4E (MS4A4E) is a type of the 
MS4A gene family and it encodes at least four transmembrane domains C- and N-
terminal cytoplasmic domains that are encoded by distinct exons. MS4A6A has an 
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effect on T cell levels in humans [270] which may explain the proinflammatory 
effects in northern Han Chinese [266].  
ABCA7 
ATP-binding cassette, sub-family A (ABC1), and member 7 (ABCA7) are 
associated with the superfamily of ATP-binding cassette (ABC) transporters [271]. 
ABC proteins transport various molecules across extra- and intra-cellular membranes. 
It consists of seven distinct subfamilies (ABC1, MRP, OABP, MDR/TAP, ALD, 
GCN20, and White). The function of this protein is still unclear, however, the gene 
expression is related to lipid homeostasis especially cholesterol in cells of the immune 
system [272]. It has been believed that cytokine levels such as IFN-γ, IL-1β and 
platelet-derived growth factor (PDGF) may decrease ABCA7 expression. However, 
other cytokines such as IL-10 have been shown to increase ABCA7 expression [273, 
274].   
DTNA 
Dystrobrevin, alpha (DTNA) is a dystrophin-associated protein complex 
(DPC) and it has been identified as having different isomers when mutated [275]. This 
gene was found to be involved in the formation and stability of synapses and the 
clustering of nicotinic acetylcholine receptors. Studies had shown that DTNA gene 
polymorphisms are related to left ventricular defects when patients had congenital 
heart defects [275].  
HTR2C          
 5-Hydroxytryptamine (serotonin) receptor 2C, G protein-coupled (HTR2C) is 
a coupled receptor for 5-hydroxytryptamine and it is considered a neurotransmitter. In 
certain areas of the brain, this gene inhibits dopamine and norepinephrine releases by 




EPH receptor A1 (EPHA1) is a member of the protein-tyrosine kinase family 
in the ephrin receptor subfamily. EPHA1 has been found in some human cancer cell 
lines and has been associated with carcinogenesis [277]. EPHA1 has been linked to 
inflammation as it plays a role in apoptosis [201, 278]. It has been reported that 
EPHA1 plays an important role during endothelial cell activation by enhancing 
proinflammatory gene expression in mouse and human atherosclerotic plaques [279]. 
SORCS1 
The sortilin-related VPS10 domain containing receptor 1 (SORCS1) is one of 
the vacuolar proteins sorting 10 (VPS10) family members. It mediates intracellular 
protein trafficking and sorting [280]. It has many functions in a developing and 
maturing central nervous system, and it displays neuropeptide receptor activity [281]. 
SORCS 1 has been linked to AD pathogenesis by increasing Aβ production [282].  
PPP3R1          
 Protein phosphatase 3, regulatory subunit B, and alpha (PPP3R1), calcium 
dependent, have many functions such as by being a calmodulin stimulated protein 
phosphatase, and a regulatory subunit of calcineurin [283]. Mutation in this gene has 
been linked to increasing AD risk by affecting calcium signaling pathways [284].   
MAPT/STH 
STH is known as MAPT. The transcripts of MAPT can be found in the 
nervous system and it is expressed differently depending on the neuron type and cell 
maturation. Studies have shown that MAPT is related to many neurodegenerative 
disorders such as Pick's disease, front temporal dementia, corticobasal degeneration 
and progressive supranuclear palsy, and AD [285-287]. STH is considered to be like a 
tau protein and is linked to many neurodegenerative disorders [288]. In 2008, a study 
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conducted in China found that a polymorphism in STH may increase 
neuroinflammation and abnormal phosphorylation of TAU proteins in AD patients 
[289]. It has also been proposed that mutation in MAPT/STH may cause front 
temporal dementia [290].   
In conclusion, GWA is a great technique to discover novel susceptibility 
gene/loci for AD. All of these genes (APOE, BIN1, CLU, CD2AP, AGTR1, MMP8, 
MPP7, TOMM40, CR1, CD33, PICALM, MS4A6A, MS4A4E, ABCA7, DTNA, 
HTR2C, EPHA1, SORCS1, PPP3R1, MAPT/STH) have been associated with AD 
which may facilitate new research in human genetics and genomics with biological 









Type Inflammatory types 






Pentadecanoic acid SFA 
Pro-inflammatory No references found related to pro-inflammation 
 
Anti- inflammatory No references found related to ant-inflammation 
Palmitic acid SFA 
Pro-inflammatory [291-299]  
[300, 301] 
Anti- inflammatory No references found related to ant- inflammation 
Margaric acid SFA 
Pro-inflammatory No references found related to pro-inflammation 
 
Anti- inflammatory [302-304] 
Stearic acid  SFA 
Pro-inflammatory [294, 298, 299, 305-307]  
[300, 308] 
Anti- inflammatory [309] 
Arachidic acid SFA 
Pro-inflammatory No references found related to pro-inflammation 
 
Anti- inflammatory No references found related to ant-inflammation 
Behenic acid SFA 
Pro-inflammatory [298] 
 
Anti- inflammatory No references found related to ant-inflammation 
Lignoceric acid SFA 
Pro-inflammatory No references found related to pro-inflammation 
 
Anti- inflammatory No references found related to anti-inflammation 
Palmitoleic acid MUFA 
Pro-inflammatory [299] 
 
Anti- inflammatory [310-314]  
Oleic acid  MUFA 
Pro-inflammatory [315, 316] 
[317, 318] 




Pro-inflammatory No references found related to ant-inflammation 
 
Anti- inflammatory No references found related to pro-inflammation 
Erucic acid MUFA 
Pro-inflammatory No references found related to pro-inflammation 
 
Anti- inflammatory No references found related to ant-inflammation 
Nervonic acid MUFA 
Pro-inflammatory No references found related to pro-inflammation 
 





[322, 323]  
Anti- inflammatory [324, 325]  
Linoleic acid (LA) PUFA 
Pro-inflammatory [289, 291-293, 320, 326, 327] 
[296, 328, 329] 
Anti- inflammatory [330, 331]  
α-Linolenic acid  
(ALA)        
PUFA 
Pro-inflammatory No references found related to pro-inflammation 
 
Anti- inflammatory [126, 293, 320, 330-333] 
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Eicosadienoic acid PUFA 
Pro-inflammatory [334] 
 










Pro-inflammatory No references found related to pro-inflammation 
 




Pro-inflammatory No references found related to pro-inflammation 
 
Anti- inflammatory [126, 293, 320, 330-333] 
Arachidonic acid 
PUFA 
Pro-inflammatory [136, 292, 335, 337] 
[296, 338, 339]  
Anti- inflammatory No references found related to anti-inflammation 
Adrenic acid PUFA 
Pro-inflammatory No references found related to pro-inflammation 
[317] 
Anti- inflammatory 
No references found related to anti-inflammation 
Docosapentaenoic 
acid  n-3 
PUFA 
Pro-inflammatory No references found related to pro-inflammation 
 




Pro-inflammatory No references found related to pro-inflammation 
 




Pro-inflammatory No references found related to pro-inflammation 
 
Anti- inflammatory 
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THE ROLE OF THE DIETARY APPROACH TO STOP HYPERTENSION (DASH) 
AND MEDITERRANEAN DIETARY PATTERNS IN SYSTEMIC 
INFLAMMATION 
IN THE CACHE COUNTY MEMORY STUDY  
Abstract 
 Objective: To evaluate whether healthy dietary patterns, defined by the Dietary 
Approaches to Stop Hypertension (DASH) and Mediterranean dietary patterns 
(MED), are associated with a reduced level of systemic inflammation as indicated by 
levels of inflammatory CRP in plasma in a prospective, population-based study.  
 Design: Participants included 1,713 men and women ≥65 y at baseline of age 
who were residents of Cache County, Utah, in 1995. Diet-adherence scores were 
computed by summing across the energy-adjusted rank-order of individual food and 
nutrient components and categorizing participants into quintiles (Q) of the distribution 
of the diet accordance score. Multiple logistic regression models were used to 
examine the risk of elevated CRP level (> 3.0mg/L) across increasing quintiles of 
accordance dietary scores and individual food components that comprised each score. 
 Results: High adherence score to the DASH and MED dietary patterns were 
similarly associated with a reduced risk of elevated CRP (odds ratio for Q5 vs Q1: 
DASH (aOR= 0.74, 95% CI 0.53- 1.05; MED: aOR= 0.73 (0.52- 1.0)). This 
association appeared stronger among overweight and obese participants (DASH: 
aOR= 0.65 (0.41- 1.0), p-trend = 0.027; MED: aOR= 0.55 (0.35- 0.8), p-trend= 0.018) 
than among normal weight (DASH aOR= 0.86 (0.52- 1.4), p-trend= 0.46; MED aOR= 
0.98 (0.58- 1.6), p-trend= 0.916. Food component dietary scores associated with 
reduced risk of elevated CRP included nuts and legumes (DASH), legumes (MED), 
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fruits (MED), and high-fat dairy (MED) was associated with an increased risk; these 
food associations were generally not observed among the low-BMI participants.  
 Conclusions: The DASH and Mediterranean dietary patterns may play an 
important role in reducing systemic inflammation, especially in overweight and obese 
elderly persons.  
Introduction 
Systemic inflammation is a risk factor for the development of Alzheimer 
Disease (AD) [1]. AD is the most common form of dementia among aging men and 
women worldwide [2]. Studies in elderly patients with mild cognitive impairment 
(MCI), AD and normal elderly have suggested that measuring peripheral 
inflammatory markers including tumor necrosis factor α (TNF-α) in AD patients 
helped to detect early progression of both MCI and AD [3, 4]. Despite the 
complicated etiology of inflammation, C-reactive protein (CRP) is one of the 
strongest and most commonly reported inflammatory biomarker [5]. Concomitantly, 
CRP has been linked to many diseases including metabolic syndrome, diabetes, 
cardiovascular [6], and AD [7].  
Dietary quality scores method have been used widely to assess the relationship 
between diet adherence and CRP levels [8-10]. Two dietary quality scores of interest 
are the Mediterranean diet (MED) and the Dietary Approach to Stop Hypertension 
(DASH) scores. The Mediterranean diet is a traditional dietary pattern from different 
countries bordering the Mediterranean Sea. MED diet is characterized by a high 
consumption of fruits, vegetables, whole grains, full-fat dairy foods, meat, fish, 
poultry, nuts and beans. MED diet is also limited in sugar-sweetened foods and 
beverages, red meat, and added fats and includes a moderate consumption of alcohol 
[11]. Mediterranean diet is usually higher in n-3 (α-linolenic acid) and lower in n-6 
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(linoleic acid) which may explain the anti-inflammatory effects of MED diet. Olive 
oil is the primary fat in this diet [12]. Much epidemiologic research indicates that 
MED diet adherence was associated with beneficial health outcomes including 
improved quality of life [13-15], reduction in mortality risk,  and major chronic 
disease incidence [16, 17] such as cancer, cardiovascular mortality, Parkinson’s 
disease [18], and Alzheimer’s disease [14, 19-21].  
The Dietary Approaches to Stop Hypertension (DASH) was developed to 
lower and control hypertension by Appel and others and funded by the U.S.-based 
National Heart, Lung, and Blood Institute [22]. It includes a high consumption of  
fruits, vegetables, low fat and nonfat dairy, beans and nuts, with small amounts of 
lean meats, fish, poultry, and grains (at least 3 servings of whole grains per day), low 
intake of fats and sweets, and sodium intake should be limited to 2,300 mg each day 
[22, 23]. Evidence gathered from studies conducted approximately a decade ago 
indicated that the DASH diet helps lower the risk of several diseases including 
hypertension [24], coronary heart disease [25], stroke [24], cancer [26], osteoporosis 
[27], cognitive function [28], kidney diseases [29], bone health by reducing bone 
turnover [30], and AD [21, 31]. In the current study, we examined the associations 
between MED and DASH dietary adherence scores and systemic inflammation levels 
as indicated by levels of inflammatory CRP, using the data from the Cache County 
Memory Study (CCMS). 
Methods 
Study Participants and Data Collection 
The Cache County Memory Study is a prospective cohort study among elderly 
who were 65 years old and older in 1995 and who were permanent residents of Cache 
County, Utah. This population is largely non-Hispanic White and the genetic makeup 
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is mostly from Northern European ancestry. The institutional review boards of each 
collaborating site at Utah State University, Duke University Medical Center, and The 
Johns Hopkins University approved the protocol of the study.  
On January 1, 1995, trained personnel from Center for Epidemiologic Studies 
at Utah State University visited and interviewed 5,092 residents representing a 90 
percent response rate in the baseline interview. The baseline interview included 
information about demographic characteristics, health history, and family history of 
dementia, use of medications, alcohol, tobacco, other lifestyle factors, and extensive 
cognitive testing. Reassessments of this study were completed in different years with 
a decline in the screening sample size: Wave 2, 1998-1999, with 3,411; Wave 3, 
2002-2003, with 2,344; and Wave 4, 2005-2006, with 1,137. Details of the study 
protocols have been previously published [32].  
Diet Assessment 
A food frequency questionnaire (FFQ), patterned after the Nurses’ Health 
Study [33, 34], was used to assess usual dietary intake at the Wave 3 interview 
examination [21]. Many studies have shown that FFQ is an appropriate tool for 
populations of different demographic characteristics and different ages [34]. The Food 
Processor Program (ESHA Research, Portland) was used for the nutrient analysis. All 
nutrients from foods were adjusted for total caloric intake via the regression-residual 
methods of Willett [35]. Nutrient intakes from supplements were added to energy 
adjusted nutrient intake levels from food to obtain an accurate measure of total 
nutrient intake. 
In Wave 3, the FFQ included 150 food items with specified serving sizes 
described by using usual portions (e.g., 1 orange, 1 slice of bread) of the servings 
commonly consumed in this study population. For each food item, participants 
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indicated their average frequency of consumption over the past year in terms of the 
specified serving size by checking 1 of 9 frequency categories ranging from “almost 
never, <1 per month” to “≥6 times/d.” Participants were asked to report the name 
brands of some food items such as cereal and margarine. Also, participants were 
asked to list any food items that were not mentioned in the FFQ and report the serving 
size of that food and how many times they had it. The last part of the FFQ includes 
questions about following a specific diet such as: Do you follow a special diet? How 
many years do you follow it? Was the diet prescribed by a doctor? How many years 
have you been following this diet? What kind of diet did you follow? 
Mediterranean diet and DASH Assessment  
Based on the nutrient and food components, the Mediterranean diet (MED) 
and DASH diet adherence scores were computed. The Mediterranean diet contained 
eight components: a high intake of vegetables, fruits, grains, fish, legumes, and a ratio 
of monounsaturated fatty acids to saturated fatty acids (MUFA:SFA), low intakes of 
meat and meat products, and high-fat dairy products. Alcohol consumption was not 
used to define the MED diet score because of low rates of alcohols consumption in 
the population. The DASH diet adherence scores were contained the following 
components: a high intake of vegetables, fruits, nuts and legumes, whole grains, and a 
low intake of fat from dairy products, sodium, sweetened beverages, and red and 
processed meats. Both diet components were selected to represent food groups 
targeted in the DASH diet [36] and the Mediterranean diet [16] as described 
previously by Wengreen [21].  
Participants were categorized based on their consumption of each food 
component in both the Mediterranean and DASH diets including: fruits, vegetables, 
whole grains, total grains, full-fat dairy foods, nuts, legumes (nuts and legumes), 
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MUFA/SUFA ratio, and fish (Table 6). Based on the adopted method used by 
Wengreen et al., (Table 3.1). For each component, participants were ranked based on 
the distribution of food or nutrient component intake levels. Mediterranean diet 
adherence and DASH scores were determined by summing across the ranked scores 
of each relevant nutrient and food component. The sum score of the ranked scores of 
each relevant nutrient or food component defined the diet adherence scores. The score 
range for each food group is from 1-5. Therefore, higher values indicate greater 
adherence to the Mediterranean diet and DASH. Positive scoring meant that 
participants who consumed the lowest amount in the food group received a low rank 
score of 1, and participants who consumed the highest amount in the food group 
received the highest rank score. Inverse scoring study samples were arranged in the 
opposite order based on their intake levels of sweetened beverages, sodium, red and 
processed meat, and full fat dairy food. Negative scoring meant that the participants 
who consumed the lowest amount received the highest rank score; while participants 
who consumed the highest amount received a rank score of 1 [37, 38]. 
CRP assessment 
Blood samples were collected and assayed for CRP from participants in Wave 
3 at McKay Dee Hospital Laboratory, Ogden, UT by Dade Behring BNII (BN for 
Behring Nephelometer) for high-sensitivity CRP (hs-CRP) in 2002.  Dade's 
nephelometry method has been considered for quite some time as a gold standard for 
these tests in the laboratory industry [39].  Many large reference studies refer to the 
Dade BNII assay that uses particle enhanced immunonephelometry.  Dade was one of 
the first vendors to receive FDA approval for cardiac marker claims for their sensitive 
CRP assay [40]. The method uses polystyrene particles coated with mouse 
monoclonal antibodies to CRP that are agglutinated when mixed with samples 
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containing CRP [41].  The intensity of the scattered light in the nephelometer depends 
on the CRP content of the sample and, therefore, the CRP concentration. Typically, 
expected values for healthy individuals are found to be < 3.0 mg/L, or < 0.3 mg/dL 
[42]. The measuring range is determined by the lower limit of the reference curve and 
depends on the concentration of the standard used.  The typical limit of detection for 
the method was 0.175 mg/L or 0.0175 mg/dL. The upper level of detection was 
typically 1500 mg/L or 150 mg/dL. We defined elevated CRP as values >3.0 mg/L. 
 
Statistical Analyses 
SPSS version 22.0 was used for statistical analysis. The Analysis of Variance 
(ANOVA) test for continuous variables and Chi-square test for categorical were used 
to evaluate differences between quintiles of diet scores (Tables 3.2 and 3.3).  
Logistic regression analyses were used to evaluate the risk of elevated CRP 
(>3.0 mg/L) by quintiles of each dietary pattern score with quintile 1 as the reference 
category while controlling the potential confounding variables. Obesity is associated 
with systemic inflammation [43-45]; thus, we further examined whether the diet-
inflammation association was different among overweight and obese versus non-
overweight (body mass index ≥25 versus <25 kg/m2). Potential confounding variables 
included in the model were gender (male, female), age (years), body mass index (BMI 
weight in kilograms/ height in meters2), educational level (less than high school, high 
school, college and graduate), drinking and smoking habits (never, former, current); 
health variables included diabetes (no, yes), stroke (no, yes), and heart attack (no, 
yes), multivitamin and minerals use (yes vs. no), APOE genotype (no e4, 1 or 2 e4). 
Participants with no dementia (n= 154) were excluded from all analyses. Reported p-




The range of rank-order DASH and Mediterranean diet scores was 1,602 - 
14,049 and 2,033 - 13,525, respectively. The DASH diet scores and Mediterranean 
diet scores were positively correlated (r = 0.512, p-value <0.001). Participants in the 
highest quintile of DASH or Mediterranean diet scores were more likely to be women, 
more educated, less likely to have ever smoked or drank alcohol than were subjects in 
lower quintiles of either score. Participants in the highest quintile of the DASH or 
Mediterranean diet scores consumed less total fat, saturated fat, and cholesterol than 
did subjects in the lowest quintile of either diet score. Moreover, participants in the 
highest quintile of the DASH or Mediterranean diet scores consumed more fiber, 
vitamin C, folate, and vitamin B6, than did subjects in the lowest quintile of either 
diet score. The pattern of vitamin B12 intake was different between the two diet 
scores; no differences were observed across quintiles of the DASH diet score (P = 
0.218), but vitamin B12 intake was lower in quintiles 4 and 5 compared to the lower 
quintiles of the Mediterranean diet score (P = <0.001). Subjects in the highest quintile 
of either accordance score consumed more potassium, magnesium, and zinc than did 
subjects in lower quintiles. Calcium intake increased across increasing quintiles of the 
DASH score, but the pattern was the opposite for the MED quintiles. An increasing 
quintile of the DASH diet but not Mediterranean accordance scores was associated 
with decreasing sodium intake. An increasing quintile of the Mediterranean diet but 
not DASH diet accordance scores was associated with increasing omega-3 and 
omega-6 fatty acid intake. There was no association between DASH and MED scores 
with age, APOE genotype, diabetes, or stroke. The heart attack was significantly 
associated with the Mediterranean diet but not with the DASH diet. Conversely, CRP 
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and multivitamin and mineral use was significant with the DASH diet but not with the 
Mediterranean diet (Tables 3.2 and 3.3).  
Logistic regression analyses were used to evaluate the association between 
DASH and MED diet scores and elevated CRP levels (>3.0 mg/L). After controlling 
for covariates, The DASH diet score and MED diet score were similarly associated 
with a reduced risk of elevated CRP levels adjusted OR (aOR) and 95% confidence 
intervals (CIs)) for Q5 vs Q1: DASH (aOR=0.74 [95%CI 0.53- 1.05]30); MED 
(aOR=0.73 [95%CI 0.52- 1.0]). Nuts and legumes (DASH) and legumes (MED) were 
associated to reduce the risk of elevated CRP (aOR=0.72 [95%CI 0.51- 1.0]) and 
(aOR=0.75 [95%CI 0.54- 1.0]), respectively. Full fat dairy (MED) was associated 
with increased risk of elevated CRP (aOR=1.30 [95%CI 0.99- 1.9]), shown in Table 
3.4.  
Because obesity is associated with inflammation, we stratified the data by 
BMI to examine whether the associations between diet patterns and CRP differed in 
BMI strata. Mean plasma CRP concentrations were found in overweight and obese 
participants compared to non-overweight participants by using multiple logistic 
regression (Table 3.5) and (Table 3.6). Among overweight and obese persons there 
were significant decreases in plasma CRP across increasing DASH quintiles (aOR for 
quintile 5 vs. quintile 1= 0.65 [95%CI 0.41- 1.0]), MED (aOR = 0.55 [95%CI 0.35- 
0.89]), nuts and legumes (DASH) (aOR = 0.60 [95%CI 0.38- 0.94]), legumes (MED) 
(aOR = 0.59 [95%CI 0.38- 0.93]), fruits (MED) (aOR = 0.71 [95%CI 0.45- 1.1]). Full 
fat dairy (MED) (aOR = 1.4 [95%CI 0.96- 2.3]) was associated with increased CRP 
plasma across quintile 5 vs. quintile 1. In non-overweight and non-obese participants, 




Both MED and DASH scores were positively correlated with carbohydrate, 
fiber, total sugar, monosaccharide, disaccharide, vitamin B1, and vitamin B6, vitamin 
C, folate, pantothenic acid, copper, iron, magnesium, manganese, potassium, and zinc. 
The scores of MED but not DASH were positively correlated with intakes of vitamin 
B3, selenium, omega 3, and omega 6; the scores of DASH but not MD were 
positively correlated with phosphorus and calcium. Also, all three diet indices were 
negatively correlated with total fats, saturated fats, monounsaturated fats, cholesterol, 
vitamin B2, and caffeine. MED but not DASH scores were negatively correlated with 
intakes of total calorie intake, vitamin B12, calcium, and omega6:omega3 ratio; 
sodium was the only nutrients that are correlated negatively with DASH score (Table 
3.6). 
While the associations between DASH and MED diet patterns and reduced 
risk of elevated CRP appeared to be present only in overweight and obese persons and 
not among normal weight persons, there was not a significant multiplicative 
interaction between these diet patterns and CRP elevation ( p > 0.05).  
Discussion 
 Diet may influence the risk of Alzheimer’s disease through its effects on 
systemic inflammation [46]. Overeating of certain specific dietary components is an 
important factor that should be considered in inflammatory processes [43, 47].  We 
report a reduction in risk of having a high level of CRP among overweight and obese 
elderly Utah study participants who were free of dementia in the highest versus lowest 
DASH and MED quintiles. A higher consumption of nuts and legumes, included in 
the DASH score, and legumes, included in the MED score, were the food items most 
strongly associated with a reduced risk of elevated CRP. Other individual food items 
appeared to contribute to the protective effect of both patterns particularly fruits and 
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vegetables. Conversely, higher consumption of full fat dairy was associated with an 
increase in CRP level. 
 Evidence gathered from studies conducted approximately a decade ago 
indicated that obesity plays an important role in the inflammation [43, 48]. The 
initiation step of inflammation in obesity starts with overeating that activates 
metabolic signals in adipose tissues, causing the increased production of bioactive 
molecules called adipokines [49]. Adipokines are cytokines (small proteins) that 
function as hormones and growth factor and influence inflammatory cells such as 
macrophages. The main function of adipokines is to regulate food intake, glucose and 
fatty acid metabolism, and energy expenditure [50]. Then, low grade inflammation 
causes changes in macrophages in the adipose and muscle tissue of obese individuals, 
which encourages pro-inflammatory responses and disturbs the normal physiological 
function [43, 51]. Over time, nutrient excess distresses the immune cell responses 
from metabolic cellular signals and reinforces inflammatory pathways, which cause 
unresolved chronic inflammation [43]. In normal conditions, feeding induces a low 
level of inflammation, but after the nutrients are metabolized inflammation levels 
diminish. Compared with lean persons, obese persons tend to consume high calorie 
food causing high fat deposition in abdominal fat and fatty liver. Thus, the resolution 
of inflammation become less efficient which activates adipokines activity and 
increase cell death. Consequently, the production of inflammatory mediators increases 
including interleukin 1β (IL-β), TNF-α, and CRP [43, 52-55]. Because of the previous 
evidence regarding the relationship between obesity and inflammation, we examined 
the relationship between DASH and MED dietary patterns adherence and CRP levels 
among the group that we thought more vulnerable and susceptible to inflammation 
that are overweight and obese participants.   
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The Mediterranean diet (MED) is a modern nutritional recommendation 
inspired by the way of eating traditional foods and drinks in Mediterranean olive 
grove areas [56]. This diet is rich in fruits, vegetables, legumes, and complex 
carbohydrates, with a moderate consumption of fish. The main source of fat is the 
consumption of olive oil and a low-to-moderate amount of red wine during meals 
[57]. The conceptual origins of the “Mediterranean Diet” in human studies were 
expanded to reflect the typical dietary patterns followed mainly in Greece, Spain, and 
Southern Italy [58]. In the early 1960s, the Seven Country Studies (SCS) was the first 
to recognize the health benefits of MED diet. SCS participants were from the United 
States, Japan, Italy, Greece, Netherlands, Finland, and Yugoslavia. The SCS team 
found low rates in the prevalence of coronary heart disease and cancers [58].  
Our findings on the association between MED adherence and CRP were partly 
supported by previous human observational studies. A growing body of evidence 
suggests that Mediterranean diets could serve as an anti-inflammatory dietary pattern, 
which could help in fighting diseases that are related to chronic inflammation, 
including cardiovascular disease, metabolic syndrome diseases [59], and cognitive 
function [37]. Longitudinal studies reported a 3.2-20% reduction in CRP level among 
participants that consumed high levels of MED [60-62]. A significantly lower CRP 
level was found in three different populations including 180 metabolic syndrome 
patients, 690 nurses from The Nurses' Health Study, and 112 participants from 
PREDIMED (Prevención con Dieta Mediterránea), when comparing patients that 
consumed the intervention diet (cases) with the control diet (control) [10, 63, 64]. 
Two more clinical trials among individuals with metabolic syndrome participants 
have been conducted to estimate the prevalence of metabolic syndrome show that 
high consumption and strong adherence score to a Mediterranean diet had 
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significantly lowered pro-inflammatory CRP levels [65, 66]. However, other findings 
from human observational studies have been inconsistent. Five studies reported no 
preventive effect from strong adherence to MED diet on inflammatory biomarkers. 
Two Cohort studies found that high consumption of MED diet affects inflammatory 
markers TNF-α and IL-6 with no change in plasma levels of CRP [57, 67]. A study 
conducted in Spain, Greece, and Sweden showed no strong or consistent association 
between the Mediterranean Diet and inflammatory markers [68]. A crossover clinical 
trials from Spain, Greece, and Sweden showed no strong or consistent association 
between the Mediterranean Diet and inflammatory markers [69-71]. Another 
population-based case-control study using data from patients with coronary artery 
disease also did not reveal reduced CRP levels among these patients [72].   
Even though a significant association between DASH accordance and the 
sensitive biomarker CRP was found in our study, studies on the association between 
DASH and CRP levels have produced mixed results. The DASH diet found in many 
studies to decrease inflammation levels by decreasing blood triglycerides, systolic 
blood pressure, diastolic blood pressure, colorectal cancer, insulin resistance, and 
increased HDL cholesterol [73, 74] due to dietary pattern components. The DASH 
diet is considered an anti-inflammatory diet for diabetes patients because it helps 
reduce liver aminotransferase and fibrinogen levels [75]. King et al. and Saneei et al. 
both reported a significant reduction of CRP levels when DASH was followed for 
three weeks [76] and for six weeks, respectively [77]. Two crossover clinical trials 
have been conducted to examine the effect of metabolic syndrome and diabetes 
reported the beneficial effect of DASH adherence in these participants because of the 
decrease in CRP plasma and other inflammatory markers when was DASH consumed 
more [78, 79]. In contrast, Asemi et al. found that consumption of the DASH diet and 
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a control diet for four weeks for randomized controlled clinical tests of 32 pregnant 
women had no effect on CRP levels [80]. Similarly, an observational study did not 
reveal reduced CRP levels among participants with metabolic syndrome [81].  
 The mechanisms by which the DASH and MED diets might affect CRP are 
unknown. Nuts and legumes were the food group with the strongest anti-inflammatory 
association in our study. Many health benefits have been reported for legumes on 
blood lipids [82], low glycemic index [83]. Legumes include dried beans, peas, 
lentils, tofu, soybeans, and green beans, all of which are sources of dietary fiber and 
resistant starch, which are rich in proteins, oligosaccharides, dietary fiber, potassium, 
calcium, and magnesium, polyunsaturated fatty acids, and phytochemicals. Legumes 
are also good sources of L-arginine (a precursor of nitric oxide) and polyunsaturated 
fatty acids, which have anti-inflammatory effects [84, 85]. Many studies did not 
report an inverse association between high legume consumption and lower CRP levels 
[86-88], whereas one crossover study resulted in a reduction of CRP [89]. In 2015, a 
meta-analysis of eight studies with 464 participants reported that high consumption of 
non-soy legumes reduced CRP levels and had a significant effect on CRP in parallel 
studies [90]. Nuts are a good source of fiber, phenolic compounds and other anti-
inflammatories. Nuts are also rich in unsaturated fatty acids and contain sizeable 
amounts of L-arginine, which is a precursor of the endogenous vasodilator nitric 
oxide [91]. Nuts have been linked to reducing inflammatory biomarkers. A cross-
sectional study of 6,050 participants including Americans age 45–84 years report that 
high consumption of nuts was associated with lower CRP levels among the Multi-
Ethnic Study of Atherosclerosis [92]. The same result was observed in 339 men and 
433 women age 55-80 years at high cardiovascular risk [91]. Few studies report an 
association between the combination of nuts and legumes, the food group used in the 
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DASH score, and CRP. A systemic review of cohort studies found that high 
consumption of the combination of nuts and legumes helps to reduce the risk of 
depression [93]. Cross-sectional data from diabetes-free female participants in the 
Nurses’ Health Study of 3690 female age 30-55 concluded that nuts and legumes 
replacement for unprocessed red meat reduces inflammatory biomarkers CRP but 
after adjustment for BMI, the association did not demonstrate any significant 
difference [94].   
       In the present study, we found an association between increasing of full fat 
dairy, which is a negatively-scored MED component and elevated CRP levels 
similarly in overweight and obese and non-overweight and obese participants. Full fat 
dairy includes whole milk, chocolate milk, ice cream, cheddar and other hard cheese. 
In 2010, dairy consumption was associated with improved inflammatory profile by 
lowering inflammatory biomarkers [95]. In 2013, Kratz et al. reported that the 
beneficial effect of high fat dairy is still unclear, however, low fat dairy, which 
includes milk, yogurt, frozen yogurt, and cottage cheese, is related to many health 
benefits especially in metabolic syndrome markers including diabetes and blood 
pressure [96]. No previous study, to our knowledge, has reported an association 
between full fat dairy and CRP level. Da Silva et al. reported a correlation between 
adherences to dairy, which are composed of high and low levels of fat with CRP 
levels; the data suggest that strong adherence to dairy increases CRP levels. 
Concomitantly, the data reported that due to the study design, there was no causal 
relationship found between dairy intake and CRP levels [97].  
 To our knowledge, this is the first study that examines the multiplicative 
interaction between DASH and MED diet patterns and reduced risk of elevated CRP. 
Thus, further studies are needed to confirm our results.  
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The strength of the present population-based study is that the Cache County 
Memory Study (CCMS) is a large population-based study of white non-Hispanic 
elderly men and women. The Cache County Memory Study includes the repetitive 
detailed assessment of anthropometric and physiological variables at mean age of 74 
at baseline for the same individuals in different subsets of the cohort, which makes the 
present study population unique and appropriate for investigating the impact of 
DASH and MED diet adherence and related inflammatory marker CRP. Over the last 
two decades, Food Frequency Questionnaires (FFQ) become a widely accepted 
method to assess the usual intake and has been used widely in epidemiologic studies 
[98]. 
However, several limitations need to be acknowledged. Cache County 
Memory Study does not have a collection of blood for inflammatory markers at the 
Wave 1 baseline examination that would allow a prospective study of CRP levels and 
subsequent cognitive outcomes. We also used a single inflammatory marker, CRP, to 
determine the plasma level of inflammatory biomarkers, but due the complexity of 
systemic inflammation [94], examining multiple inflammatory biomarkers would help 
to strengthen our results.  
In conclusion, the results of the present study confirmed that MED and DASH 
are associated with lower risk of elevated systemic inflammation as indicated by CRP 
levels. This association appears to be modified by BMI, with overweight and the 
obese person having a stronger association than normal weight person. These results 
observed after controlling for gender, age, educational level, drinking and smoking 
habits, diabetes, stroke, heart attack, multivitamin and minerals use, and APOE 
genotype. MED is a formula for healthy day-to-day eating over a period, and people 
have eaten it for centuries, and adherents live longer with lower rates of heart disease, 
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cancer, and dementia. DASH diet was demonstrated to lower blood pressure. DASH 
also has been found to improve health by lowering cholesterol and preventing 
diabetes and increasing life expectancy. Thus, there is good scientific support 
recommending MED and DASH diets because both of these diets serve as anti-
inflammatory diets and offer health benefits that can promote substantial protection 
against many conditions influenced by inflammatory biomarkers.  
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Table 3.1: Food groups and nutrient scoring criteria for Mediterranean Diet (MED) 
score and Dietary Approach to Stop Hypertension (DASH) score; Cache County 
Memory Study (n =1713) 











All fruits and 100% fruit 
juices  
Positive 2.8 (2.0, 3.8) Yes Yes 
Vegetables 
(serv/d) 
All vegetables except 
potatoes and legumes  
Positive 2.7 (1.9, 3.8) Yes Yes 
All meat 
(serv/d) 
Beef, pork, lamb, 
chicken, turkey, liver, 
salami, bologna, hot 
dogs, bacon, sausage, 
other processed meats 





Beef, pork, lamb, liver, 
salami, bologna, hot 
dogs, bacon, sausage, 
other processed meats  
Inverse 0.63 (0.38, 1.1) Yes No 
Whole grains 
(serv/d)  
Dark bread or pita, 
whole-grain cold 
breakfast cereals, 
cooked cereal, oatmeal, 
popcorn, other grains 
(e.g. bulgur, kasha, 
couscous)  
Positive 1.5 (1.0, 2.5) Yes No 
Nuts (serv/d) 
Peanuts, peanut butter,  
other  nuts  
Positive
2
 0.35 (0.14, 0.86) Yes No 
Legumes 
(serv/d) 
Dried beans, peas, 




 0.34 (0.22, 0.57) Yes Yes 
Full-fat dairy  
(serv/d) 
Whole milk, chocolate 
milk, ice cream, cheddar 
and other hard cheese 
Negative 1.5 (0.89, 2.4) No Yes 
Low-fat 
dairy (serv/d) 
Skim or low-fat milk, 
yogurt, cottage or ricotta 
cheese  





including soda pop, 
punch, and other 
sweetened beverages  
Inverse 0.14 (0.00, 0.500) Yes No  
Fish (serv/d) 
Dark meat fish, other 
white meat fish 
Positive 0.16 (0.09, 0.27) No Yes 
 
MUFA/SUF
A ratio  
Ratio of total 
monounsaturated fatty 
acids/total saturated fatty 
acids 
Positive 0.11 (0.10, 0.12) No Yes 
Sodium 
(mg/d)  
Sum of sodium content 
of all foods 
Inverse 2653 (2033, 3416) Yes No 
 
1Positive scoring in Wave 3 of the CCMS: participant consuming the lowest amount received a rank 
score of 1, participant with highest amount received rank score of 1713; negative scoring: participant 
consuming the lowest amount received a rank score of 1713, participant with the highest amount 
received rank score  
of 1. 
2 Nuts and legumes combined for DASH-style diet pattern score. 
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Table 3.2: Participant characteristics by quintiles of the 8-component DASH diet 
score in the Cache County Study on Memory. 
Characteristic 










5694-  6815 
Quintile 3 

















4.9± 7.3 4.7± 6.5 4.3± 6.0  4.1± 6.0 4.0± 6.6 0.033 
Gender (%)  
- Male 
























25.9± 4.6 27.1± 4.7 26.3± 3.9 26.5± 4.2 25.6± 4.0 
<0.001 
More than high 
school education 
(%) 
17.8 20.5 17.9 15.3 14.7 <0.001 










   
18.5 20.0 20.1 20.1 20.8 
0.018 
At least one 
APOE e4 allele 
(%) 
18.6 20.7 18.1 19.1 23.1 0.434 
Diagnosed with 
diabetes (%)  
18.2 24.2 16.2 19.9 21.5 0.181 
Diagnosed with 
stroke (%) 
26.6 21.6 18.7 15.1 18.1 0.210 
Diagnosed with 
heart attack (%) 



















 79.4± 11.0 75.8± 12.8 73.0± 11 69.1± 10.9 66.0± 12.6 <0.001 
Carbohydrate (g)
4
 81.8± 19.7 83.9± 19.2 83.2± 18.5 86.9± 16.0 85.1± 17.6 0.014 
Protein (g)
4
 74.9± 14.9 75.3± 13.7 76.1± 13.4  74.8± 12.5  74.8± 13.3 0.340 
Saturated fats (g)
4











11.2± 3.4 11.5± 3.6 11.2± 3.2 11± 3.4 11.5± 3.6 0.321 
Ratio MUFAs to 
SFSAs 












9.2± 3.2 9.5± 3.4 9.3± 2.9 9.0± 3.1 9.6± 3.4 0.332 
Cholesterol (mg)
4
 333± 194  294± 141 276± 97 255± 947 236± 123 <0.001 
Fiber (g)
4
 15.7± 4.1 17± 4.4 19.8± 4.3 21.5± 4.2 24.8± 6.8 <0.001 
Vitamin C (mg)
4
 106± 49.8 117± 48.8 134± 47 144± 52.4 167± 62.6 <0.001 
Folate (µg)
4











5.1± 2.3 5.6± 2.9 5.4± 2.2 6.0±5.3 5.1± 2.2 0.003 
Sodium (mg)
4
 3019± 456 2901±532 2774± 509 3050±472 2523± 469 0.023 
Calcium (mg)
4
 813± 261  927± 305 968± 263 1055± 298 1057± 313 <0.001 
Potassium (mg)
4
 2637± 508 2902± 434 3095± 448 3287± 456 3588± 538 <0.001 
Magnesium (mg)
4
 253± 45 287± 43 304± 36 326± 39 357± 48 <0.001 
Zinc (mg)
4
 10± 2.7 10.6±2.9 10.7± 2.7 11.2± 3.1 11.1± 2.9 <0.001 
 
1 
p-values were obtained by using the Chi-square test for categorical variables and Analysis of Variance 
(ANOVA) for continuous variables. DASH, Dietary Approaches to Stop Hypertension; MVM, multivitamin-
mineral supplement; BMI, Body Mass Index, CRP, C-reactive protein. 
2
 Means ± standard deviation (SD). 
3
 An ever smoker was defined as a subject who reported ever regularly smoking; an ever drinker was defined 
as a subject who reported ever regularly drinking alcohol. 
4




Table 3.3 Participant characteristics by quintiles of the 8-component Mediterranean 
diet score in the Cache County Study on Memory. 
 
Characteristic 






















































26.5± 4.4 26.5± 3.9 26.6± 4.3 26.4± 4.3 26.0± 4.1 0.178 
More than high 
school education 
(%) 
18.6 17.9 19.0 20.1 24.3 0.004 
MVM use (%) 21.7 19.6 19.9 19.1 19.8 0.239 
Ever smoke (%)
3
 18.0 20.9 19.4 20.1 21.5 <0.001 
Ever alcohol (%)
3
 18.8 20.3 20.2 20.3 20.4 <0.001 
At least one APOE 
e4 allele (%) 
19.6 20.2 20.8 20.0 19.4 0.235 
Diagnosed with 
diabetes (%) 
19.9 20.4 20.0 20.5 20.0 0.787 
Diagnosed with 
stroke (%) 
20.2 19.8 19.6 20.3 20.1 0.486 
Diagnosed with 
heart attack (%) 


















 80± 11.8 75± 10.9 72± 11.3 70± 11.7 64± 11.6 <0.001 
 Carbohydrate (g)
4
 235± 29 247± 27 251± 27 260± 28 273± 29 <0.001 
 Protein (g)
4
 74.3± 14.4 75.5± 13.3 76.4± 13.9 75.5± 13.5 76.1± 12.8 0.402 
 Saturated fats (g)
4





27± 6.1 25± 5.8 24± 5.4 23± 5.6 22± 5.3 <0.001 
 Polyunsaturated (g)
4
 10± 3.3 10± 3.7 11± 3.4 11± 3.3 12± 3.4 <0.001 
 Ratio MUFAs to 
SFSAs 





0.95± 0.38 0.99± 0.43 1.1± 0.42 1.1± 0.43 1.3± 0.58 
<0.001 








 311± 160 297± 128 289± 165 266± 113 228± 97 <0.001 
Fiber (g)
4





 100± 47.9 122± 49.3 128± 46.8 147± 48.4 171± 61.6 <0.001 
Folate (µg)
4
 349± 88 395± 89.7 416± 87.2 445± 91.9 494± 108 <0.001 
Vitamin B-6 (mg)
4
 1.6± 0.44 1.8± 0.41 1.8± 0.44 1.9± 0.41 2.1± 0.45 <0.001 
Vitamin B-12 (µg)
4
 5.7± 2.8 5.5± 2.2 5.7± 5.3 5.3± 2.3 4.9± 2.3 <0.021 
Sodium (mg)
4
 2694± 569 2830± 506 2860± 533  2827± 520 3045± 471 0.421 
Calcium (mg)
4
 1046± 349 1013± 297 951± 298 913± 278 902± 257 <0.001 
Potassium (mg)
4
 2780± 530 3000± 507 3052±530 3235± 499 3466± 582 <0.001 
Magnesium (mg)
4
 271± 50 293± 43 299± 47 319± 46 347± 56 <0.001 
Zinc (mg)
4
 10.4± 2.7 10.7± 2.6 10.8± 3.2 10.8± 2.8 11.1± 3.03 0.135 
 
1 
p-values were obtained by using the Chi-square test for categorical variables and Analysis of Variance 
(ANOVA) for continuous variables. DASH, Dietary Approaches to Stop Hypertension; MVM, multivitamin-
mineral supplement; BMI, Body Mass Index, CRP, C-reactive protein. 
2
 Means ± standard deviation (SD). 
3
 An ever smoker was defined as a subject who reported ever regularly smoking; an ever drinker was defined 
as a subject who reported ever regularly drinking alcohol. 
4





Table 3.4: Odds ratio of clinically relevant elevation of  CRP (> 3.00 mg/L) by 
quintile of the DASH diet score, Mediterranean diet score, and their respective food 
items in the Cache County Memory (n = 1713). 





Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
DASH and components (multivariable adjusted)
1
 




Whole grain 1.00 [reference] 1.10 (0.82- 1.5) 0.89 (0.64- 1.2) 0.74 (0.53- 1.0) 1.00 (0.74- 1.4) 0.348 
Nuts and 
legumes 
1.00 [reference] 0.99 (0.71- 1.3) 0.86 (0.62- 1.2) 0.84 (0.60- 1.1) 0.72 (0.51- 1.0) 0.039 
Fruits 1.00 [reference] 1.20 (0.88- 1.7) 0.98 (0.70- 1.3) 1.00 (0.71- 1.4) 0.89 (0.63- 1.2) 0.249 




1.00 [reference] 1.20 (0.86- 1.6) 1.00 (0.72- 1.4) 1.30 (0.98- 1.9) 1.20 (0.89- 1.7) 0.136 
Low-fat 
dairy 
1.00 [reference] 1.00 (0.75- 1.4) 0.88 (0.63- 1.2) 1.20 (0.89- 1.6) 1.00 (0.77- 1.5) 0.366 
Sweetened 
beverages 
1.00 [reference] 0.66 (0.48- 0.9) 0.70 (0.50- 97) 0.78 (0.56- 1.0) 0.89 (0.64- 1.2) 0.801 
Sodium 1.00 [reference] 1.00 (0.74- 1.4) 1.20 (0.89- 1.4) 1.10 (0.79- 1.5) 1.10 (0.85- 1.6) 0.284 





1.00 (0.72- 1.4) 0.73 (0.52- 1.0) 1.00 (0.74- 1.4) 0.73 (0.52- 1.0) 0.131 
All grains  
1.00 [reference] 
0.94 (0.68- 1.3) 0.81 (0.58- 1.1) 1.00 (0.76- 1.4) 0.91 (0.65- 1.2) 0.864 
Legumes 
1.00 [reference] 
0.96 (0.69- 1.3) 0.74 (0.53- 1.0) 0.78 (0.56- 1.1) 0.75 (0.54- 1.0) 0.048 
Fruits 
1.00 [reference] 
1.30 (0.98- 1.9) 0.91 (0.65- 1.2) 1.00 (0.76- 1.5) 0.88 (0.63- 1.2) 0.204 
Vegetables 
1.00 [reference] 




1.00 [reference] 1.00 (0.73- 1.4) 1.00 (0.72- 1.3) 0.97 (0.70- 1.3) 0.93 (0.67- 1.3) 0.651 
Full fat 
dairy 1.00 [reference] 
0.94 (0.67- 1.3) 1.10 (0.81- 1.6) 1.40 (0.99- 1.9) 1.30 (0.99- 1.9) 0.006 
Fish 
1.00 [reference] 





0.70 (0.50- 0.9) 0.94 (0.67- 1.3) 0.91 (0.65- 1.2) 0.55 (0.54- 1.0) 0.514 
 
1
The multivariable model included the following covariates: age, sex, BMI, education, APOE, history of 





Table 3.5: Odds ratio of clinically relevant elevation of  CRP (> 3.00 mg/L) by 
quintile of the DASH diet score, Mediterranean diet score, and their respective food 
items in the Cache County Memory (n= 914): overweight and obese participants 
(BMI ≥25) only. 
 
Quintile of accordance score or food group 
p-linear 
trend 
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 
DASH and components (multivariable adjusted)
2
 
DASH 1.00 [reference] 1.05 (0.68- 1.6) 0.81 (0.68-1.2) 0.76 (0.49- 1.2) 0.65 (0.41-1.0) 0.027 
Whole grain 1.00 [reference] 1.00 (0.772- 1.4) 0.84 (0.61-1.1) 0.72 (0.52- 1.0) 0.99 (0.72- 1.3) 0.383 
Nuts and 
legumes 
1.00 [reference] 0.88 (0.57- 1.3) 0.74 (0.48-1.1) 0.55 (0.35- .88) 0.60 (0.38 - .94) 0.004 
Fruits 1.00 [reference] 1.20 (0.80- 1.9) 0.94 (0.61-1.4) 0.79 (0.51- 1.2) 0.77 (0.49- 1.2) 0.067 




1.00 [reference] 1.40 (0.93- 2.3) 1.10 (0.73- 1.8) 1.50 (0.95- 2.4) 1.30 (0.84- 2.1) 0.329 
Low-fat dairy 1.00 [reference] 0.96 (0.62- 1.5) 0.75 (0.47-1.2) 1.20 (0.81- 2.0) 0.98 (0.62- 1.5) 0.070 
Sweetened 
beverages 
1.00 [reference] 0.65 (0.42- 1.0) 0.19 (0.50-1.2) 0.61 (0.61- 1.4) 0.70 (0.46- 1.0) 0.505 
Sodium 1.00 [reference] 1.10 (0.71- 1.8) 1.20 (0.76- 1.9) 1.30 (0.86- 2.2) 1.20 (0.75- 1.9) 0.306 
Mediterranean and components (multivariable adjusted)
1
 
Mediterranean 1.00 [reference] 0.78 (0.50- 1.2) 0.62 (0.40-.97) 0.73 (0.47- 1.1) 0.55 (0.35-0.89) 0.018 
All grains  1.00 [reference] 0.89 (0.57- 1.3) 0.72 (0.46 1.1) 1.00 (0.66- 1.5) 0.78 (0.50- 1.1) 0.488 
Legumes 1.00 [reference] 0.87 (0.56- 1.3) 0.75 (0.48-1.1) 0.74 (0.47- 1.1) 0.59 (0.38-0.93) 0.021 
Fruits 1.00 [reference] 1.30 (0.86- 2.0) 0.85 (0.55-1.3) 0.89 (0.57- 1.4) 0.71 (0.45- 1.1)  0.049 
Vegetables 1.00 [reference] 0.74 (0.48- 1.1) 0.65 (0.42-1.0) 0.74 (0.46- 1.1) 0.66 (0.42- 1.0) 0.131 
Meat and 
meat products  
1.00 [reference] 0.86 (0.54- 1.3) 0.81 (0.52-1.2) 0.79 (0.50- 1.2) 0.86 (0.55- 1.3) 0.509 
Full fat dairy 1.00 [reference] 0.94 (0.60- 1.4) 0.97 (0.61-1.5) 1.30 (0.85- 2.1) 1.40 (0.96- 2.3) 0.020 




1.00 [reference] 0.73 (0.47- 1.1) 0.76 (0.49-1.1) 0.88 (0.56- 1.3) 0.63 (0.40- 1.0) 0.172 
 
1The multivariable model included the following covariates: age, sex, education, BMI, APOE, history of drinking 
and smoking, and history of diabetes, heart attack, and stroke. 




Table 3.6: Odds ratio of clinically relevant elevation of  CRP (> 3.00 mg/L) by 
quintile of the DASH diet score, Mediterranean diet score, and their respective food 
items in the Cache County Memory (n = 914): non-overweight and non-obese 
participants (BMI <25) only. 





Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 









































0.916 (0.55- 1.5) 1.30 (0.85- 2.1) 0.767 (0.46- 1.2) 1.20 (0.74- 1.9) 0.71 





1.30 (0.80- 2.3) 0.878 (0.51-1.4) 1.40 (0.90- 2.4) 0.980 (0.58-1.6) 0.91 
All grains  1.00 
[reference] 
0.968 (0.58- 1.6) 0.886 (0.52 1.4) 1.00 (0.62- 1.8) 1.07 (0.61- 1.7) 0.67 
Legumes 1.00 
[reference] 
1.20 (0.72- 2.01) 0.681 (0.40-1.1) 0.832 (0.49- 1.3) 1.00 (0.60- 1.6) 0.52 
Fruits 1.00 
[reference] 
1.4 (0.85- 2.4) 0.985 (0.58-1.6) 1.36 (0.808- 2.3) 1.10 (0.66- 1.8) 0.82 
Vegetables 1.00 
[reference] 
0.866 (0.52- 1.4) 1.05 (0.63- 1.7) 0.806 (0.48- 1.3) 1.12 (0.68- 1.8) 0.78 




1.26 (0.78- 2.0) 1.20 (0.77- 2.0) 1.20 (0.77- 2.0) 1.02 (0.60- 1.7) 0.86 
Full fat dairy 1.00 
[reference] 
0.928 (0.55- 1.5) 1.44 (0.67-2.3) 1.50 (0.94- 2.6) 1.50 (0.80- 2.2) 0.05 
Fish 1.00 
[reference] 
0.601 (0.35- 1.0) 1.09 (0.66-1.8) 0.915 (0.55- 1.5) 1.26 (0.77- 2.0) 0.13 
Ratio of 
MUFAs to SFA 
1.00 
[reference] 
0.689 (0.40- 1.1) 1.20 (0.77- 2.0) 0.976 (0.58- 1.6) 0.95 (0.58- 1.5) 0..69 
 
1
The multivariable model included the following covariates: age, sex, education, BMI, APOE, history of 




Table 3.7: Spearman rank order correlation coefficients of the CRP and 
Mediterranean Diet (MED) and the Dietary Approaches to Stop Hypertension 
(DASH) scores with nutritional factors; Cache County Memory Study. 
 
Nutrients 
Correlation with MED 
(p-values) 
Correlation with DASH 
(p-values) 
Correlation with  CRP 
(p-values) 
Total calorie intake  -0.071** (0.003) 0.000 (0.992) -0.015 (0.516) 
Protein  0.026 (0.278) 0.014 (0.591) 0.049* (0.049) 
Carbohydrate  0.421** (0.010) 0.063** (0.018) -0.026 (0.298) 
Fiber 0.639** (<0.001) 0.589** (<0.001) -0.063* (0.010**) 
Total sugar  0.076** (0.004) 0.134** (<0.001) 0.015 (0.556) 
Monosaccharide  0.409** (<0.001) 0.488** (<0.001) -0.030 (0.220) 
Disaccharide 0.272** (<0.001) 0.248** (<0.001) 0.006 (0.821) 
Total fats -0.424** (<0.001) -0.397** (<0.001) -0.004 (0.870) 
Saturated fats -0.612** (<0.001) -0.397** (<0.001) 0.014 (0.579) 
Monounsaturated 
fats  
-0.279** (<0.001) -0.182** (<0.001) -0.015 (0.553) 
Polyunsaturated  0.193** (<0.001) -0.003 (0.791) 0.061* (0.013) 
Cholesterol -0.228** (<0.001) -0.260** (<0.001) 0.073** (0.003) 
Thiamine (B1) 0.333** (<0.001) 0.292** (<0.001) -0.018 (0.473) 
Riboflavin (B2) -0.104** (<0.001) 0.241** (<0.001) 0.018 (0.458) 
Niacin (B3) 0.263** (<0.001) 0.044 (0.132) -0.026 (0.300) 
Pyridoxine (B6) 0.363** (<0.001) 0.324** (<0.001) -0.015 (0.381) 
Cobalamin (B12) -0.123** (<0.001) 0.031 (0.218) -0.022 (0.226) 
Ascorbic acid ©  0.435** (<0.001) 0.397** (<0.001) 0.030 (0.681) 
Folate 0.483** (<0.001) 0.387** (<0.001) -0.035 (0.151) 
Pantothenic acid 0.113** (<0.001) 0.324** (<0.001) 0.026 (0.295) 
Calcium  -0.179** (<0.001) 0.318** (<0.001) -0.011 (0.464) 
Copper  0.486** (<0.001) 0.409** (<0.001) -0.020 (0.418) 
Iron  0.355** (<0.001) 0.208** (<0.001) -0.033 (0.177) 
Magnesium  0.482** (<0.001) 0.699** (<0.001) -0.026 (0.293) 
Manganese  0.561** (<0.001) 0.576** (<0.001) -0.048 (0.051) 
Phosphorus  -0.029 (0.266) 0.355** (<0.001) 0.046 (0.062) 
Potassium 0.413** (<0.001) 0.598** (<0.001) 0.009 (0.713) 
Selenium  0.189** (<0.001) 0.020(0.458) 0.046 (0.063) 
Sodium 0.028 (0.282) -0.338** (<0.001) 0.018 (0.459) 
Zinc  0.052* (0.048) 0.139** (<0.001) 0.010 (0.671) 
Omega 3 0.268** (<0.001) 0.032 (0.462) -0.048 (0.054) 
Omega 6  0.192** (<0.001) 0.008 (0.757) -0.064** (0.010) 
Omega6:omega3  -0.126** (<0.001) -0.040 (0.095) 0.046 (0.395) 
Alcohol 0.096** (<0.001) 0.018(0.498) 0.004 (0.861) 
Caffeine  -0.107** (<0.001) -0.172** (<0.001) 0.046 (0.063) 
 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed). 
Note: Nutrients in which correlations are different between DASH, the Mediterranean Diet (MED), and C-








1. Holmes, C., Review: systemic inflammation and Alzheimer's disease. Neuropathol 
Appl Neurobiol, 2013. 39(1): p. 51-68. 
2. Alzheimer's, A., 2014 Alzheimer's disease facts and figures. Alzheimers Dement, 
2014. 10(2): p. e47-92. 
3. Bermejo, P., et al., Differences of peripheral inflammatory markers between mild 
cognitive impairment and Alzheimer's disease. Immunology letters, 2008. 117(2): p. 
198-202. 
4. Kamer, A.R., Systemic inflammation and disease progression in Alzheimer disease. 
Neurology, 2010. 74(14): p. 1157; author reply 1157-8. 
5. Emerging Risk Factors, C., et al., C-reactive protein concentration and risk of coronary 
heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet, 
2010. 375(9709): p. 132-40. 
6. Casas, J.P., et al., C-reactive protein and coronary heart disease: a critical review. 
Journal of Internal Medicine, 2008. 264(4): p. 295-314. 
7. Schultz, D.R. and P.I. Arnold, Properties of four acute phase proteins: C-reactive 
protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin 
Arthritis Rheum, 1990. 20(3): p. 129-47. 
8. Puglisi, M.J. and M.L. Fernandez, Modulation of C-reactive protein, tumor necrosis 
factor-alpha, and adiponectin by diet, exercise, and weight loss. J Nutr, 2008. 
138(12): p. 2293-6. 
9. Fung, Adherence to a DASH-style diet and risk of coronary heart disease and stroke in 
women (vol 168, pg 713, 2008). Archives of Internal Medicine, 2008. 168(12): p. 
1276-1276. 
10. Fung, T.T., et al., Diet-quality scores and plasma concentrations of markers of 
inflammation and endothelial dysfunction. American Journal of Clinical Nutrition, 
2005. 82(1): p. 163-173. 
11. Lopes, H.F., et al., DASH diet lowers blood pressure and lipid-induced oxidative stress 
in obesity. Hypertension, 2003. 41(3): p. 422-30. 
12. Whayne, T.F., Jr. and N. Maulik, Nutrition and the healthy heart with an exercise 
boost. Can J Physiol Pharmacol, 2012. 90(8): p. 967-76. 
13. Giugliano, D. and K. Esposito, Mediterranean diet and metabolic diseases. Current 
Opinion in Lipidology, 2008. 19(1): p. 63-68. 
14. Sofi, F., et al., Adherence to Mediterranean diet and health status: meta-analysis. 
British Medical Journal, 2008. 337(7671). 
15. Kant, A.K., Dietary patterns and health outcomes. Journal of the American Dietetic 
Association, 2004. 104(4): p. 615-635. 
16. Trichopoulou, A., et al., Adherence to a Mediterranean diet and survival in a Greek 
population. N Engl J Med, 2003. 348(26): p. 2599-608. 
17. Knoops, K.T., et al., Mediterranean diet, lifestyle factors, and 10-year mortality in 
elderly European men and women: the HALE project. JAMA, 2004. 292(12): p. 1433-
9. 
18. Sofi, F., et al., Accruing evidence on benefits of adherence to the Mediterranean diet 
on health: an updated systematic review and meta-analysis. Am J Clin Nutr, 2010. 
92(5): p. 1189-96. 
19. Sofi, F., et al., Effectiveness of the Mediterranean diet: can it help delay or prevent 
Alzheimer's disease? J Alzheimers Dis, 2010. 20(3): p. 795-801. 
20. Solfrizzi, V., et al., Diet and Alzheimer's disease risk factors or prevention: the current 
evidence. Expert Rev Neurother, 2011. 11(5): p. 677-708. 
21. Wengreen, H., et al., Prospective study of Dietary Approaches to Stop Hypertension- 
and Mediterranean-style dietary patterns and age-related cognitive change: the 
85 
 
Cache County Study on Memory, Health and Aging. Am J Clin Nutr, 2013. 98(5): p. 
1263-71. 
22. Grimm, R.H., et al., The Influence of Oral Potassium-Chloride on Blood-Pressure in 
Hypertensive Men on a Low-Sodium Diet. New England Journal of Medicine, 1990. 
322(9): p. 569-574. 
23. Sacks, F.M., et al., A dietary approach to prevent hypertension: A review of the 
Dietary Approaches to Stop Hypertension (DASH) study. Clinical Cardiology, 1999. 
22(7): p. 6-10. 
24. Obarzanek, E., et al., Effects on blood lipids of a blood pressure-lowering diet: the 
Dietary Approaches to Stop Hypertension (DASH) Trial. American Journal of Clinical 
Nutrition, 2001. 74(1): p. 80-89. 
25. Moore, T.J., et al., DASH (Dietary Approaches to Stop Hypertension) diet is effective 
treatment for stage 1 isolated systolic hypertension. Hypertension, 2001. 38(2): p. 
155-158. 
26. A dash of bleach boosts power of cancer vaccine. New Scientist, 2006. 189(2541): p. 
17-17. 
27. Noori, N., et al., Urinary Lithogenic Risk Profile in Recurrent Stone Formers With 
Hyperoxaluria: A Randomized Controlled Trial Comparing DASH (Dietary Approaches 
to Stop Hypertension)-Style and Low-Oxalate Diets. American Journal of Kidney 
Diseases, 2014. 63(3): p. 456-463. 
28. Smith, P.J. and J.A. Blumenthal, Diet and neurocognition: review of evidence and 
methodological considerations. Curr Aging Sci, 2010. 3(1): p. 57-66. 
29. Thoms, E., The DASH diet--is it a realistic option for people with kidney disease? 
CANNT J, 2005. 15(2): p. 58-9. 
30. Doyle, L. and K.D. Cashman, The DASH diet may have beneficial effects on bone 
health. Nutrition Reviews, 2004. 62(5): p. 215-220. 
31. Gu, Y. and N. Scarmeas, Dietary patterns in Alzheimer's disease and cognitive aging. 
Curr Alzheimer Res, 2011. 8(5): p. 510-9. 
32. Breitner, J.C., et al., APOE-epsilon4 count predicts age when prevalence of AD 
increases, then declines: the Cache County Study. Neurology, 1999. 53(2): p. 321-31. 
33. Willett, W.C., et al., Validation of a semi-quantitative food frequency questionnaire: 
comparison with a 1-year diet record. J Am Diet Assoc, 1987. 87(1): p. 43-7. 
34. Feskanich, D., et al., Reproducibility and validity of food intake measurements from a 
semiquantitative food frequency questionnaire. J Am Diet Assoc, 1993. 93(7): p. 790-
6. 
35. Willett, W.C., et al., Reproducibility and validity of a semiquantitative food frequency 
questionnaire. Am J Epidemiol, 1985. 122(1): p. 51-65. 
36. Vogt, T.M., et al., Dietary Approaches to Stop Hypertension: rationale, design, and 
methods. DASH Collaborative Research Group. J Am Diet Assoc, 1999. 99(8 Suppl): p. 
S12-8. 
37. Wengreen, H., et al., Prospective study of Dietary Approaches to Stop Hypertension- 
and Mediterranean-style dietary patterns and age-related cognitive change: the 
Cache County Study on Memory, Health and Aging. American Journal of Clinical 
Nutrition, 2013. 98(5): p. 1263-1271. 
38. Bach, A., et al., The use of indexes evaluating the adherence to the Mediterranean 
diet in epidemiological studies: a review. Public Health Nutrition, 2006. 9(1A): p. 132-
146. 
39. Ledue, T.B., et al., Analytical evaluation of particle-enhanced immunonephelometric 
assays for C-reactive protein, serum amyloid A and mannose-binding protein in 
human serum. Ann Clin Biochem, 1998. 35 ( Pt 6): p. 745-53. 
40. Center, U.o.W.M., D.o.L. Medicine, and I. Division, Laboratory Procedure Manual 
86 
 
C-Reactive Protein. United States Centers for Disease Control and Prevention, 2007. 
41. Wilkins, J., et al., Rapid automated high sensitivity enzyme immunoassay of C-
reactive protein. Clin Chem, 1998. 44(6 Pt 1): p. 1358-61. 
42. Kusnierz-Cabala, B., et al., Comparison of High-Sensitivity C-Reactive Protein Serum 
Assay Results Obtained Using Dade-Behring BNII Nephelometer and Ortho Vitros FS 
5.1 Clinical Analyzer in Respect of CRP-Related Risk Assessment of Chronic Metabolic 
Diseases. Clinical Laboratory, 2008. 54(9-10): p. 341-346. 
43. Gregor, M.F. and G.S. Hotamisligil, Inflammatory mechanisms in obesity. Annu Rev 
Immunol, 2011. 29: p. 415-45. 
44. Freeman, D.J., et al., C-reactive protein is an independent predictor of risk for the 
development of diabetes in the West of Scotland Coronary Prevention Study. 
Diabetes, 2002. 51(5): p. 1596-1600. 
45. Kohut, M.L., et al., Aerobic exercise, but not flexibility/resistance exercise, reduces 
serum IL-18 CRP, and IL-6 independent of beta-blockers, BMI, and psychosocial 
factors in older adults. Brain Behavior and Immunity, 2006. 20(3): p. 201-209. 
46. Migliore, L. and F. Coppede, Genetics, environmental factors and the emerging role 
of epigenetics in neurodegenerative diseases. Mutat Res, 2009. 667(1-2): p. 82-97. 
47. O’Connor, M.-F. and M.R. Irwin, Links between behavioral factors and inflammation. 
Clin Pharmacol Ther, 2010. 87(4): p. 479- 482. 
48. Medzhitov, R., Origin and physiological roles of inflammation. Nature, 2008. 
454(7203): p. 428-35. 
49. Hotamisligil, G.S., Inflammation and metabolic disorders. Nature, 2006. 444(7121): 
p. 860-7. 
50. Kwon, H. and J.E. Pessin, Adipokines mediate inflammation and insulin resistance. 
Front Endocrinol (Lausanne), 2013. 4: p. 71. 
51. Emilsson, V., et al., Genetics of gene expression and its effect on disease. Nature, 
2008. 452(7186): p. 423-8. 
52. Festa, A., et al., Elevated levels of acute-phase proteins and plasminogen activator 
inhibitor-1 predict the development of type 2 diabetes: the insulin resistance 
atherosclerosis study. Diabetes, 2002. 51(4): p. 1131-7. 
53. Watt, M.J., et al., Ciliary neurotrophic factor prevents acute lipid-induced insulin 
resistance by attenuating ceramide accumulation and phosphorylation of c-Jun N-
terminal kinase in peripheral tissues. Endocrinology, 2006. 147(5): p. 2077-85. 
54. Aljada, A., et al., Increase in intranuclear nuclear factor kappaB and decrease in 
inhibitor kappaB in mononuclear cells after a mixed meal: evidence for a 
proinflammatory effect. Am J Clin Nutr, 2004. 79(4): p. 682-90. 
55. Pradhan, A.D., et al., C-reactive protein, interleukin 6, and risk of developing type 2 
diabetes mellitus. JAMA, 2001. 286(3): p. 327-34. 
56. Hepburn, P., Italian cuisine: A cultural history. Library Journal, 2003. 128(14): p. 199-
199. 
57. Scarmeas, N., et al., Mediterranean diet and mild cognitive impairment. Arch Neurol, 
2009. 66(2): p. 216-25. 
58. Tyrovolas, S. and D.B. Panagiotakos, The role of Mediterranean type of diet on the 
development of cancer and cardiovascular disease, in the elderly: a systematic 
review. Maturitas, 2010. 65(2): p. 122-30. 
59. Alvarez Leon, E., P. Henriquez, and L. Serra-Majem, Mediterranean diet and 
metabolic syndrome: a cross-sectional study in the Canary Islands. Public Health 
Nutr, 2006. 9(8A): p. 1089-98. 
60. Chrysohoou, C., et al., Adherence to the Mediterranean diet attenuates 
inflammation and coagulation process in healthy adults - The ATTICA study. Journal 
of the American College of Cardiology, 2004. 44(1): p. 152-158. 
87 
 
61. Panagiotakos, D.B., et al., Mediterranean diet and inflammatory response in 
myocardial infarction survivors. International Journal of Epidemiology, 2009. 38(3): 
p. 856-866. 
62. Gu, Y., et al., Mediterranean diet, inflammatory and metabolic biomarkers, and risk 
of Alzheimer's disease. J Alzheimers Dis, 2010. 22(2): p. 483-92. 
63. Esposito, K., et al., Effect of a Mediterranean-style diet on endothelial dysfunction 
and markers of vascular inflammation in the metabolic syndrome - A randomized 
trial. Jama-Journal of the American Medical Association, 2004. 292(12): p. 1440-
1446. 
64. Mena, M.P., et al., Inhibition of circulating immune cell activation: a molecular 
antiinflammatory effect of the Mediterranean diet. American Journal of Clinical 
Nutrition, 2009. 89(1): p. 248-256. 
65. Estruch, R., et al., Effects of a Mediterranean-style diet on cardiovascular risk factors 
- A randomized trial. Annals of Internal Medicine, 2006. 145(1): p. 1-11. 
66. Viscogliosi, G., et al., Mediterranean dietary pattern adherence: associations with 
prediabetes, metabolic syndrome, and related microinflammation. Metab Syndr 
Relat Disord, 2013. 11(3): p. 210-6. 
67. Dai, J., et al., Adherence to the Mediterranean diet is inversely associated with 
circulating interleukin-6 among middle-aged men. Circulation, 2008. 117(2): p. 169-
175. 
68. Avellone, G., et al., Effects of moderate Sicilian red wine consumption on 
inflammatory biomarkers of atherosclerosis. Eur J Clin Nutr, 2006. 60(1): p. 41-7. 
69. Ambring, A., et al., Mediterranean-inspired diet lowers the ratio of serum 
phospholipid n-6 to n-3 fatty acids, the number of leukocytes and platelets, and 
vascular endothelial growth factor in healthy subjects. Am J Clin Nutr, 2006. 83(3): p. 
575-81. 
70. Salas-Salvado, J., et al., Components of the Mediterranean-type food pattern and 
serum inflammatory markers among patients at high risk for cardiovascular disease. 
Eur J Clin Nutr, 2008. 62(5): p. 651-9. 
71. Rallidis, L.S., et al., Close adherence to a Mediterranean diet improves endothelial 
function in subjects with abdominal obesity. Am J Clin Nutr, 2009. 90(2): p. 263-8. 
72. Michalsen, A., et al., Mediterranean diet has no effect on markers of inflammation 
and metabolic risk factors in patients with coronary artery disease. European Journal 
of Clinical Nutrition, 2006. 60(4): p. 478-485. 
73. Fung, T.T., et al., The Mediterranean and Dietary Approaches to Stop Hypertension 
(DASH) diets and colorectal cancer. Am J Clin Nutr, 2010. 92(6): p. 1429-35. 
74. Shenoy, S.F., et al., Weight loss in individuals with metabolic syndrome given DASH 
diet counseling when provided a low sodium vegetable juice: a randomized 
controlled trial. Nutr J, 2010. 9: p. 8. 
75. Erlinger, T.P., et al., Inflammation modifies the effects of a reduced-fat low-
cholesterol diet on lipids: results from the DASH-sodium trial. Circulation, 2003. 
108(2): p. 150-4. 
76. King, D.E., et al., Effect of a high-fiber diet vs a fiber-supplemented diet on C-reactive 
protein level. Arch Intern Med, 2007. 167(5): p. 502-6. 
77. Saneei, P., et al., The Dietary Approaches to Stop Hypertension (DASH) diet affects 
inflammation in childhood metabolic syndrome: a randomized cross-over clinical 
trial. Ann Nutr Metab, 2014. 64(1): p. 20-7. 
78. Azadbakht, L., et al., Soy consumption, markers of inflammation, and endothelial 
function: a cross-over study in postmenopausal women with the metabolic 
syndrome. Diabetes Care, 2007. 30(4): p. 967-73. 
88 
 
79. Azadbakht, L., et al., The Dietary Approaches to Stop Hypertension eating plan 
affects C-reactive protein, coagulation abnormalities, and hepatic function tests 
among type 2 diabetic patients. J Nutr, 2011. 141(6): p. 1083-8. 
80. Asemi, Z., et al., A randomized controlled clinical trial investigating the effect of 
DASH diet on insulin resistance, inflammation, and oxidative stress in gestational 
diabetes. Nutrition, 2013. 29(4): p. 619-24. 
81. Shenoy, S.F., et al., Weight loss in individuals with metabolic syndrome given DASH 
diet counseling when provided a low sodium vegetable juice: a randomized 
controlled trial. Nutrition Journal, 2010. 9. 
82. Bazzano, L.A., et al., Non-soy legume consumption lowers cholesterol levels: a meta-
analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis, 2011. 21(2): p. 
94-103. 
83. Sievenpiper, J.L., et al., Effect of non-oil-seed pulses on glycaemic control: a 
systematic review and meta-analysis of randomised controlled experimental trials in 
people with and without diabetes. Diabetologia, 2009. 52(8): p. 1479-95. 
84. Alizadeh, M., et al., Effect of L-arginine and selenium added to a hypocaloric diet 
enriched with legumes on cardiovascular disease risk factors in women with central 
obesity: a randomized, double-blind, placebo-controlled trial. Ann Nutr Metab, 2012. 
60(2): p. 157-68. 
85. Calder, P.C., et al., Dietary factors and low-grade inflammation in relation to 
overweight and obesity. Br J Nutr, 2011. 106 Suppl 3: p. S5-78. 
86. Abeysekara, S., et al., A pulse-based diet is effective for reducing total and LDL-
cholesterol in older adults. British Journal of Nutrition, 2012. 108: p. S103-S110. 
87. Winham, D.M., A.M. Hutchins, and C.S. Johnston, Pinto bean consumption reduces 
biomarkers for heart disease risk. Journal of the American College of Nutrition, 2007. 
26(3): p. 243-249. 
88. Winham, D.M. and A.M. Hutchins, Baked bean consumption reduces serum 
cholesterol in hypercholesterolemic adults. Nutrition Research, 2007. 27(7): p. 380-
386. 
89. Hartman, T.J., et al., Consumption of a Legume-Enriched, Low-Glycemic Index Diet Is 
Associated with Biomarkers of Insulin Resistance and Inflammation among Men at 
Risk for Colorectal Cancer. Journal of Nutrition, 2010. 140(1): p. 60-67. 
90. Salehi-Abargouei, A., et al., Effects of non-soy legume consumption on C-reactive 
protein: A systematic review and meta-analysis. Nutrition, 2015. 31(5): p. 631-639. 
91. Salas-Salvado, J., et al., Components of the mediterranean-type food pattern and 
serum inflammatory markers among patients at high risk for cardiovascular disease. 
European Journal of Clinical Nutrition, 2008. 62(5): p. 651-659. 
92. Jiang, R., et al., Nut and seed consumption and inflammatory markers in the multi-
ethnic study of atherosclerosis. American Journal of Epidemiology, 2006. 163(3): p. 
222-231. 
93. Sanhueza, C., L. Ryan, and D.R. Foxcroft, Diet and the risk of unipolar depression in 
adults: systematic review of cohort studies. Journal of Human Nutrition and 
Dietetics, 2013. 26(1): p. 56-70. 
94. Ley, S.H., et al., Associations between red meat intake and biomarkers of 
inflammation and glucose metabolism in women. American Journal of Clinical 
Nutrition, 2014. 99(2): p. 352-360. 
95. Panagiotakos, D.B., et al., Dairy Products Consumption Is Associated with Decreased 
Levels of Inflammatory Markers Related to Cardiovascular Disease in Apparently 
Healthy Adults: The ATTICA Study. Journal of the American College of Nutrition, 
2010. 29(4): p. 357-364. 
89 
 
96. Kratz, M., T. Baars, and S. Guyenet, The relationship between high-fat dairy 
consumption and obesity, cardiovascular, and metabolic disease. European Journal 
of Nutrition, 2013. 52(1): p. 1-24. 
97. Da Silva, M.S., et al., Associations between dairy intake and metabolic risk 
parameters in a healthy French-Canadian population. Applied Physiology Nutrition 
and Metabolism, 2014. 39(12): p. 1323-1331. 
98. Rimm, E.B., et al., Reproducibility and Validity of an Expanded Self-Administered 
Semiquantitative Food Frequency Questionnaire among Male Health-Professionals. 





ERYTHROCYTE MEMBRANE FATTY ACID COMPOSITION AND SYSTEMIC 
INFLAMMATION IN THE CACHE COUNTY MEMORY STUDY 
Abstract 
 Objective: To evaluate whether erythrocyte membrane fatty acids composition 
(EMFAs) are associated with elevated plasma inflammatory C- reactive protein (CRP) 
levels.  
 Design: 1844 men and women aged ≥65 years and older at the baseline 
participated in the Cache County Memory Study (CCMS) and who resident of Cache 
County, Utah. Fatty acid (FA) composition was measured in serum fatty acid methyl 
esters and were examined in relation to high-sensitivity C-reactive protein. 
Multivariable logistic regression models were used to estimate the risk of CRP 
elevation (> 3.0mg/L) by increasing tertiles of EMFA, with control for potential 
confounding factors. 
Results: Risk of elevated CRP was increased in tertile 3 vs. tertile 1 of 
palmitoleic acid, and nervonic acids, both monounsaturated fatty acids (MUFA), 
(aOR=1.7 [95%CI 1.3-2.2], aOR=1.3 [95%CI 1.0-1.6], respectively), and dihomo-y-
linolenic acid (DGLA), doco-sapentaenoic acid (DPA-6), docosahexaenoic acid 
(DHA), all polyunsaturated fatty acids (PUFA), (aOR=1.5 [95%CI 1.2-1.9], aOR=1.3 
[95%CI 1.0- 1.6], aOR=1.2 [95%CI 1.0- 1.6]), respectively. Conversely, risk of CRP 
elevation was reduced in tertile 3 vs. tertile 1 of margaric acid, stearic acid, and 
arachidic acid, all saturated fatty acids (SFA), (aOR=0.67 [95%CI 0.53- 0.89], 
aOR=0.78 [95%CI 0.60- 0.99], and aOR=0.69 [95%CI 0.53- 0.88]), respectively. 
These associations appeared stronger among women compared to men.  
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Conclusions: Several erythrocyte membrane fatty acids were associated with 
plasma CRP level, a marker of systemic inflammation. Unexpectedly, all associations 
with reduced CRP level were among SFAs and all associations with increased CRP 
level were among MUFAs and PUFAs.  
Introduction 
Alzheimer’s disease (AD) is a result of a neurodegenerative disease that 
affects memory and thinking skills [1]. The prevalence of AD increases with age [1] 
and the number of people with AD are growing due to physical inactivity, social 
isolation, cardiovascular disease, diabetes, and diet [2]. Neuro- and vascular 
inflammation may participate in the pathogenesis of AD [3] and markers of systemic 
inflammation have been associated with AD [4, 5].  
The underlying cause of systemic inflammation is unclear, but one 
contributing factor may be dietary fatty acids (FAs) [6, 7]. Serum and plasma fatty 
acid composition have been used as a biomarker of dietary fat quality [8-10]. FAs 
may contribute to pro-inflammatory and anti-inflammatory mechanisms [11]. This 
concept noticeably changes the understanding of the role of high intake of FAs in the 
western diet and inflammation [12].  
FA composition has been studied extensively in experimental, observational, 
and human health studies [13-17]. FA composition of plasma also affects endogenous 
elongation and desaturation catalyzed by several enzymes [18]. Omega-3 fatty acids 
(n-3) and omega-6 FAs (n-6) make up a families of polyunsaturated fatty (PUFA) 
acids that are essential in small quantities for health benefits because humans do not 
have the mechanisms to synthesize them [19, 20]. While omega- 3 FAs come from 
fish oils and flaxseed, canola, soy, perilla, and walnut oils [21], omega-6 FAs are 
mainly found in vegetable oils including palm, soybean, rapeseed, and sunflower [22]. 
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Docosahexaenoic acid (DHA), a long chain omega-3 FA, is one of the major FAs in 
the brain and has been hypothesized as anti-inflammatory. Animal and human trials 
studies have shown that DHA is associated with decreased CRP concentration [23-25] 
and other inflammatory biomarkers [26-36]. Concomitantly, omega-6 fatty acid 
consumption is still a controversial issue, because human observational and 
experimental studies suggest that n-6 fatty acids have both pro-inflammatory [37, 38] 
and anti-inflammatory [39, 40] effects.  
Given the increased interest in research in this area, FA composition of the 
diet among elderly will be the focus of much discussion and debate. In the present 
study, we examined the associations between erythrocyte membrane fatty acid 
composition and systemic inflammation levels as indicated by level of inflammatory 
CRP levels, using the data from the Cache County Memory Study (CCMS), also 
taking several potential confounding variables into account.  
Materials and Methods 
Study participants  
The Cache County Memory Study (CCMS) is a prospective cohort study with 
participants aged ≥65 years and older at the baseline who were a resident of Cache 
County, Utah. This population is largely non-Hispanic White, and the genetic makeup 
is mostly from Northern European ancestry. The baseline interview included 
information about demographic characteristics, health history, and family history of 
dementia, use of medications, alcohol, tobacco, other lifestyle factors, and extensive 
cognitive testing. Reassessments of participants were completed in subsequent years 
with sample size at the Wave 2 examination in 1998-1999, of 3,411; Wave 3 in 2002-
2003 with 2,344; and Wave 4 in 2005-2006 with 1,137. In Wave 3, a non-fasting 
venous blood sample, diet, and cognitive data were collected from 2252 participants. 
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Exclusions included 108 participants who did not complete a dietary assessment and 
62 who did not provide a blood sample. Moreover, 203 participants were eliminated 
from the analyses because the percent contribution of fatty acids in their erythrocyte 
membranes could not be determined, and an additional 7 were excluded because they 
provided implausible dietary intakes of <500 or >5000 kcal per day. The final sample 
size was 1987. Participants provided signed consent to participate. The institutional 
review boards of each collaborating site at Utah State University, Duke University 
Medical Center, and The Johns Hopkins University approved the protocol of the 
study. Details of the study protocols have been previously published [41].  
Fatty acid assessment  
Blood samples were drawn from the arm and were collected during the third 
examination Wave in 2002. Erythrocytes (red blood cells, RBCs) were analyzed by 
using the gas chromatography (GC) method. RBCs mixed with deionized water to 
direct transesterification after the sample was thawed, and then centrifuged at 10,000 
x g for 5 minutes [42]. The resulting product was mixed with 1.9 ml of a solution 
containing 1.7 ml methanol, 100 ul acetyl chloride, and 100 ul internal standards. The 
tubes were capped and then heated to 100 ul for 60 minutes. After cooling the tubes, 
0.75 ml of hexane was added and the tubes were vortexed for 30 seconds. A 
Shimadzu GC-2010 with a flame ionization detector was used to analyze fatty acid 
methyl esters [43]. The amount of analyzed EMFA was expressed as a percentage. 
The 23 EMFAs assayed are listed in Table 4.2.  
CRP assessment 
Non-fasting blood samples were collected and assayed for high- sensitivity C-
reactive protein (hs-CRP) from 2185 participants in Wave 3 at McKay Dee 
Laboratory Hospital, Ogden, UT. A Dade Behring BNII (BN for Behring 
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Nephelometer) was used for measurement, considered as a gold standard for these 
tests in the laboratory industry [44].  Many large reference studies refer to the Dade 
BNII assay that uses particle enhanced immunonephelometry.  Dade was one of the 
first vendors to receive FDA approval for cardiac marker claims for their sensitive 
CRP assay [45]. The method uses polystyrene particles coated with mouse 
monoclonal antibodies to CRP that are agglutinated when mixed with samples 
containing CRP [46]. The intensity of the scattered light in the nephelometer depends 
on the CRP content of the sample and, therefore, the CRP concentration. Typically, 
expected values for healthy individuals are found to be < 3.0 mg/L, or < 0.3 mg/dL 
[45]. The actually measuring range is determined by the lower limit of the reference 
curve and depends on the concentration of the standard used.  The typical limit of 
detection for the method was 0.175 mg/L or 0.0175 mg/dL. The upper level of 
detection was typically 1150 mg/L or 150 mg/dL. We clinically defined elevated CRP 
as values >3.0 mg/L [45]. 
Statistical Analyses 
Baseline characteristics were analyzed and presented by CRP levels. We 
reported selected sociodemographic variables, medical, and behavior characteristic of 
the participants. Percent composition of EMFAs was categorized into tertiles of the 
cohort’s distribution of each EMFA. 
Analysis of Variance (ANOVA) was used to test whether there were 
statistically significant differences between the means of EMFAs in elevated vs. 
normal CRP levels. Potential confounding variables including body mass index (BMI) 
(kg/m2, continuous), smoking (never, former, current), age in years (65-74, 75-84, 
85+), education levels (less than high school, more than high school), and gender 
(male, female) were evaluated. We estimated the odds ratio (ORs) and 95% confident 
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intervals (CIs) for CRP elevation by increasing tertiles of EMFA levels using logistic 
regression models while controlling for potential covariates. Gender was found in 
previous studies to be associated with habitual intake of fatty acids [47, 48] and it also 
appeared to differ the ability to synthesize fatty acids [49, 50], thus models for 
adjusted odds ratios included gender as a covariate and analyses were stratified by 
gender to examine effect modification by gender. Participants with no dementia (n = 
154) were excluded from all analysis. Statistical analysis was performed using 
software package SPSS version 22. Reported p-values are two-sided, and the type I 
error rate for statistical significance was 0.05. 
Results 
 Demographic characteristics are presented in Table 4.1. The average age was 
73 ± 5.5 years. Elevated CRP levels were found more often in women, the less 
educated, current smokers, and those with a history of stroke and was associated with 
higher BMI. Apolipoprotein (APOE) ε4 allele was associated with lower CRP levels.  
  Table 4.2 shows the relative percentage of the measured 23 EMFAs. Saturated 
fatty acids (SFAs) accounted for 47% of all identified fatty acids, trans-fat (TFA) 
accounted 0.43%, and monounsaturated fatty acid (MUFA) accounted 8.3%, and 
PUFAs accounted for 16.5%; the PUFAs included 4.98% omega-6 and 3.46% from 
omega-3. All EMFAs accounted for 78.39%, and the remaining 18.8% was accounted 
for plasmalogen phospholipids that are comportment of the red blood cell membrane. 
 In the one-way ANOVA analyses of mean CRP by tertile (T) of EMFAs 
(Table 4.3), higher mean CRP was associated with tertile 3 (T3) vs. tertile 1 (T1) of 
palmitic (p= 0.053), palmitoleic acid (p= <0.001), eicosadienoic acid (p= <0.005), 
dihomo-y-linolenic acid (DGLA) (p= <0.009), and docosapentaenoic acid (DPA-6) 
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(p= <0.002). Lower mean CRP levels were found with T3 vs. T1 of margaric acid (p= 
<0.001), arachidic acid (p= 0.001), and linoleic (p=0.05).  
 Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to 
estimate the relative risk for elevated plasma CRP across the EMFA tertiles, are 
shown in Table 4.4. In a multiple logistic regression analysis that controlled for BMI, 
smoking, age, education, and gender shown in Table 4.4, the estimated relative risk 
(adjusted OR (aOR) and 95% confidence intervals (CIs)) for having elevated CRP 
levels in T3 vs. T1 of total EMFA level was increased for palmitoleic acid (aOR=1.7 
[95%CI 1.3-2.2]), nervonic acid (aOR=1.3 [95%CI 1.0-1.6]), DGLA (aOR=1.5 
[95%CI 1.2-1.9]), DPA-6 (aOR=0.1.3 [95%CI 1.0- 1.6]), and Docosahexaenoic acid 
(DHA) (aOR=1.2 [95%CI 1.0- 1.6]). In contrast, the estimated relative risk for having 
elevated CRP levels was decreased in T3 vs. T1 of margaric acid (aOR=0.67 [95%CI 
0.53- 0.89]), stearic acid (aOR=0.78 [95%CI 0.60- 0.99]), and arachidic acid 
(aOR=0.69 [95%CI 0.53- 0.88]). 
 When the data were stratified by gender, palmitic acid, palmitoleic acid, and 
DGLA were more strongly associated with increased risk of elevated CRP risk among 
women (aOR=1.5 [95%CI 1.1-2.1]), (aOR=1.9 [95%CI 1.3- 2.7]), and (aOR=1.5 
[95%CI 1.1-2.2]), respectively, compared to men. Inversely, margaric acid and stearic 
acid were more strongly associated with reduced risk of elevated CRP in women 
(aOR=0.57 [95%CI 0.42- 0.80]) and (aOR=0.67 [95%CI 0.48- 0.93]), respectively, 
than among men. Lastly, arachidic acid was associated with decreased risk of 
elevation CRP (aOR=0.66 [95%CI 0.44- 0.97]) in both men and (aOR=0.67 [95%CI 
0.49- 0.93]) in women.  
 While the associations between erythrocytes fatty acids and risk of elevated 
CRP appeared to be stronger in women and not among men, there was not a 
97 
 
significant multiplicative interaction between these erythrocytes fatty acids and CRP 
elevation ( p > 0.05). 
Discussion 
 This study provides evidence that erythrocyte membrane fatty acids 
composition influence the risk of systemic inflammation among participants in the 
CCMS. Higher levels of palmitoleic acid and nervonic acid both MUFAs, and 
dihomo-y-linolenic acid, DPA-6, and DHA, all PUFAs, were associated with 
increased risk of elevation of CRP. Increased levels of margaric acid, stearic acid, and 
arachidic acid, all saturated FAs, were associated with a lower risk of CRP elevation. 
None of the other erythrocyte membrane FAs were significantly associated with CRP. 
These associations were found to be stronger for women vs. men. High level of 
arachidic acid an SFA was associated with a reduced the risk of elevated CRP among 
both men and women. 
 The results of a higher composition of erythrocyte membrane saturated fatty 
acids and lower CRP risk are consistent with other studies of margaric acid [51-53], 
but to our knowledge, no other study has examined the association between arachidic 
acid and inflammatory biomarkers. Until now, the mechanisms of margaric acid as an 
anti-inflammatory have not been well understood [51], and one observational study 
reported that the proportion of margaric acid was correlated negatively with 
inflammatory biomarkers in men and women [52]. Similarly, Wang and Fernandes 
demonstrated that margaric acid was associated with lower CRP levels among morbid 
obese patients [51] and adolescents [54].   
Findings from studies testing for the association between inflammatory 
biomarkers and stearic acid have also been inconsistent. In human feeding trials, high 
levels of stearic acid up-regulates interleukin-6 (IL-6) [55, 56], which is the primary 
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regulatory agent for CRP [57, 58]. In relevant human tissue culture studies, it was 
found that high level of stearic acid increased intercellular adhesion molecule (ICAM-
1) expression, which activates inflammation pathways [59]. Similarly, thioglycollate-
elicited mouse peritoneal macrophages (MPMs) were collected from knockout mice 
and showed that a high level of stearic acid up regulates pro-inflammatory signals 
causing ER stress–mediated apoptosis [60]. With this in mind, many potentially 
therapeutic and anti-inflammatory effects have also been proposed for stearic acid. 
Stearic acid attenuated cholestasis-induced liver injury in rats and had an anti-
inflammatory effect by reducing Alpha-smooth muscle actin (alpha-SMA); alpha-
SMA is the actin isoform that predominates in vascular smooth-muscle cells and plays 
an important role in fibrogenesis [61],which produces fibrogenic cytokine leading to a 
transforming of growth factor beta-1 (TGF-β1) production [62]. Moreover, a 
copolymer of fatty acids, composed of oleic acid, palmitic acid and stearic acid, called 
Ara 3000 beta reduced osteoarthritis symptoms due to the FAs anti-inflammatory 
effects in human [63] and dogs [64].  
 Findings from studies associating palmitoleic acid and inflammation have also 
been inconsistent. Previously, a serum FA pattern with high palmitoleic acid was 
linked to elevated CRP among Swedish elderly [65]. Two clinical trials reported that 
palmitoleic acid composition elevated inflammatory biomarkers [66] leading to an 
increase in the risk of metabolic syndrome [66]. The same result was found when diet 
and a low-density lipoprotein (LDL) receptor genotype were examined on 
macrophage foam cell formation within the peritoneal cavities of mice [67]. In a 
human adipocyte cell culture, palmitoleic acid induced pro-inflammatory effect by 
activating a Toll-like receptor-4/nuclear factor-kB (TLR-4/NF-kB) pathway [68]. In 
contrast, a prospective cohort study of 86 ambulatory patients and 45 healthy subjects 
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reported that palmitoleic acid was not associated with inflammation [69]. Until now, 
no study to our knowledge has investigated the effect of monounsaturated nervonic 
acid on plasma CRP level or any other inflammatory biomarkers. 
 Our results are not consistent with the reported anti-inflammatory effect of 
DGLA which is an omega-6 FA [39, 40, 70]. Metabolic studies reported that gamma-
linolenic acid (GLA) fatty acids convert to dihomo-γ-linolenic acid (DGLA) by 
competing with arachidonic acid (AA) to express an anti-inflammatory effect in cells 
by inhibiting enzymes that come from the breakdown of AA accumulation in cells 
[71, 72]. This inhibition reduces prostaglandin cyclooxygenase-2 (COX-2), 
lipoxygenase (LOX), and leukotrienes [73] causing a reduction of inflammatory 
molecules [74, 75] in lung function, autoimmune conditions, cardiovascular disease, 
and diabetes [71, 72].  
Our results confirmed the limited evidence that investigated Docosapentaenoic 
acid n6 (DPA-6) fatty acids [76, 77]. In rats, a high administration of DHA lowered 
the conversion of DPA-6 to arachidonic acid (AA) [77].  
  There is literature on using plasma and erythrocyte levels to reflect the 
measured dietary intake of fatty acids [43, 78, 79]. Due to the different structure and 
function properties of plasma and erythrocyte membrane, it is not surprising that level 
and the relevant composition of the FA is different between these two compartments 
of the blood [80]. Plasma measurement is considered the most immediate biomarker 
for each individual fatty acid [81, 82] because it reflects the dietary intake of the 
previous hours (triglyceride) or the past few days (cholesterol ester and phospholipid 
fatty acids). Erythrocyte measures of fatty acids are of interest for fatty acid analysis 
[82]. The half-life of erythrocytes has been estimated to be 120 days, which is much 
longer than that of plasma lipoproteins. Thus, erythrocytes reflect fat intake over 
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longer term [83, 84]. Sun et al. reported moderate-to-strong correlations between the 
dietary intake of n-3 fatty acids from marine origin and trans fatty acids and their 
levels in erythrocytes and plasma and the correlations with dietary intakes were 
stronger for erythrocytes than for plasma [85]. Because of these differences in long 
term stability FA analysis of erythrocytes is more suitable to test the association 
between long term FAs intake and inflammatory biomarkers [27, 86].  
Regarding fatty acid composition in human subjects, Petersson et al. [65] 
reviewed compilation of a studies on total plasma fatty acid composition in the 
elderly, and among the fatty acids analyzed, linoleic acid, oleic acid, and palmitic acid 
had the highest proportions, respectively. In the present study, palmitic acid and 
stearic acid had the highest proportions, respectively. Other studies with elderly 
showed a similar pattern compared to the results found in the current work, with high 
amounts of SFA and low amount of PUFA [87, 88] in the erythrocyte membrane. 
 The association between plasma CRP levels and DHA composition is unusual 
and requires further investigation. The literature on the association between DHA and 
high risk of CRP bring mixed results. Over the last decade, many biochemical and 
observational studies have suggested that DHA works as anti-inflammatory, which is 
not in line with our results [89-92]. Many observational studies reported that high 
consumption of omega-3 including DHA did not affect CRP levels among type 2 
diabetics, healthy individuals, and elderly [93-97].  Recently, a study of double 
blinded randomized trial of 2425 patients found that there was no effect of high 
consumption of EPA-DHA on CRP levels [98]. Ours is the first study to our 
knowledge that showed evidence of increased CRP risk among elderly participants 
who have higher levels of erythrocyte DHA. Biochemical studies have suggested that 
FAs compete for the same set of enzymes to form a long chain of PUFA derivatives 
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[13, 18, 99, 100]. Despite this finding, more studies are needed to confirm and explain 
the association between total DHA fatty acid composition and CRP levels, 
particularly in the elderly. 
In our analysis, we observed CRP levels were higher in women compared with 
men. Piéroni et al. reported that CRP values were higher among women than men 
when they measured CRP levels in healthy adults in Paris [101] and Rifai and Ridker 
reported the same results when they measured CRP levels in healthy men and women 
in the United States [102]. The relationship between gender and erythrocyte 
membrane fatty acids needs further work, but it appears that erythrocyte membrane 
fatty acids have a greater effect on CRP levels in women compared to men. 
To our knowledge, this is the first study that examines the multiplicative inter-
action between erythrocyte fatty acids and risk of elevated CRP. Thus, further studies 
are needed to confirm our results. 
Our study has several key strengths: the study is population-based of the 
elderly and relatively robust against selection bias because of higher participation 
rates.  EMFA assays also reflect the combination of dietary factors, metabolic and 
genetic effects. CRP was used to assess low grade systemic inflammation because a 
large amount of work using CRP has been done over the last two decades to assess 
inflammation levels in humans. Thus, our results are more valuable and reliable thru 
the use of CRP levels and a large number of study participants. The results of our 
analysis must be considered in light of its limitations chiefly that the analysis was 
cross-sectional as the Cache County Memory Study did not have a collection of blood 
for CRP at the Wave 1 baseline examination that would allow for a prospective study 
of CRP levels and subsequent outcomes. 
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In this Cache County cohort of elderly participants, increasing levels of 
palmitoleic acid and nervonic acid, both MUFAs, and dihomo-y-linolenic acid, 
docosapentaenoic acid n6, docosahexaenoic acid, all PUFAs, were associated with 
elevates CRP. Conversely, increasing levels of margaric acid, stearic acid, and 
arachidic acid, all SFAs, were related to decreased CRP. The relationship between 
CRP and another FA was not significant even after controlling the covariates. 
In summary, our results suggest that the higher SFA composition of EMFAs 
including margaric, stearic, and arachidic fatty acids are anti-inflammatory. 
Concomitantly, our finding suggests that higher levels of the MUFAs palmitoleic and 
nervonic and the PUFAs DGLA, DPA-6 and DHA are pro-inflammatory. Further 
prospective and experimental studies should be conducted to gain a better 
understanding of the controversies regarding dietary intake of FAs, cell membrane FA 




Table 4.1: Demographic characteristics by level of C- reactive protein (CRP) in the 
Cache County Study on Memory, Health and Aging in Wave 3 (N= 2031). 
Characteristic 
Plasma CRP composition (mg/L) 
 p-value
1 
<3.0 (mg/L) >3.0 (mg/L) 
Gender  
- Male (%) 








- Less than high school education (%) 






Age in years (SD)
2
 73.0± 5.4 73.1± 5.5 0.480 




  25.9± 4.0 27.2± 4.4 <0.001 
Current smoke (%)
3
  1.4 2.9 0.042 
Current alcohol (%)
3
   4.4 3.7 0.442 
At least one APOE e4 allele (%) 35.8 26.2 <0.001 
Diagnosed with diabetes (%)  17.4 20.0 0.078 
Diagnosed with stroke (%) 7.3 10.1 0.018 
Diagnosed with heart attack (%) 14.4 16.0 0.178 
 
1 p-values were obtained by using the Chi-square test for CRP (low vs. high) for categorical variables and 
One-way analysis of variance (ANOVA) for continuous variables. 
2
 Means ± standard deviation (SD). 
3
 A current smoker was defined as a subject who reported currently smoking; a current drinker was defined 












  Molecular Formula C:D
3
 Percent concentration  Food Sources References 
Pentadecanoic acid  SFA 
C15H30O2 15:0 0.14 (0.04- 0.59) 
Cow milk [103] 








23.3 (7.75- 36.21) 
Meat, including poultry, beef and game meats [104] 
Margaric acid  SFA 
C17H34O2 17:0 0.40 (0.12- 1.9) 
Cow milk [105] 








19.6 (6.3- 33.3) 
Meat, poultry, fish, grain products, and milk/ 
milk products, cocoa butter, lard, and butter  
[56] 
Arachidic acid SFA C20H40O2 20:0 0.31 (0.08- 1.32) 
Peanut oil (1.1%–1.7%) and corn oil [106] 








1.1 (0.06- 3.9) 
Peanut oil and peanut butter [107] 








2.6 (0.11- 6.8) 











0.11 (0.01- 0.59) 
 Animal oils, vegetable oils, marine oils, 
macadamia oil, and sea buckthorn oil  
[108] 








0.42 (0.07- 1.72) 
Vegetable oils such as olive, canola and 





C20H38O2 20:1 3.4 (0.09- 6.7) 
Plant oils and nuts [110] 
Erucic acid  
(Omega 9) 
MUFA 
C22H42O2 22:1 2.8 (0.23- 4.2) 
Wallflower seed and mustered oil  [111] 








1.3 (0.28- 3.9) 














0.43 (0.07- 0.89) 
Meat and dairy fat such as milk, and buttr [113] 








4.7 (1.17- 8.0) 
Vegetable oils such as flaxseed (linseed) oil, 












0.06 (0.01- 0.37) 
Fish oils, flaxseed oil, and in canola, soy, perilla, 












0.11 (0.02- 0.63) 
Poultry, nuts, and cereals  [115] 
Dihomo-y-linolenic 
acid (DGLA)  
(Omega 6) 
PUFA C18H30O2 20:3 0.62 (0.14- 1.41) Animal-source foods, such as meat, egg, fish. [116] 












0.18 (0.03- 1.2) 











1.4 (0.43- 2.3) 
Poultry, nuts, cereals, and whole grain breads [115] 
Docosapentaenoic 










1.0 (0.17- 2.0) 
Bearded seal (Alaska Native), fish oil, 
menhaden, salmon, and sardine 
[119] 
Docosapentaenoic 










0.28 (0.05- 0.76) 












1.6 (0.22- 5.3) 
Fish oils, eggs and meats [118] 
 
1 
FA are presented as percentage of FA analyzed.  
2 
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; TFA, trans fatty acids; PUFA, polyunsaturated fatty acids.
 
3 





Table 4.3: Mean of plasma biomarker concentration of C-reactive protein (CRP) 
across tertiles of erythrocyte membrane fatty acid in the Cache County Memory 
Study. 




Mean plasma CRP concentration (mg/L)
2 




T1 T2 T3 
Pentadecanoic acid  SFA 4.8± 7.2 4.8± 7.2 4.2± 7.6 0.125 
Palmitic acid  SFA 4.6± 7.3 4.2± 6.9 5.1± 8.2 0.053 
Margaric acid  SFA 5.2± 7.6 4.5± 6.9 4.1± 7.9 <0.001 
Stearic acid  SFA 4.8± 7.4 4.7± 7.3 4.2± 7.7 0.105 
Arachidic acid  SFA 4.8± 7.0 5.0± 8.4 4.0± 6.9 0.001 
Behenic acid  SFA 4.6± 7.0 4.9± 8.4 4.2± 6.9 0.244 
Lignoceric acid  SFA 4.6± 8.0 4.9± 7.2 4.3± 7.3 0.103 
Palmitoleic acid  MUFA 4.2± 8.2 4.4± 6.5 5.1± 7.7 <0.001 
Oleic acid MUFA 4.7± 7.1 4.5± 7.3 4.5± 8.1 0.184 
Gondoic acid  MUFA 4.4± 6.5 4.8± 8.2 4.6± 7.7 0.266 
Erucic acid  MUFA 4.1± 6.3 4.8± 8.3 4.9± 7.7 0.052 
Nervonic acid  MUFA 4.4± 8.0 4.2± 5.6 5.1± 8.5 0.149 
Vaccenic acid TFA 4.5± 7.3 4.7± 7.6 4.6± 7.6 0.426 
Linoleic acid  PUFA 5.1± 8.3 4.4± 8.1 4.2± 5.7 0.050 
a-Linolenic acid (ALA)  PUFA 4.7± 8.0 4.8± 8.2 4.2± 6.1 0.791 
Eicosadienoic acid  PUFA 4.9± 8.1 3.8± 6.0 5.1± 8.2 0.005 
Dihomo-y-linolenic acid (DGLA)  PUFA 4.6± 8.2 4.5± 7.2 4.7± 6.9 0.009 
Arachidonic acid  PUFA 3.9± 5.3 4.9± 9.0 4.9± 7.6 0.127 
Eicosapentaenoic acid (EPA) PUFA 5.3± 9.3 4.4± 6.5 4.1± 6.2 0.900 
Adrenic acid  PUFA 4.1± 6.3 4.8± 7.6 4.9± 8.3 0.357 
Docosapentaenoic acid (DPA-3)  PUFA 5.0± 8.0 4.4± 6.8 4.3± 7.6 0.090 
Docosapentaenoic acid (DPA-6)  PUFA 4.3± 7.3 4.2± 6.7 5.3± 8.0 0.002 
Docosahexaenoic acid (DHA) PUFA 4.7± 8.6 4.7± 7.6 4.3± 6.0 0.386 
 
 SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; TFA, trans fatty acids; PUFA, 
polyunsaturated fatty acids.  
2 Means± standard deviation (SD) 
3 p-values were obtained by using Analysis of Variance (ANOVA)  
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Table 4.4: Odds ratio of clinically relevant elevation of CRP (> 3.00 mg/L) by tertiles 
of erythrocyte membrane fatty acid in the Cache County Memory (n= 1844). 
 
RBC Fatty acids  Type
1 





Pentadecanoic acid  SFA 1.00 [reference] 1.2 (0.97- 1.5) 1.0 (0.85- 1.4) 0.497 
Palmitic acid  SFA 1.00 [reference] 0.90 (0.70- 1.1) 1.2 (0.95- 1.6) 0.121 
Margaric acid  SFA 1.00 [reference] 0.92 (0.73- 1.2) 0.68 (0.53- 0.89) 0.004 
Stearic acid  SFA 1.00 [reference] 0.90 (0.72- 1.1) 0.78 (0.60- 0.99) 0.040 
Arachidic acid  SFA 1.00 [reference] 0.89 (0.70- 1.1) 0.69 (0.53- 0.88) 0.002 
Behenic acid  SFA 1.00 [reference] 1.0 (0.81- 1.3) 0.89 (0.70- 1.1) 0.294 
Lignoceric acid  SFA 1.00 [reference] 1.2 (0.98- 1.6) 1.0 (0.81- 1.3) 0.840 
Palmitoleic acid   MUFA 1.00 [reference] 1.3 (0.98- 1.6) 1.7 (1.3- 2.2) <0.001 
Oleic acid  MUFA 1.00 [reference] 0.98 (0.77- 1.2) 0.80 (0.63- 1.0) 0.089 
Gondoic acid  MUFA 1.00 [reference] 1.0 (0.79- 1.2) 0.90 (0.70- 1.1) 0.414 
Erucic acid  MUFA 1.00 [reference] 1.1 (0.85- 1.3) 1.0 (0.82- 1.3) 0.748 
Nervonic acid  MUFA 1.00 [reference] 1.1 (0.86- 1.4) 1.3 (1.0- 1.6) 0.038 
Vaccenic acid TFA 1.00 [reference] 1.1 (0.89- 1.4) 1.1 (0.83- 1.3) 0.606 
Linoleic acid  PUFA 1.00 [reference] 0.80 (0.63- 1.0) 1.0 (0.81- 1.3) 0.695 
a-Linolenic acid (ALA)  PUFA 1.00 [reference] 1.1  (0.90- 1.5) 1.1 (0.87- 1.4) 0.415 
Eicosadienoic acid  PUFA 1.00 [reference] 0.83 (0.65- 1.0) 1.1 (0.86- 1.3) 0.435 
Dihomo-y-linolenic acid (DGLA)  PUFA 1.00 [reference] 1.3 (0.99- 1.6) 1.5 (1.2- 1.9) 0.001 
Arachidonic acid  PUFA 1.00 [reference] 1.1 (0.84- 1.3) 1.0 (0.79- 1.2) 0.984 
Eicosapentaenoic acid (EPA)  PUFA 1.00 [reference] 1.2 (0.96- 1.5) 1.1 (0.85- 1.4) 0.510 
Adrenic acid  PUFA 1.00 [reference] 1.1 (0.89- 1.4) 0.98 (0.76- 1.2) 0.818 
Docosapentaenoic acid n3 (DPA-3)  PUFA 1.00 [reference] 0.90 (0.70- 1.1) 0.95 (0.75- 1.2) 0.681 
Docosapentaenoic acid n6 (DPA-6)  PUFA 1.00 [reference] 0.99 (0.77- 1.2) 1.3 (1.0- 1.6) 0.026 
Docosahexaenoic acid (DHA) PUFA 1.00 [reference] 1.4 (1.1- 1.8) 1.2 (1.0- 1.6) 0.039 
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Total n-3 fatty acids
3
 PUFA 1.00 [reference] 1.16 (0.91- 1.5) 1.06 (0.84- 1.4) 0.605 
Total n-6 fatty acids
3
 PUFA 1.00 [reference] 0.90 (0.70- 1.1) 1.02 (0.80- 1.30) 0.810 
Total n-6/ n-3 fatty acids  PUFA 1.00 [reference] 0.95 (0.74- 1.2) 1.06 (0.82- 1.4) 0.640 
 
1 SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; TFA, trans fatty acids; PUFA, 
polyunsaturated fatty acids. 
2 
Values are 95% Confidence Interval in parentheses (all such values). Adjusted variables in multivariate 
models included body mass index (kg/m2, continuous), smoking (never, former, current), age, in years (65-
74, 75-84, 85+), education levels (less than high school, high school, more than high school), and gender 
(male, female). 
3
 Total n-3 fatty acids included ALA, EPA, DPA-3, and DHA; Total n-6 fatty acids included linoleic acid, 







Table 4.5: Odds ratio of clinically relevant elevation of CRP (> 3.00 mg/L) by tertiles of erythrocyte membrane fatty acid in the Cache 
County Memory stratified by gender. 
RBC Fatty acids  Type
1
 
Male  Female  










Pentadecanoic acid  SFA 
1.00 
[reference] 
0.93 (0.63- 1.3) 1.00 (0.70- 1.4) 0.209 
1.00 
[reference] 
1.40 (1.0- 2.0) 1.10 (0.79- 1.5) 0.520 
Palmitic acid  SFA 
1.00 
[reference] 
0.66 (0.45- 0.95) 0.88 (0.61- 1.2) 0.459 
1.00 
[reference] 
1.10 (0.81- 1.5) 1.50 (1.1- 2.1) 0.015 
Margaric acid  SFA 
1.00 
[reference] 
1.30 (0.85- 1.8) 0.91 (0.61- 1.3) 0.557 
1.00 
[reference] 
0.78 (0.57- 1.0) 0.57 (0.42- 0.80) 0.001 
Stearic acid  SFA 
1.00 
[reference] 
1.10 (0.72- 1.5) 0.92 (0.62- 1.3) 0.631 
1.00 
[reference] 
0.82 (0.60- 1.1) 0.67 (0.48- 0.93) 0.019 
Arachidic acid  SFA 
1.00 
[reference] 
0.76 (0.52- 1.1) 0.66 (0.44- 0.97) 0.035 
1.00 
[reference] 
0.98 (0.71- 1.3) 0.67 (0.49- 0.93) 0.021 
Behenic acid  SFA 
1.00 
[reference] 
0.90 (0.62- 1.3) 0.89 (0.62- 1.3) 0.571 
1.00 
[reference] 
1.10 (0.80- 1.5) 0.85 (0.61- 1.2) 0.375 
Lignoceric acid  SFA 
1.00 
[reference] 
1.00 (0.69- 1.5) 0.97 (0.67- 1.4) 0.883 
1.00 
[reference] 
1.40 (1.0- 1.9) 1.00(0.76- 1.4) 0.717 
Palmitoleic acid   MUFA 
1.00 
[reference] 
1.20 (0.83- 1.7) 1.30 (0.92- 2.0) 0.101 
1.00 
[reference] 
1.30 (0.96- 1.9) 1.90 (1.3- 2.7) <0.001 
Oleic acid  MUFA 
1.00 
[reference] 
0.95 (0.65- 1.3) 0.78 (0.53- 1.1) 0.222 
1.00 
[reference] 
0.98 (0.71- 1.3) 0.83 (0.60- 1.1) 0.270 
Gondoic acid  MUFA 
1.00 
[reference] 
0.93 (0.64- 1.3) 0.99 (0.68- 1.4) 0.980 
1.00 
[reference] 
1.10 (0.79- 1.5) 0.84 (0.61- 1.1) 0.300 
Erucic acid  MUFA 
1.00 
[reference] 
1.10 (0.72- 1.5) 1.30 (0.90- 1.9) 0.140 
1.00 
[reference] 
1.10 (0.79- 1.5) 0.89 (0.64- 1.2) 0.461 
Nervonic acid  MUFA 
1.00 
[reference] 
0.79 (0.54- 1.2) 1.10 (0.79- 1.6) 0.480 
1.00 
[reference] 
1.30 (0.98- 1.8) 1.40 (1.0- 1.9) 0.042 
Vaccenic acid TFA 
1.00 
[reference] 
1.10 (0.76- 1.6) 1.00 (0.70- 1.4) 0.893 
1.00 
[reference] 
1.10 (0.81- 1.5) 1.00 (0.77- 1.4) 0.672 
Linoleic acid  PUFA 
1.00 
[reference] 
0.78 (0.52- 1.1) 1.10 (0.71- 1.5) 0.701 
1.00 
[reference] 
0.82 (0.60- 1.1) 1.10 (0.76- 1.4) 0.774 
a-Linolenic acid (ALA)  PUFA 
1.00 
[reference] 
1.30  (0.95- 1.9) 1.10 (0.76- 1.6) 0.488 
1.00 
[reference] 
1.00 (0.71- 1.3) 1.10 (0.79- 1.5) 0.554 
Eicosadienoic acid  PUFA 
1.00 
[reference] 
0.57 (0.38- 0.84) 0.95 (0.65- 1.3) 0.791 
1.00 
[reference] 






1.20 (0.83- 1.7) 1.30 (0.91- 1.9) 0.128 
1.00 
[reference] 
1.20 (0.92- 1.7) 1.50 (1.1- 2.2) 0.005 
Arachidonic acid  PUFA 
1.00 
[reference] 
1.10 (0.73- 1.5) 1.20 (0.83- 1.7) 0.307 
1.00 
[reference] 
1.10 (0.77- 1.4) 0.90 (0.64- 1.2) 0.453 
Eicosapentaenoic acid (EPA)  PUFA 
1.00 
[reference] 
1. 20 (0.96- 1.5) 1.10 (0.85- 1.4) 0.510 1.00 
[reference] 
1.00 (0.71- 1.3) 1.10 (0.79- 1.5) 0.554 
Adrenic acid  PUFA 
1.00 
[reference] 
1.10 (0.75- 1.6) 1.10 (0.76- 1.6) 0.566 
1.00 
[reference] 















0.79 (0.52- 1.1) 1.10 (0.77- 1.6) 0.422 
1.00 
[reference] 
0.95 (0.69- 1.2) 0.79 (0.57- 1.1) 0.169 
Docosapentaenoic acid n6 




0.93 (0.63- 1.3) 1.40 (0.97- 2.1) 0.077 
1.00 
[reference] 
1.10 (0.76- 1.4) 1.20 (0.91- 1.7) 0.156 
Docosahexaenoic acid (DHA) PUFA 
1.00 
[reference] 
1.30 (0.95- 2.0) 1.20 (0.85- 1.8) 0.235 
1.00 
[reference] 
1.40  (1.0- 2.1) 1.30 (0.95- 1.8) 0.118 





1.2 (0.78- 1.7) 1.2 (0.81- 1.7) 0.391 
1.00 
[reference] 
1.14 (0.83- 1.6) 0.98 (0.71- 1.4) 0.938 





1.1 (0.75- 1.6) 1.06 (0.72- 1.5) 0.760 
1.00 
[reference] 
0.78 (0.56- 1.1) 1.02 (0.74- 1.4) 0.867 
Total n-6/ n-3 fatty acids PUFA 
1.00 
[reference] 
0.93 (0.62- 1.4) 1.1 (0.72- 1.5) 0.757 
1.00 
[reference] 
0.98 (0.70- 1.4) 1.1 (0.77- 1.5) 0.661 
 
1
 SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; TFA, trans fatty acids; PUFA, polyunsaturated fatty acids.
 
2 Values are 95% Confidence Interval in parentheses (all such values). Adjusted variables in multivariate models included body mass index (kg/m2, continuous), smoking 
(never, former, current), age, in years (65-74, 75-84, 85+), education levels (less than high school, high school, more than high school), and gender (male, female). 
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Table 4.6: Spearman rank order correlation coefficients of the dietary intake of total fats, saturated fatty acids, monounsaturated fatty 
acids, polyunsaturated fatty acids, omega 3, omega 6, omega6:omega3 ratio, CRP and with erythrocyte membrane fatty acid in the Cache 
County Memory Study. 
 
Erythrocyte membrane fatty 
acid 
Correlation with 




Correlation with  
MUFA (p-values) 
Correlation with  
PUFA (p-values) 
Correlation with  
Omega 3 (p-
values) 
Correlation with  
Omega 6 (p-
values) 
Correlation with  
Omega6:omega3 
(p-values) 
Correlation with  
CRP 
(p-values) 
Saturated fatty acids 
Pentadecanoic acid  0.029 (0.267) 0.176
**
 (<0.001) 0.023 (0.362) -0.192
**




 (<0.001) -0.031 (0.190) 
Palmitic acid  -0.071
**









Margaric acid  0.000 (0.985) 0.016 (0.525) -0.020 (0.449) -0.070
**







Stearic acid  -0.056
*
 (0.029) 0.035 (0.170) 0.042 (0.101) 0.025 (0.331) 0.016 (0.537) 0.014 (0.595) 0.024 (0.367) -0.041 (0.080) 
Arachidic acid  0.022 (0.398) 0.011 (0.669) 0.011 (0.667) 0.006 (0.821) 0.029 (0.254) -0.001 (0.969) -0.017 (503) -0.080
**
 (0.001) 
 Behenic acid  0.050 (0.054) 0.046 (0.074) 0.032 (0.218) 0.006 (0.811) 0.011 (0.673) 0.004 (0.865) -0.007 (0.786) -0.043 (0.063) 
Lignoceric acid  0.036
**
 (0.157) 0.017 (0.501) 0.036 (0.157) 0.020 (0.439)  0.014 (0.597) 0.017 (0.517) -0.009 (0.742) -0.013 (0.567) 
Monounsaturated fatty acids  













Oleic acid 0.044 (0.085) 0.016 (0.539) 0.005 (0.839) 0.070
**
 (0.006) 0.018 (0.484) 0.066
*
 (0.010) 0.039 (0.133) -0.059
*
 (0.012) 
Gondoic acid  -0.061
*




 (0.003) -0.027 (0.293) -0.072
**
 (0.005) -0.021 (0.424) -0.025 (0.282) 
Erucic acid  0.032 (0.215) 0.014 (0.583) 0.039 (0.134) 0.039 (0.132) -0.018 (0.486) 0.045 (0.080) 0.041 (0.112) 0.049
*
 (0.035) 
Nervonic acid  -0.026 (0.320) -0.070
**
 (0.007) -0.015 (0.558) 0.022 (0.385) 0.025 (0.332) 0.023 (0.377) -0.020 (0.454) 0.035 (0.135) 















Polyunsaturated fatty acids  
Linoleic acid  0.120
**















 (<0.001) -0.082 (0.001) 0.035 (0.177) 0.072
**
 (0.005) 0.046 (0.075) -0.019 (0.456) -0.004 (0.867) 
Eicosadienoic acid  -0.025 (0.338) -0.169
**













 (0.032) -0.026 (0.311) -0.031 (0.232) -0.055
*




















 (<0.001) -0.097 (<0.001) -0.183
**
 (<0.001) 0.018 (0.434) 








 (0.011) -0.069 (0.011) 0.069
**
 (0.007) 0.023 (0.318) 
Docosapentaenoic acid 
(DPA-3)  
-0.038 (0.141) -0.029 (0.262) -0.024 (0.347) -0.011 (0.660) 0.063
*











 (<0.001) 0.081 (0.002) -0.028 (0.282)  0.122
**











(<0.001) -0.108** (<0.001) 0.023 (0.377) 0.142** (<0.001) 0.007 (0.780)  -0.150** (<0.001) 0.022 (0.348) 
 
* Correlation is significant at the 0.05 level (2-tailed). 
** Correlation is significant at the 0.01 level (2-tailed).  
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THE ROLE OF ALZHEIMER'S- RELATED GENES IN SYSTEMIC 
INFLAMMATION IN THE CACHE COUNTY MEMORY STUDY 
Abstract 
 Objective: To evaluate whether Alzheimer’s Disease (AD)-related genes, 
identified in previous genome-wide association studies, are associated with elevated 
levels of inflammatory C-reactive protein (CRP) in a prospective, population-based 
study.  
 Design: We analyzed data from dementia-free participants in the Cache County 
Memory Study (CCMS). In a total of 2031 men and women ≥ 65 years of age at the 
baseline, we examined the association between polymorphisms of 20 AD-related genes 
and biomarker of systemic inflammation.  
Results: After controlling multiple covariates, risk of elevated CRP was increased 
in minor allele homozygotes vs. major allele homozygotes for APOE rs439401 (aOR= 
1.4 [95%CI 1.4- 1.7]) and TOMM40 rs157580 (aOR= 1.2 [95%CI 0.96- 1.46]). In 
contrast, risk of CRP elevation was reduced in minor allele homozygotes for MMP8 
rs1892886 (aOR = 0.78 [95%CI 0.64- 0.90]). These and other associations appeared 
stronger among male than women; risk of elevated CRP in males was increased in minor 
allele homozygotes for APOE rs439401 (aOR= 1.6 [95%CI 1.1- 2.1]) and TOMM40 
rs157580 (aOR= 1.5 [95%CI 1.1- 2.1]) and reduced for MMP8 rs1892886 (aOR = 0.64 
[95%CI 0.46- 0.89]), CR1 rs665401 (aOR = 0.60 [95%CI 0.42- 0.84]), CR1 rs3818361 
(aOR= 0.43 [95%CI 0.28- 0.66]), and CR1 rs4844609 (aOR = 0.38 [95%CI 0.19- 0.80]). 
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Conclusions: The AD associated genes APOE, TOMM40, CR1, and MMP8 are 
associated with altered CRP levels, a marker of systemic inflammation and these 
associations appear stronger for men compared to women.  
Introduction 
 Alzheimer’s disease (AD) is the sixth leading cause of death in the United States 
[1]. It is the most common form of dementia. In 2015, Alzheimer’s disease affected 5.3 
million Americans, and it affects 44 million worldwide. Alzheimer's prevalence is 1 in 9 
older Americans [1]. Inflammation plays a key role in the pathogenesis of AD [2]. 
Scientific knowledge is far from complete regarding the relationship between 
inflammatory biomarkers and AD. However, scientific advances recently have been 
noticeably changing the understanding of the role of high levels of inflammatory 
biomarker C-reactive protein (CRP) in AD patients and other chronic diseases [3, 4]. 
CRP is a plasma protein synthesized by the liver in response to cytokines including 
interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor α (TNF-α)[5]. A 
growing number of cross-sectional studies reported that high level of CRP was found in 
AD patients when they were compared to controls [6-8]. Concomitantly, several 
observational studies have provided convincing evidence that the low-grade 
inflammatory process that is indicated by high levels of CRP in older adults correlates 
with AD risk [9, 10].  
  Recent large genome-wide association studies (GWAS) have identified many 
genes/loci that are associated with late-onset Alzheimer's disease (LOAD) including 
BIN1, CLU, PICALM, MS4A6A, CD33, MS4A4E, CD2AP, CR1, ABCA7, AGTR1, 
APOE, TOMM40, DTNA, HTR2C, EPHA1, MMP8, MPP7, SORCS1, PPP3R1, and 
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MAPT/STH [11]. Genetic data reveal that some risks of disease initiation, progression, 
and severity are linked to different alleles of genes by affecting inflammation pathways. 
Genetic diversity plays an important role in immunity, inflammation, and inflammatory 
disease [12].  
Genes affecting the risk of systemic inflammation have gathered increasing 
attention from geneticists and epidemiologists interested in related inflammatory diseases 
including Alzheimer’s disease [13]. APOE (chromosome 19q12-13.2) is known to have a 
key role in determining the risk of AD. APOE has many polymorphisms including 
epsilon (ε2, ε3, and ε4), rs439401, and rs4420638 [14]. Functionally, APOE 
polymorphisms contribute to neuronal development, regeneration, and repair in the 
central nervous system (CNS) [13, 15]. APOE also plays a major role in the cholesterol 
and triglyceride metabolism [16-18]. Most studies have reported that ε2 and ε4 have an 
opposing biological effect on lipid metabolism [19-21].  
In regards of inflammation, APOE ε4 genotype is still a controversial issue, 
because much scientific evidence suggests that APOE ε4 works as a pro-inflammatory 
that induces the production of inflammatory biomarkers via several mechanisms [22-29]. 
Concomitantly, in the scientific literature, there are a few studies that suggest the benefits 
arising from the having a copy of APOE ε4 because it works as an anti-inflammatory [30, 
31].  
In the current study, the Cache County Memory Study (CCMS) was used to 
examine the influence of APOE-epsilon genotypes and SNPs in 20 genes previously 
associated with AD with plasma CRP levels. The hypotheses of this study are divided 
into primary hypotheses and exploratory hypotheses (Table 5.1). Primary hypotheses, 
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which are based on previously published reports, include genes that are associated with 
either increased or decreased levels of inflammatory biomarkers. Exploratory hypotheses 
included genes that are associated with Alzheimer's disease, but not known to be 
associated with inflammation. 
 
Materials and Methods 
Study participants  
This investigation used data from the Cache County Memory Study, a prospective 
cohort study among elderly who were 65 years old and older at the baseline in 1995 and 
who were permanent residents of Cache County, Utah. This population is largely non-
Hispanic White (5,092 residents), and the genetic makeup is mostly from Northern 
European ancestry. The institutional review boards of each collaborating site at Utah 
State University, Duke University Medical Center, and The Johns Hopkins University 
approved the protocol of the study. Participants were interviewed about demographic 
characteristics, health history, and family history of dementia, use of medications, 
alcohol, tobacco, other lifestyle factors, and extensive cognitive testing. Re-examination 
of the study participants was completed three more times in subsequent years. Details of 
the study protocols have been previously published [32].  
CRP assessment 
In 2002, fasting blood samples were obtained and assayed for CRP from 2185 
participants in Wave 3 at McKay Dee Laboratory Hospital, Ogden, UT. Dade's 
nephelometry method has been considered for quite some time as a gold standard for 
these tests in the laboratory industry [33].  Many large reference studies refer to the Dade 
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BNII assay that uses particle enhanced immunonephelometry to detect high-sensitivity 
CRP (hs-CRP).  Dade was one of the first vendors to receive FDA approval for cardiac 
marker claims for their sensitive CRP assay [34, 35]. Typically, expected values for 
healthy individuals are found to be less than 3.00 mg/L, or 0.3 mg/dL [36]. The 
measuring range is determined by the lower limit of the reference curve and depends on 
the concentration of the standard used. The typical limit of detection for the method was 
0.175 mg/L or 0.0175 mg/dL. The upper level of detection was typically 1150mg/L or 
150 mg/dL. We defined elevated CRP as values >3.0 mg/L [34]. 
Genotyping  
At the baseline of the CCMS, DNA buccal samples were obtained from 4,654 
participants to genotype APOE at Duke University School of Medicine. Later, a mixture 
of 2,974 DNA buccal and blood samples were genotyped for 20 non-APOE LOAD risk 
alleles at Brigham Young University by Dr. Kauwe using custom TaqMan assays [37, 
38]. The genotype assays included BIN1, CLU, CD33, PICALM, MS4A6A, MS4A4E, 
CD2AP, APOE, ABCA7, AGTR1, DTNA, HTR2C, MMP8, MPP7, EPHI1, SORCS1, 
TOMM40, PPP3R1, CR1, and MAPT/STH.  
Statistical Analyses 
Descriptive analyses were conducted to examine the association between CRP 
and other factors, such as gender (male, female), age (years), body mass index (BMI 
weight in kilograms/ height in meters
2
), educational level (less than high school, and 
more than high school), drinking and smoking habits (never, former, current); health 
variables included diabetes (no, yes), stroke (no, yes), and heart attack (no, yes), APOE 
genotype (no e4, 1 or 2 e4), and cholesterol (mg, continues). 
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The epsilon polymorphism in the APOE gene was defined by six- levels (ε3/ ε2, 
ε2/ ε3, ε2/ ε4, ε3/ ε3, ε3/ ε4, and, ε4/ ε4). Chi-square analyses of contingency tables of 
CRP levels (low:< 3.00 mg/L, high:> 3.0 mg/L) by genotype categories were performed 
to evaluate associations. Analysis of Variance (ANOVA) was used to test for differences 
between the mean of CRP across levels of genotypes. We also tested the associations 
between APOE- epsilon genotypes and APOE rs439401, TOMM40 rs1160985. 
AD-related genotypes define three-level categorical variables (major allele 
homozygote, heterozygote, minor allele homozygote). The three-level genotype variables 
were used in additive genetic models to test for an effect of 0, 1, or 2 alleles.  Analysis of 
Variance (ANOVA) was used to test for differences between the mean of CRP across 
levels of genotypes. Potential confounding variables including BMI, smoking, age, 
diabetes, stroke, heart attack, and gender were evaluated. Logistic regression models 
were used to estimate the risk of CRP elevation (> 3.0 mg/L) by genotype level. The 
major allele homozygote was used as a reference in these models to estimate the odds 
ratio (ORs) and 95% confident intervals (CIs) for CRP elevation (coded 0, 1). All tests 
were performed first with gender as covariates, and then models were stratified by 
gender. This stratification provides a means of comparing CRP- genotype association 
between males and females [39], thus making it possible to observe the differences. 
Participants with dementia (n= 154) were excluded from all analysis. Statistical analyses 
were conducted using SPSS, version 22. 
Results 
 Baseline demographic characteristics of the study participants are shown in Table 
5.2. Participants with a high level of CRP were more likely to be women, less educated 
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and had higher BMI. High CRP levels were also associated with current smoking. Those 
in the higher vs. lower CRP level reported more strokes (10.1 vs. 7.3 percent) and the 
prevalence of diabetes was slightly higher in the high CRP group. 
 The genotype distribution of the APOE-epsilon genotypes and the mean plasma 
CRP level for APOE-epsilon genotype and the percent of normal and elevated CRP by 
genotype group are presented in Table 5.3. A Chi-square test for association between 
APOE-epsilon genotypes and CRP levels revealed that mean CRP level was significantly 
different between APOE-epsilon genotypes (p= <0.001). Lower mean CRP was observed 
among APOE-epsilon genotype ε2/ ε2 and ε4/ε4, and the highest mean CRP was 
observed among ε2/ ε4 allele genotype. 
 A Chi-square test for association was conducted between APOE-epsilon 
genotypes and APOE and TOMM40 polymorphisms. There was a statistically significant 
association between gene APOE-epsilon genotypes and APOE rs439401, TOMM40 
rs157580, and TOMM40 rs157580, (χ
2 
(5) = 33.8, p = <0.001), (χ
2 
(10) = 400, p = 
<0.001), and (χ
2 
(10) = 454, p = <0.001), respectively (Table 5.4). 
 The genotype distribution of AD-related genes appears in Table 5.5. Mean plasma 
of CRP by the AD-related genotypes are presented in Table 5.6. Mean CRP levels were 
significantly different between APOE rs439401 and TOMM40 rs157580 genotypes (P= 
<0.001, P= <0.001, P= 0.002), respectively. Higher mean plasma CRP concentrations 
were found in the minor allele heterozygotes and homozygotes compared to the major 
allele homozygotes for both APOE and TOMM40. 
The results of the logistic regression models that estimated the relative risk of 
having an elevated plasma CRP are shown in Table 5.7. The models presented were 
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adjusted for gender, age, education, BMI, smoking, alcohol intake, diabetes, stroke, 
myocardial infarction. The adjusted multivariate logistic analysis of 20 AD-related genes 
found that individuals compared to major allele as the reference category had increased 
the risk of elevated CRP level for minor allele homozygotes; adjusted OR (aOR) and 
95% confidence intervals (CIs)); APOE rs439401(aOR = 1.4 [95%CI 1.1- 1.7]), 
TOMM40 rs157580 (aOR= 1.2 [95%CI 0.96- 1.46]). In contrast, individuals compared to 
major allele homozygote as the reference category had decreased the risk of elevated 
CRP levels for minor allele homozygotes MMP8 rs1892886 (aOR = 0.78 [95%CI 0.64- 
0.9]). No associations between others genes and CRP elevation were observed levels was 
observed.  
 When the data were stratified by gender, we found that mean CRP levels were 
strongly associated with APOE-epsilon genotype in both. Lower mean plasma CRP 
concentrations were found in major allele homozygotes compared to minor allele 
heterozygotes and homozygotes in SNPs APOE rs439401 in both men and women. 
TOMM40 rs157580 genotype was associated with CRP in males but not in females. 
Higher mean plasma CRP concentration was found in the major allele homozygote 
compared to minor allele heterozygotes and homozygotes in MMP8 and HTR2C for 
males and MS4A6A in females (Table 5.9 and Table 5.10).  
The results of the logistic regression analyses for the relative risk of having an 
elevated plasma CRP stratified by gender are shown in Table 5.11. The adjusted 
multivariate logistic analysis of 20 AD-related genes found that individuals compared to 
major allele homozygotes as the reference category, increased risk of elevated CRP level 
for minor allele homozygotes for males were: APOE rs439401(aOR = 1.6 [95%CI 1.1- 
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2.1]) and TOMM40 rs157580 (aOR= 1.5 [95%CI 1.07- 2.1]). Decreased risk of elevated 
CRP for minor allele homozygotes in males was found for MMP8 rs1892886 (aOR = 
0.64 [95%CI 0.46- 0.89]), CR1 rs665401 (aOR = 0.59 [95%CI 0.42- 0.84]), CR1 
rs3818361 (aOR = 0.43 [95%CI 0.28- 0.66]), and CR1 rs4844609 (aOR = 0.38 [95%CI 
0.19- 0.80]). These associations were not observed in women. 
While the associations between AD-related genes and risk of elevated CRP 
appeared to be present only in men and not among women, there was not a significant 
multiplicative interaction between most AD-related genes and CRP elevation (p > 0.05). 
Only TOMM40 rs157580, CR1 rs665401, CR1 rs3818361, and CR1 rs4844609 were 
significant with the multiplicative interaction between most AD-related genes and CRP 
elevation (p= 0.0418, 0.005, 0.002, 0.0193), respectively.  
Discussion 
 The present study found that APOE-epsilon genotypes influence the risk of 
systemic inflammation but in an unexpected direction the ε4/ε4 genotype, associated with 
the highest risk of AD, had among the lowest mean CRP compared to other APOE 
genotype. Plasma CRP differed in a similar pattern across APOE-epsilon genotypes in 
both genders. When major allele homozygotes were compared to minor allele 
homozygotes, the risk of elevation CRP increased in those who have APOE rs439401 and 
TOMM40 rs157580. In contrast, the risks of elevation CRP decrease in those who have 
minor allele homozygotes MMP8 rs1892886, CR1 rs665401, CR1 rs3818361, and CR1 
rs4844609. These associations were found to be stronger in men vs. women. 
 Several prospective studies have demonstrated that CRP is an independent predictor 
of future risk for AD, and it may aid in identifying subjects at high risk [6-9, 40]. The 
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observation of elevated CRP in subjects with AD has led to extensive studies on the role 
of inflammatory reactions in the pathogenesis of AD [9, 10, 41]. 
The link between plasma CRP and the common allelic variants ε2, ε3, and ε4 of 
the APOE gene has been observed in some earlier studies. Five studies of APOE [34, 99-
102] showed that APOE-epsilon genotypes had no effect on inflammatory biomarkers. 
Other studies were consistent with our current results. Angelopoulos et al., and Haan et 
al., examined the association between APOE ε3/ε4 in healthy elderly Latinos. They found 
that ε3/ε4 reduced CRP levels among participants [42, 43]. In Japanese Americans, CRP 
levels were found to be low in ε4/ε4 and ε3/ε4 participants, but not with ε/ε2 genotype 
[44]. Moreover, a data from the Czech part of the HAPIEE (Health, Alcohol, and 
Psychosocial factors In Eastern Europe) study reported that ε3/ε4 and ε4/ε4 was 
associated with reduced CRP levels among 2,886 males and 3,344 females [45]. This 
pattern of association is consistent with other studies that indicated ε4 carriers have lower 
levels of plasma CRP in the elderly and different patient groups [29, 46-52]. APOE ε4 
were associated with higher CRP levels, the sensitive inflammatory biomarker and 
predictor of Alzheimer disease [53], only one study of young participants stratified by 
gender and they found that APOE ε4 was associated with lower mean CRP, but only for 
men not for women [54].  
The present result that is consistent with the most previously published studies 
highlighted the contradiction regarding the relationship between APOE genotypes, CRP, 
and AD. Until now the mechanism has been unknown for how APOE isoforms affect 
inflammation and risk of AD but it has been suggested that each APOE isoform has been 
implicated in different modulation mechanisms in regards to inflammatory responses 
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(apoE2 > apoE3 > apoE4) [55]. Some studies suggest anti-inflammatory benefits arising 
from having genotypes of APOE ε2/ ε3 [24, 56-61], ε3/ ε4 [43, 62], ε4 [29, 46-52], ε4/ ε4 
[19, 29, 49-52, 63-66] which suggest that this association may be influenced by different 
independent mechanism. Other studies suggest the pro-inflammatory effect of APOE ε4 
[22-28]. Over the last decades, high level of CRP has been used widely to estimate the 
risk of several chronic diseases including cancer [67], type 2 diabetes [68], coronary 
artery disease risk, damage from a heart attack [69], inflammatory bowel disease [70], 
some forms of arthritis [71], pelvic inflammatory disease [72], lupus [71], and AD [73]. 
Moreover, individuals with APOE ε4 genotype are at increased risk of cardiovascular 
disease, end stage renal disease [74], and AD [75]. Genetic data also revealed that high 
levels of CRP are related to gene polymorphisms by increasing the risk of some disease 
such as cardiovascular disease rather than inflammatory status, which may explain the 
limited effects of the environmental factors [45, 76]. Thus, further experimental studies 
are needed to explain this conflict evidence that came from only observational studies.       
No previous study, to our knowledge, has examined associations between 
rs439401 in APOE and rs157580 in TOMM40 with inflammatory biomarkers in males. 
On the other hand, The Women’s Health Initiative (WHI) study of 8,280 African 
American reported [77] and 7,570 African Americans (AA) from the Candidate Gene 
Association Resource (CARe) study [78] reported that CRP is significantly associated 
with APOE rs157580 and TOMM40 rs439401 loci. The biologic mechanism of the 
relationship between these polymorphisms and CRP is not clear [45]. Both TOMM40 and 
APOE are located on chromosome 19 [79]. AD pathology in multiple brain regions have 
been associated with SNPs in APOE and TOMM40 genes [80]. Even though the effect of 
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length variation between TOMM40 and APOE has been reported [79, 81], there are no 
studies conducted, to our knowledge, that have analyzed the interaction effect of 
rs157580 and rs439401 polymorphisms on CRP levels, thus more studies are needed to 
explore and explain the effect of the interaction between APOE rs157580 and TOMM40 
rs439401 on CRP levels as a dependent variable, particularly among elderly. 
 No previous study, to our knowledge, has examined associations between 
rs6656401, rs3818361, and rs4844609 in CR1, rs1892886 in MMP8, and CRP levels in 
men. The mechanisms underlying inflammation and the immunological network leading 
to AD are not well known. Genes including BIN1 [82, 83], and AGTR1 [84] have been 
linked to inflammation as both pro-inflammatory and anti-inflammatory. In the scientific 
literature, there are a few studies that reported BIN1 [85-90] and CLU [91-94] as anti-
inflammatory. Other evidence suggests that CD2AP [95-98], AGTR1 [99-101], MMP8 
[102-106], MMP7 [107-111], TOMM40 [28, 112], CR1 , CD33 [113], and MS4A6A 
[113] work as a pro-inflammatory that induces the production of inflammatory 
biomarkers via several mechanisms. Three studies of CLU studies [114-116] reported that 
these genes have no effect on inflammatory biomarkers.  
 To our knowledge, this is the first study that explores the multiplicative interaction 
between AD-related genes and the risk of elevated CRP. Thus, further studies are needed 
to confirm our results. 
  Our study has several key strengths, including a large sample size for determining 
the association between APOE-epsilon genotypes and 20 Alzheimer’s Disease-related 
genes and CRP levels in both males and females. Participants in our sample were 
Caucasians, and populations with other genetic background may have different 
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associations. The results of our analysis must be considered in light of its limitations. 
CRP is a single measure of systemic inflammation that is a complex process, and further 
studies of additional inflammatory biomarkers would be useful [117].  
 In conclusion, our finding supports the hypothesis that among Caucasian males, the 
presence of minor alleles of APOE (C/C) rs439401 and TOMM40 (A/A) rs157580 may 
be a risk factor to increase inflammation in elderly. Conversely, the minor allele of 
MMP8 (T/T) rs1892886, CR1 (G/G) rs6656401, CR1 (A/A) rs3818361, and CR1 (A/A) 
rs4844609 is associated with decreased risk of CRP elevation in Caucasian males. More 
mechanistic studies or using other inflammatory biomarkers are needed to show how 
genetic polymorphisms affect systemic inflammation, which has long term effects on the 















Table 5.1: Studies reporting on the relationship between Alzheimer’s- associated genes 
and  inflammatory biomarkers.  
Genes Inflammatory type  
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Pro-inflammatory No references found related to pro-inflammation 
---------------------------- 
Anti-inflammatory No references found related to anti-inflammation 
 
1
 Note: Studies were identified in PubMed and Scopus using the following combinations of search terms: (“SNPs 
number” or “ gene names” ) and (“genotype” or “gene” or “polymorphisms”) and (“crp” or “c-reactive protein”). 
2
 Genes hypothesized to be associated with systemic inflammation based on literature review. 
3






Table 5.2: Demographic characteristics by levels of C- reactive protein (CRP) in the 
Cache County Study on Memory, Health and Aging in Wave 3 (N= 2031). 
Characteristic 




<3.0 (mg/L) >3.0 (mg/L) 
Gender  
- Male (%) 








- Less than high school education (%) 






Age in years (SD)
2
 73.0± 5.4 73.1± 5.5 0.480 




  25.9± 4.0 27.2± 4.4 <0.001 
Current smoke (%)
3
  1.4 2.9 0.042 
Current alcohol (%)
3
   4.4 3.7 0.442 
At least one APOE e4 allele (%) 
35.8 26.2 <0.001 
Diagnosed with diabetes (%)  
17.4 20.0 0.078 
Diagnosed with stroke (%) 
7.3 10.1 0.018 
Diagnosed with heart attack (%) 14.4 16.0 0.178 
 
1 p-values were obtained by using the Chi-square test for CRP (low vs. high) for categorical variables and 
Analysis of Variance (ANOVA) for continuous variables. 
2
 Means± standard deviation (SD). 
3
 A current smoker was defined as a subject who reported currently smoking; a current drinker was defined as a 







Table 5.3: Genotype distributions and mean levels of C-reactive protein (CRP) by APOE 












 <3.0 (mg/L) ≥3.0 (mg/L) 
n (%) n (%) 
Epsilon 




ε2/ ε3 14.4 135 (46.2) 157 (53.8) 5.6± 8.2 
ε2/ ε4 4.2 54 (63.5) 31 (36.5) 6.4± 13.0 
ε3/ ε3 52.7 615 (57.6) 453 (42.4) 4.6± 7.3 
ε3/ ε4 25.5 335 (64.8) 182 (35.2) 3.8± 6.3 
ε4/ ε4 2.4 37 (75.5) 12 (24.5) 3.0± 6.6 
 
1  
APOE-epsilon genotypes defined by variants in APOE SNPs rs429358 and rs7412. 
2
 p-values were obtained by using the chi-square test for CRP (low vs. high) for categorical variables.                         
3
 Means± standard deviation (SD).                     
4





Table 5.4: Cross-tabulations of APOE-epsilon genotype and APOE and TOMM40 
polymorphisms in the Cache County Memory Study (CCMS).  






















































ε2/ ε2 0.8 0.0 0.0 
<0.001 
0.4 0.4 0.1 
<0.001 
0.1 0.3 0.3 
<0.001 
ε2/ ε3 7.1 6.1 0.2 4.5 6.2 3.2 3.3 6.1 3.8 
ε2/ ε4 3.2 0.3 0.0 2.0 1.4 0.0 1.3 2.1 0.2 
ε3/ ε3 15.1 26.5 14.5 14.2 26.9 13.7 16.8 27.0 12.3 
ε3/ ε4 12.4 10.7 0.7 11.8 12.1 0.6 12.8 10.6 0.8 
ε4/ ε4 2.2 0.1 0.0 2.4 0.1 0.0 2.1 0.1 0.0 
 
1
 R is the major allele and C is the minor allele. 
2
 p-values were obtained by using the chi-square test for APOE-epsilon genotype and AD-related genes.            
         
138 
 
Table 5.5: Genotype distributions of the Alzheimer’s associated genes in the Cache 
County Memory Study (CCMS). 
Gene ID SNP Full name gene n 


















35.4 50.1 14.5 
BIN1 
rs744353 Bridging integrator 1  1810 50.2 40.3 9.5 
CLU 
rs11136000 Clusterin 1959 37.2 48.8 13.9 
CD2AP 
rs9349407 CD2-associated protein 1975 53.1 39.1 7.8 
AGTR1 
rs2131127 Angiotensin II receptor, type 1  1931 42.5 44.8 12.7 
MMP8 
rs1892886 Matrix metallopeptidase 8 1913 56.9 36.6 6.4 
MPP7 
rs1457177 Membrane protein, palmitoylated 7  1961 85.2 14.4 0.4 
TOMM40 rs1160985 Translocase of outer mitochondrial 
membrane 40 homolog 
1782 33.7 50.2 16.1 
rs157580 1959 32.1 49.8 18.0 
CR1 
rs6656401 
Complement receptor 1 
1974 68.4 28.8 2.7 
rs3818361 1331 67.3 29.5 3.1 
rs4844609 1956 95.0 4.8 0.2 
CD33 




Clathrin Assembly Protein  




subfamily A, member 6A/   




subfamily A, member 4E 
1580 35.9 47.9 16.1 
ABCA7 rs3752246 
ATP-binding cassette, sub-family A 
(ABC1), 
1976 66.3 30.3 3.4 
DTNA rs4458079 Dystrobrevin, alpha 1963 78.7 19.2 2.1 
HTR2C rs6318 
5-hydroxytryptamine (serotonin) 
receptor 2C, G protein-coupled 
1962 74.7 16.5 8.8 




Sortilin-related VPS10 domain 
containing receptor 1 
1854 38.0 49.2 12.7 
PPP3R1 
rs1868402 
Protein phosphatase 3, regulatory 
subunit B, and alpha 
1961 48.9 41.8 9.3 
MAPT/STH rs3785883 
Microtubule-associated protein tau 
and saitohin 
1966 67.6 28.9 3.5 
 
1




Table 5.6: Mean levels of C-reactive protein (CRP) by genotype of Alzheimer’s 
associated genes in the Cache County Memory Study. 
Gene ID SNP 
Mean CRP1 
p-value3 
R/R2 C/R2 C/C2 
Primary hypotheses 
APOE rs439401 4.3± 7.6 4.8± 7.6 4.9± 7.8 <0.001 
BIN1  rs744353 4.6± 7.7 4.6 ± 7.8 4.1± 8.4 0.750 
CLU  rs11136000 4.3± 6.4 4.7± 8.2 5.0± 7.53 0.492 
CD2AP  rs9349407 4.4± 7.0 4.9± 8.4 4.5± 7.2 0.890 
AGTR1  rs2131127 4.7± 7.8 4.5± 7.3 4.7± 8.6 0.448 
MMP8  rs1892886 4.9± 7.6 4.3± 7.3 4.3 ± 9.9 0.078 
MPP7  rs1457177 4.7± 7.8 4.3± 7.0 2.5± 2.3 0.238 
TOMM40  rs1160985 4.0± 4.9 4.8± 8.4 4.6± 7.7 0.868 
TOMM40  rs157580 3.9± 6.1 5.1± 8.7 4.8± 7.1 0.002 
CR1 rs6656401 4.7± 7.8 4.6± 7.4 4.1± 6.7 0.682 
CR1  rs3818361 4.9± 7.7 4.8± 7.3 4.3± 7.2 0.670 
CR1 rs4844609 5.0± 2.5 3.7± 5.8 4.6± 7.7 0.155 
Exploratory hypotheses  
CD33  rs3865444 5.0± 8.9 4.2± 5.9 5.1± 8.0 0.642 
PICALM rs3851179 4.7± 8.3 4.8± 8.3 4.8± 4.8 0.967 
MS4A6A  rs610932  4.3± 7.1 4.8± 8.1 4.8± 7.7 0.107 
MS4A4E  rs670139 4.6± 7.0 4.7± 8.5 4.1± 6.1 0.176 
ABCA7  rs3752246 4.6± 7.6 4.5± 7.5 4.6± 6.4 0.834 
DTNA  rs4458079 4.6± 7.3 4.8± 9.1 4.7± 4.7 0.493 
HTR2C  rs6318 4.5± 7.1 4.9± 8.9 4.5± 8.1 0.222 
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EPHA1  rs11767557 4.6± 7.5 4.8± 8.2 .3.3± 3.1 0.532 
SORCS1  rs7093634 4.4± 6.9 4.9± 8.1 4.2± 8.5 0.170 
PPP3R1  rs1868402 4.4± 6.7 4.9± 8.8 4.9± 7.2 0.828 
MAPT/STH rs3785883 5.1± 6.5 4.1± 5.5 4.8± 8.5 0.467 
 
1 Means± standard deviation (SD). 
2
 R is the major allele and C is the minor allele. 






Table 5.7: Estimated effects of Alzheimer’s associated genes of plasma biomarker 
concentration C-reactive protein (CRP) levels (high vs. low) from conditional logistic 
regression in the Cache County Memory Study. 





R/R1 C/R1 C/C1 
APOE  rs439401 
1.00 
[reference] 
1.3 (1.01- 1.8) 1.4 (1.1- 1.7) 0.004 








CLU  rs11136000 
1.00 
[reference] 




CD2AP  rs9349407 
1.00 
[reference] 




AGTR1  rs2131127 
1.00 
[reference] 




MMP8  rs1892886 
1.00 
[reference] 




MPP7  rs1457177 
1.00 
[reference] 




TOMM40   rs1160985 
1.00 
[reference] 




TOMM40  rs157580 
1.00 
[reference] 







0.82(.475- 1.4) 0.89 (.73- 1.1) 0.224 
CR1  rs3818361 
1.00 
[reference] 











CD33  rs3865444 
1.00 
[reference] 






















MS4A4E  rs670139 
1.00 
[reference] 




ABCA7  rs3752246 
1.00 
[reference] 




DTNA  rs4458079 
1.00 
[reference] 












EPHA1  rs11767557 
1.00 
[reference] 




























R is the major allele and C is the minor allele. 
2
 Values are 95% Confidence Interval in parentheses (all such values). Adjusted variables in multivariate models 
included body mass index (kg/m2, continuous), smoking (never, former, current), Age, in years (65-74, 75-84, 






Table 5.8: Demographic Characteristics by C- reactive protein (CRP) and stratified by 
gender in the Cache County Study on Memory, Health and Aging in Wave 3. 
Characteristic 
Plasma CRP concentration (mg/L) 
n%
 















- Less than high school (%) 











Age in years (SD)
2
 72.1± 5.0  73.3± 5.6 0.033 
73.5± 
5.8 
72.8± 5.4 0.002 






26.0± 3.7  26.7± 4.0 0.017 
24.4± 
4.5 
26.6± 5.2 0.000 
Current smoke (%)
3
  1.9 5.4 0.002 0.9 1.5 0.580 
Current alcohol (%)
3
   6.6 5.4 0.95 2.7 2.7 0.883 
At least one APOE e4 allele 
(%) 
36.6 23.7 0.000 35.1 27.7 0.004 
Diagnosed with diabetes 
(%)  
19.7 20.7 0.420 15.6 19.7 0.036 
Diagnosed with stroke (%) 7.3 8.8 0.261 7.3 10.8 0.024 
Diagnosed with heart attack 
(%) 
17.1 23.1 0.021 12.2 11.9 0.470 
 
1 P values were obtained by using the chi-square test for CRP (low vs. high) for categorical variables and 
Spearman rank correlation for continues variables.                                                      
2
 Means ± standard deviation (SD).  
3
 A current smoker was defined as a subject who reported currently smoking; a current drinker was defined 





Table 5.9: Mean levels of C-reactive protein (CRP) by genotype of APOE gene 
stratified by gender in the Cache County Memory Study. 














ε2/ ε2 2 1.7± 0.63 
<0.001 
12 3.0± 2.7 
0.006 
ε2/ ε3 134 5.5± 8.7 158 5.7± 7.8 
ε2/ ε4 32 5.7± 14.5 53 6.9± 12.2 
ε3/ ε3 435 4.2± 6.9 633 4.9± 7.6  
ε3/ ε4 210 3.6± 6.3 307 4.0± 6.3 
ε4/ ε4 25 1.6± 1.2 24 4.4± 9.3 
 
1 
Means± standard deviation (SD). 
2 P values were obtained by using Analysis of Variance (ANOVA). 
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Table 5.10: Mean levels of C-reactive protein (CRP) by genotype of Alzheimer’s associated genes stratified by gender in the Cache 
County Memory Study. 




p-value3 Male Female 
R/R2 C/R2 C/C2 R/R
2 C/R2 C/C2 
Primary hypotheses  
APOE rs439401 3.9± 7.7 4.3± 6.8 5.1± 8.9 0.003 4.5± 7.6 5.2± 8.1 4.8± 6.9 0.040 
BIN1  rs744353 3.8± 4.9 4.4± 9.3 4.8± 10.4 0.547 5.8± 9.1 5.4± 8.7 4.4± 6.7 0.292 
CLU  rs11136000 3.6± 4.6 4.2± 8.2 5.0± 11.4 0.921  5.1± 6.9 4.9± 8.2 4.7± 7.2 0.423 
CD2AP  rs9349407 3.7± 5.3 5.4± 12.2 5.3± 11.9 0.787 5.0± 7.8 4.9± 7.8 4.5± 5.5 0.956 
AGTR1  rs2131127 4.4± 8.3 4.8± 11.2 3.5± 3.6 0.549 4.9± 7.2 4.8± 7.3 5.2± 10.2 0.823 
MMP8  rs1892886 5.1± 9.3 4.1± 10.2 2.6± 3.3 0.005 5.4± 12.5 4.6± 7.4 5.0± 7.0 0.926 
MPP7  rs1457177 4.6± 9.9 3.8± 4.9 2.4± 1.9 0.949 5.0± 7.7 4.4± 7.2 2.7± 2.6 0.069 
TOMM40  rs1160985 4.2± 8.2 4.7± 10.6 4.2± 8.4 0.642 4.4± 4.8 5.0± 8.6 4.9± 7.4 0.997 
TOMM40  rs157580 3.7± 7.5 4.9± 10.6 5.1± 9.4 0.011 4.1± 5.2 5.5± 9.5 4.6± 5.2 0.153 
CR1 rs6656401 4.6± 9.6 4.3± 8.7 4.1± 8.5 0.242 5.0± 8.4 4.6± 6.0 4.1± 4.2 0.765 
CR1  rs3818361 4.7± 8.1 4.9± 12.7 4.6± 9.9 0.221 5.1± 8.3 5.0± 6.5 4.1± 4.5 0.638 
CR1 rs4844609 4.5± 9.3 4.6± 9.4 
3.4± 7.2 
 
0.105 6.2± 1.9 3.9± 4.2 4.9± 7.8 0.545 
Exploratory hypotheses  
CD33  rs3865444 5.1± 11.8 4.0± 6.6 4.2± 8.1 0.720 5.2± 8.7 4.4±  6.5 5.3± 7.2 0.220 
PICALM  rs3851179 3.5± 5.7 4.3± 7.6 5.1± 12.0 0.424 4.2± 4.2 4.9± 7.1 5.0± 9.1 0.919 
MS4A6A  rs610932  5.9± 14.8 4.1± 7.2 4.3± 7.8 0.397 4.8± 5.9 5.3± 8.4 4.5± 7.4 0.014 
MS4A4E  rs670139 4.4± 6.8 4.2± 8.5 5.1± 11.9 0.151 4.6± 8.4 5.0± 8.2 4.7± 6.5 0.106 
ABCA7  rs3752246 5.0± 7.6 3.9± 7.7 4.7± 9.9 0.645 4.3± 5.1 5.0± 7.7 4.8± 7.7 0.313 






HTR2C  rs6318 4.7± 8.8 0.38± 0.13 4.0± 6.7 0.002 3.9± 4.3 4.0± 9.0 4.9± 7.4 0.691 
EPHA1  rs11767557 5.0± 11.0 3.8± 5.2 2.5± 2.5 0.133 4.5± 5.9 5.7± 10.4 3.7± 3.3 0.833 
SORCS1  rs7093634 3.4± 6.3 4.8± 8.9 
4.6± 10.9 
 
0.262 5.5± 11.7 5.0± 7.4 4.6± 6.5 0.424 
PPP3R1  rs1868402 4.8± 8.2 4.9± 10.0 
4.2± 9.0 
 
0.956 5.0± 6.3 5.0± 8.3 4.8± 7.3 0.895 
MAPT/STH rs3785883 4.6± 9.3 4.4± 10.3 3.9± 5.9 0.969 5.1± 8.5 4.2± 5.0 5.8± 6.6 0.344 
 
1
 Means± standard deviation (SD). 
2 
R is the major allele and C is the minor allele. 






Table 5.11: Estimated effects of Alzheimer’s associated genes on plasma biomarker concentration C-reactive protein (CRP) 
levels (high vs. low) from conditional logistic regression stratified by gender in the Cache County Memory Study. 
Genes  SNP 













 p- value2 
APOE  rs439401 1.00 [reference] 1.9 (1.2- 3.1) 1.6 (1.1- 2.1) 0.001 1.00 [reference] 1.0 (0.74- 1.6) 1.3 (1.00- 1.7) 0.259 
BIN1  rs744353 1.00 [reference] 1.2 (0.71- 2.3) 1.1 (0.80- 1.5) 0.337 1.00 [reference] 0.99 (0.63- 1.5) 1.07 (0.82- 1.4) 0.791 
CLU  rs11136000 1.00 [reference] 0.95 (0.58- 1.5) 0.87 (0.63- 1.2) 0.658 1.00 [reference] 1.01 (0.68- 1.5) 0.86 (0.66- 1.1) 0.717 
CD2AP  rs9349407 1.00 [reference] 0.82 (0.46- 1.4) 0.84 (0.62- 1.1) 0.281 1.00 [reference] 1.04 (0.66- 1.6) 1.06 (0.82- 1.3) 0.668 
AGTR1  rs2131127 1.00 [reference] 1.4 (0.87- 2.4) 1.17 (0.85- 1.6) 0.123 1.00 [reference] 1.06 (0.72- 1.5) 1.06 (0.81- 1.3) 0.654 
MMP8  rs1892886 1.00 [reference] 0.62 (0.35- 1.2) 0.64 (0.46- 0.89) 0.014 1.00 [reference] 0.82 (0.50- 1.3) 0.89 (0.68- 1.1) 0.304 
MPP7  rs1457177 1.00 [reference] 0.54 (0.56- 5.2) 1.2 (0.79- 1.8) 0.540 1.00 [reference] 0.69 (0.11- 4.2) 0.79 (0.56- 1.11) 0.171 
TOMM40  rs1160985 1.00 [reference] 0.80 (0.50- 1.2) 1.04 (0.73- 1.4) 0.479 1.00 [reference] 1.1 (0.75- 1.6) 0.92 (0.70- 1.2) 0.748 
TOMM40  rs157580 1.00 [reference] 1.9 (1.2- 3.0) 1.5 (1.1- 2.1) 0.002 1.00 [reference] 1.2 (0.85- 1.7) 0.99 (0.75- 1.3) 0.372 
CR1 rs6656401 1.00 [reference] 0.50 (0.17- 1.09) 0.60 (0.42- 0.87) 0.001 1.00 [reference] 1.4 (0.67- 3.0) 1.2 (0.91- 1.6) 0.129 
CR1  rs3818361 1.00 [reference] 0.54 (0.18- 1.6) 0.43 (0.28- 0.66) <0.001 1.00 [reference] 1.3 (0.60- 3.2) 1.2 (0.92- 1.7) 0.120 
CR1 rs4844609 1.00 [reference] No observation 0.38 (0.19- 0.79) 0.009 1.00 [reference] No observation 1.2 (0.71- 2.1) 0.160 
CD33  rs3865444 1.00 [reference] 0.74 (0.46- 1.2) 1.03 (0.75- 1.4) 0.414 1.00 [reference] 1.11 (0.74- 1.6) 0.92 (0.71- 1.1) 0.905 
PICALM  rs3851179 1.00 [reference] 0.87 (0.51- 1.2) 1.04 (0.75- 1.4) 0.698 1.00 [reference] 1.1 (0.78- 1.6) 0.97 (0.75- 1.2) 0.638 







MS4A4E  rs670139 1.00 [reference] 1.2 (0.75- 1.9) 0.82 (0.57- 1.1) 0.712 1.00 [reference] 0.70 (0.46- 1.06) 1.01 (0.74- 1.3) 0.167 
ABCA7  rs3752246 1.00 [reference] 1.11 (0.54- 2.2) 0.97 (0.70- 1.3) 0.943 1.00 [reference] 0.69 (0.334- 1.4) 1.1 (0.84- 1.4) 0.980 
DTNA  rs4458079 1.00 [reference] 2.25 (0.61- 8.3) 0.66 (0.45- 0.95) 0.192 1.00 [reference] 1.4 (0.578- 3.5) 1.18 (0.87- 1.6) 0.193 
HTR2C  rs6318 1.00 [reference] 1.2 (0.83- 1.7) No observation 0.360 1.00 [reference] 0.72 (0.346- 1.4) 0.95 (0.72- 1.2) 0.467 
EPHA1  rs11767557 1.00 [reference] 0.56 (0.24- 1.3) 0.92 (0.66- 1.2) 0.242 1.00 [reference] 1.1 (0.655- 2.0) 0.86 (0.66- 1.1) 0.653 
SORCS1  rs7093634 1.00 [reference] 0.99 (0.61- 1.6) 1.1 (0.823- 1.5) 0.778 1.00 [reference] 1.13 (0.751- 1.7) 1.12 (0.86- 1.4) 0.416 
PPP3R1  rs1868402 1.00 [reference] 1.20 (0.68- 2.1) 1.06 (0.78- 1.4) 0.499 1.00 [reference] 1.3 (0.86- 2.1) 1.1 (0.91- 1.5) 0.103 
MAPT/ST
H 
rs3785883 1.00 [reference] 1.01 (0.46- 2.2) 1.1 (0.86-0 .1.6) 0.403 1.00 [reference] 1.3 (0.598- 2.9) 0.89 (0.68- 1.1) 0.760 
 
1 
R is the major allele and C is the minor allele. 
2 
Values are 95% Confidence Interval in parentheses (all such values). Adjusted variables in multivariate models included body mass index (kg/m2, continuous), 
smoking (never, former, current), age, in years (65-74, 75-84, 85+), diabetes (No, Yes), stroke (No, Yes), heart attack (yes or no), cholesterol (mg, continues), 
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SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
 
Summary 
 The overall objective of this dissertation was to determine the extent to which 
dietary factors, erythrocyte membrane fatty acids, and genes are independently associated 
with C-reactive protein (CRP) concentration among elderly residents of Cache County, 
Utah. Evidence for the role of inflammation in AD is limited. Epidemiologic and genetic 
evidence suggest that inflammatory biomarkers are involved in the pathogenesis of AD 
by releasing inflammatory mediators such as cytokines, chemokines, and 
neurotransmitters [1]. There is strong evidence of an etiologic role of both genetic and 
environmental factors with inflammation. Diet and erythrocyte membrane fatty acids 
(EMFAs), which are considered environmental factors, may influence the risk of AD and 
through its effects on systemic inflammation [2]. Concomitantly, genes associated with 
AD may influence AD risk via their effects on inflammation [3]. 
 The results of this dissertation support the roles of nutrition and genes in systemic 
inflammation as indicated by CRP. Our dietary pattern analysis confirmed the importance 
of the elderly diet in the etiology of inflammation, which may lower AD risk. Among 
elderly individuals whose diets highly resembled the ideal high adherence of Dietary 
Approach to Stop Hypertension (DASH) diet and Mediterranean dietary (MED) patterns, 
there was a lowered risk of having high CRP levels. Interestingly, a greater reduction in 
the risk of CRP was found with high accordance of both DASH and MED among 
overweight and obese compared to normal weight participants.  
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Eight of the erythrocyte membrane fatty acid concentrations were associated with 
the inflammatory biomarker CRP. When comparing higher levels of palmitoleic acid and 
nervonic acids, both monounsaturated fatty acids (MUFAs), dihomo-y-linolenic acid 
(DGLA), docosapentaenoic acid (DPA-6), docosahexaenoic acid (DHA), all 
polyunsaturated fatty acids (PUFAs) with lower levels, risk of elevated plasma CRP was 
lower among the CCMS participants. Conversely, higher levels of margaric acid, stearic 
acid, and arachidic acid, all saturated fatty acids (SFAs), were associated with a lower 
risk of elevated CRP. Among those with higher EMFA high levels of pentadecanoic acid, 
palmitic acid, behenic acid, lignoceric acid, oleic acid, gondoic acid, erucic acid, vaccenic 
acid, linoleic acid, a-linolenic acid, eicosadienoic acid, arachidonic acid, 
eicosapentaenoic acid, adrenic acid, docosapentaenoic acid n3, there was no discernable 
effect on CRP levels. 
 In our study, we also found an association with APOE-epsilon genotypes and four 
SNPs of AD-related genes on CRP inflammatory biomarker. APOE-epsilon genotypes 
were associated with CRP levels among elderly men and women. When data were 
stratified by gender, major allele of APOE (C/C) rs439401, TOMM40 (A/A) rs157580, 
and minor allele of MMP8 (T/T) rs1892886, CR1 (A/A) rs6656401, rs3818361, and 
rs4844609 lowered the risk of elevated CRP among elderly men. Among those with 
BIN1, CLU, CD2AP, AGTR1, MS4A6A/ MS4A4E, MPP7, ABCA7, CD33, PICALM, 
DTNA, HTR2C, EPHI1, SORCS1, PPP3R1, and MAPT/STH, there was no significant 





Limitations and Future Directions 
    The dissertation described here provides evidence of the roles that dietary 
patterns, defined by DASH and MED adherence, erythrocyte membrane fatty acids 
composition, and AD-related genes, have on the risk of systemic inflammation CRP 
levels after adjusting for potential confounders. There are some limitations that must be 
discussed and addressed in future work. Cache County Memory Study does not have a 
collection of blood for inflammatory biomarkers at the Wave 1 baseline examination that 
would allow a prospective study of CRP levels and subsequent outcomes. We also used a 
single inflammatory marker CRP to determine the serum level of inflammatory 
biomarkers, but it has been proposed that systemic inflammatory markers change over 
time [4], so examining multiple inflammatory biomarkers would help to strengthen our 
results.  
The following recommendations are also offered for related research on systemic 
inflammation biomarker CRP:  
1. Replication studies are needed to confirm the effect of a DASH diet and MED on 
systemic inflammation by lowering CRP level among elderly in different populations.  
2. Further prospective studies examining erythrocyte membrane fatty acids, including 
palmitoleic acid, dihomo-y-linolenic acid (DGLA), docosapentaenoic acid (DPA-6), 
docosahexaenoic acid (DHA), nervonic fatty, margaric acid, stearic acid, pentadecanoic 
acid, palmitic acid, behenic acid, lignoceric acid, oleic acid, gondoic acid, erucic acid, 
vaccenic acid, linoleic acid, a-linolenic acid, eicosadienoic acid, arachidonic acid, 
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eicosapentaenoic acid, adrenic acid, docosapentaenoic acid n3, and arachidic acid, 
inflammation, and other disease would strengthen the present findings.  
3. We examined the association of erythrocyte membrane fatty acid concentration and 
plasma CRP level in depth, but further examination of the associations between food 
sources for each fatty acid with EMFA concentration and CRP would be valuable 
additions regarding these associations.   
4. Genotypic imputations, study of additional variants from gene sequencing, and study 
of gene-nutrient interaction to increase our understanding of systemic inflammation and 
to further assess the consistency of evidence in terms of both significance and direction of 
effects observed in our study. 
5. Our hypothesis-driven genetic study only assessed individual SNPs and did not take 
into account correlation among SNPs or genes. 
6. Further studies are needed to explore and explain the effects of the interactions 
between APOE rs157580 and TOMM40 rs439401 on CRP level as a dependent variable, 
particularly among elderly individuals. 
Public Health Significance 
 Although more research is needed to characterize the relationship between elderly 
nutrition and the risk of systemic inflammation, healthy elderly diets with adherence to a 
DASH diet or MED are safe and feasible interventions that may reduce the risk of AD 
among the elderly by reducing CRP and other inflammatory biomarkers. Fatty acid 
consumption is still a controversial issue. Thus, more scientists and clinicians need to join 
in the efforts to understand the impact of FAs on health outcomes. 
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 The discovery of the effects of AD-related genes on CRP may provide clinicians 
specific targets for more effective intervention strategies. For example, in our study, we 
observed that the presence of major allele APOE rs439401 and TOMM40 rs157580 and 
minor allele of MMP8 rs1892886, CR1 rs6656401, rs3818361, and rs4844609 decrease 
the risk of having elevated CRP levels.  Men with the minor allele of APOE rs439401 
and TOMM40 rs157580, and major allele of MMP8 rs1892886, CR1 rs6656401, 
rs3818361, and rs4844609 can be targeted for more aggressive treatment to reduce their 
CRP levels, which may lower the chance of having AD later in their life.  
 Reduction in the prevalence of AD could have tremendous importance. The 
results of this dissertation may help identify factors important to AD etiology and, in turn, 
provide valuable targets for preventive intervention. Until now, there is no cure for AD; 
individuals with AD require medical care to maintain quality of life, maximize function 
in daily activities, foster a safe environment, and enhance cognition, mood, and behavior. 
The costs incurred in caring for elderly with AD not only include multi-disciplinary 
clinical care, but also involves emotional disturbance and social and employment 
exclusion for affected individuals. Reducing the risk of AD would lessen considerable 
financial and emotional burdens for families and society. 
Conclusions 
 In conclusion, this dissertation presents additional insight into the possible dietary 
patterns, erythrocyte membrane fatty acids composition, and AD-related genes associated 
with systemic inflammation. The findings indicate that adherence to dietary pattern 
DASH and MED influence the risk of systemic inflammation. While saturated 
erythrocyte membrane fatty acids composition may be anti-inflammatory, MUFAs and 
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PUFAs may increase the risk of systemic inflammation. Additionally, the results support 
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